Investigation of human papilloma viruses infections in prostate cancer by Azzawi, Mous'ab
Middlesex University Research Repository: 
an open access repository of
Middlesex University research
http://eprints.mdx.ac.uk
Azzawi, Mous’ab, 2013. Investigation of human papilloma viruses
infections in prostate cancer. Available from Middlesex University’s
Research Repository.
Copyright:
Middlesex University Research Repository makes the University’s research available electronically.
Copyright and moral rights to this thesis/research project are retained by the author and/or 
other copyright owners. The work is supplied on the understanding that any use for 
commercial gain is strictly forbidden. A copy may be downloaded for personal, non-
commercial, research or study without prior permission and without charge. Any use of the 
thesis/research project for private study or research must be properly acknowledged with 
reference to the work’s full bibliographic details.
This thesis/research project may not be reproduced in any format or medium, or extensive 
quotations taken from it, or its content changed in any way, without first obtaining permission
in writing from the copyright holder(s).
If you believe that any material held in the repository infringes copyright law, please contact 
the Repository Team at Middlesex University via the following email address:
eprints@mdx.ac.uk
The item will be removed from the repository while any claim is being investigated. 
  
 
 
 
 
INVESTIGATION OF HUMAN PAPILLOMA VIRUSES INFECTIONS 
IN PROSTATE CANCER 
 
 
 
 
MOUS’AB AZZAWI 
SCHOOL OF SCIENCE AND TECHNOLOGY 
MIDDLESEX UNIVERSITY 
 
 
 
 
A THESIS SUBMITTED TO MIDDLESEX UNIVERSITY 
FOR THE TITLE OF DOCTOR OF PHILOSOPHY  
August 2013 
 
 
 
 
 
 
  
1 
 
 
 
TABLE OF CONTENTS 
TABLE OF CONTENTS ................................... 1 
LIST OF FIGURES ....................................... 6 
ABBREVIATIONS ....................................... 11 
DECLARATION ........................................ 13 
ACKNOWLEDGEMENTS ................................. 14 
ABSTRACT ............................................ 15 
CHAPTER 1: INTRODUCTION ............................. 17 
1.1. Prostate cancer epidemiology ........................... 17 
1.2. Prostate cancer risk factors ............................. 18 
1.3. Prostate pathology .................................. 21 
1.4. Human papilloma viruses (HPVs) ....................... 28 
1.5. Viral particle and its genomic organisation ................. 31 
1.6. Viral genes and proteins .............................. 32 
1.7. E1 protein of HPVs .................................. 33 
1.8. E2 Protein of HPVs .................................. 34 
1.9.  E4 Protein of HPVs .................................. 35 
1.10. E5 Protein of HPVs ................................. 35 
1.11. E6 protein of HPVs ................................. 36 
1.12. E7 Protein of HPVs ................................. 37 
1.13. L1 Protein of the HPVs ............................... 40 
1.14. L2 Protein of the HPVs ............................... 40 
1.15. Human papilloma viruses (HPVs) life cycle ................ 40 
1.16. Viral Characteristics ................................. 44 
1.17. The role of HPV oncoprotiens in inducing genomic instability .. 46 
2 
 
 
 
1.18. Molecular mechanisms of high-risk HPV-mediated cellular 
transformation in cervical cancer ........................... 49 
1.19. HPVs infections and prostate cancer ..................... 51 
1.20. Host response towards HPV infection .................... 52 
1.21. HPV Infections risk factors ............................ 54 
1.22. Latency of HPV infections ............................ 55 
1.23. Prevention from HPV infections ........................ 55 
1.24. Hypothesis ....................................... 56 
1.25. Aims of the research ................................ 56 
CHAPTER 2:  MATERIALS AND METHODS ................... 58 
2.1. STUDY AND CONTROL SAMPLES ...................... 58 
2.1.2. Case selection ................................... 58 
2.1.3. The study (prostate cancer) population ................. 59 
2.1.4. Inclusion criteria in the study group ................... 59 
2.1.5. Exclusion criteria from the study group ................. 59 
2.1.6. The control population ............................. 60 
2.1.7. Inclusion criteria in the control group .................. 60 
2.1.8. Exclusion criteria  from the control group ............... 60 
2.1.9. Age of the patients at presentation .................... 60 
2.1.10. Prostate cancer cases staging at presentation ............ 61 
2.1.11. Serum prostate specific antigen (PSA) values ............ 62 
2.1.12. Specimen collection and storage ..................... 63 
2.2. DNA EXTRACTION FROM PARAFFIN-EMBEDDED TISSUES .. 64 
2.2.1. Introduction .................................... 64 
3 
 
 
 
2.2.2. Materials ....................................... 64 
2.2.3. Method ........................................ 65 
2.3. ISOLATION OF DNA FROM HeLa CULTURED CELL LINE .... 67 
2.3.1. Introduction .................................... 67 
2.3.2. Materials ....................................... 67 
2.3.3. Method ........................................ 67 
2.4. DNA QUANTIFICATION AND NORMALISATION ......... 69 
2.4.1. Introduction .................................... 69 
2.4.2. Materials ....................................... 69 
2.4.3. Method ........................................ 70 
2.5. POLYMERASE CHAN REACTION (PCR) ................. 73 
2.5.1. Introduction .................................... 73 
2.5.2. Materials ....................................... 74 
2.5.3. Method ........................................ 75 
2.6. AGAROSE GEL ELECTROPHORESIS .................... 79 
2.6.1. Introduction .................................... 79 
2.6.2. Materials ....................................... 80 
2.6.3. Method ........................................ 81 
2.7. HPV DNA QUANTIFICATION ......................... 83 
2.7.1. Introduction .................................... 83 
2.7.2. Materials ....................................... 83 
2.7.3. Method ........................................ 84 
2.8. HPV GENOTYPING ................................. 85 
2.8.1. Introduction .................................... 85 
4 
 
 
 
2.8.2. Materials ....................................... 85 
2.8.3. Method ........................................ 86 
2.9. p53 GENE CODON 72 POLYMORPHISM .................. 87 
2.9.1. Introduction .................................... 87 
2.9.3. Materials ....................................... 88 
2.9.3. Method ........................................ 89 
2.10. HAEMATOXYLIN AND EOSIN (H&E) .................. 90 
2.10.1. Introduction .................................... 90 
2.2.2. Materials ....................................... 91 
2.10.3. Method ....................................... 91 
2.11. TUMOUR GRADING BY GLEASON SYSTEM ............. 92 
2.11.1. Introduction .................................... 92 
2.11.2. Method ....................................... 92 
2.12. IMMUNOHISTOCHEMISTRY ......................... 93 
2.12.1. Introduction .................................... 93 
2.12.2. Materials ...................................... 93 
2.12.3. Method ....................................... 94 
2.13. COLORIMETRIC in situ APOPTOSIS ASSAY .............. 96 
2.13.1. Introduction .................................... 96 
2.13.2. Materials ...................................... 97 
2.13.3. Method ....................................... 98 
2.14. STATISTICAL ANALYSIS ........................... 100 
CHAPTER 3: MOLECULAR STUDIES RESULTS ................ 101 
3.1. TESTING THE STUDY AND CONTROL GROUPS BY PCR .... 101 
5 
 
 
 
3.2. HPV GENOTYPING BY REVERSE HYBRIDISATION LINE PROBE 
ASSAY ............................................. 104 
3.3. QUANTITATIVE STUDIES RESULTS ................... 109 
3.4. GENETIC POLYMORPHISM STUDIES .................. 112 
3.5. DISCUSSION ..................................... 114 
CHAPTER 4: MORPHOLOGICAL STUDIES RESULTS ........... 127 
4.1. TUMOUR GRADING USING GLEASON SCORING SYSTEM .. 127 
4.2. HPV EXPRESSION IN THE TOTAL STUDY AND CONTROL 
GROUPS ........................................... 130 
4.3. DETECTION OF E6 PROTEIN OF THE HIGH-RISK HPVs .... 135 
4.4. THE STATUS OF THE P53 PROTEIN IN THE TOTAL AND STUDY 
GROUPS ........................................... 139 
4.5. THE STATUS OF THE p16INK4a IN THE TOTAL STUDY AND 
CONTROL GROUPS ................................... 142 
4.6. in situ TUNEL APOPTOSIS ASSAY ..................... 145 
4.7. DISCUSSION ..................................... 147 
 CHAPTER 5: GENERAL DISCUSSION ...................... 158 
APPENDICES ......................................... 165 
APPENDIX 1:  Data extraction sheet ........................ 165 
APPENDIX 2: Table showing the tumour grading, staging, PSA and 
survival for each individual prostate cancer case which showed 
positivity for the high-risk HPV infections, along with the P53 codon 72 
polymorphism, viral load, P53, P16 and E6 protein statuses. ...... 168 
REFERENCES ......................................... 170 
 
6 
 
 
 
 
LIST OF FIGURES 
Figure 1-1: Age standardised (world) incidence and mortality rates of 
prostate cancer in selected countries during the year 2002. .......... 18 
Figure 1-2: Prostate cross section (coronal): ..................... 22 
Figure 1-3.: Prostate cross section (sagittal): ..................... 22 
Figure 1-4: Gleason scoring grades . .......................... 25 
Figure 1-5: Genomic organisation of HPV 16 . ................... 32 
Figure 1-6: HPV16 life cycle in cervical cancer. ................... 44 
Figure 2-1: Primer targets of the HPV primer sets and their amplimer size  
. .................................................... 77 
Figure 2-2: The functional domains of the P53 gene, the location of the 
polymorphism at codon 72, and the position of the primers used for PCR
 ..................................................... 90 
Figure 3-1: MY09/11 PCR assay (450bp). M = DNA molecular weight 
marker. Sample of positive PCR- reactions are seen in specimens 3 and 6. + 
= positive control, - = negative control. ....................... 102 
Figure 3-2: GP5+/GP6+ PCR assay (150bp). M = DNA molecular weight 
marker. Sample of positive PCR- reactions are seen in specimens 2 and 3. 1 
= positive control, - = negative control. ....................... 103 
Figure 3-3: SPF1/2 PCR assay (65bp). M = DNA molecular weight marker. 
Sample of positive PCR- reactions are seen in specimens 1, 3, 4, 8 and 9. 1 
= positive control, - = negative control ........................ 103 
Figure 3-4: Kaplan-Meier survival plot for the three PCa subgroups: a) 
negative for HPV DNA; b) positive for low-risk HPV DNA; d) positive for 
high-risk HPV DNA. .................................... 109 
7 
 
 
 
Figure 3-5: Print Screen from Microchip Electrophoresis System for 
DNA/RNA Analysis (MCE®-202 MultiNA) interface showing the DNA 
concentration in sample no. 12 as 133.97 ng/µl. ................. 110 
Figure 3-6: p53 gene codon 72 polymorphism PCR assay. p53-Pro allele 
yields a 177-bp fragment which can be seen in samples 3 and 4. p53-Arg 
allele yields a 141-bp fragment which can be seen in samples 1 and 2. M = 
DNA molecular weight marker. 5 = negative control. ............. 113 
Figure 4-1: Sample of Gleason grade 3+3=6 (x400) ............... 128 
Figure 4-2: Sample of Gleason grade 4+3=7(x200) ................ 128 
Figure 4-3: Sample of Gleason grade 4+4=8 (x400) ............... 129 
Figure 4-4: Sample of Gleason grade 5+5=10 (x400) .............. 129 
Figure 4-5: Immunostaining of prostate cancer showing HPV positive 
(x400) ............................................... 131 
Figure 4-6: Immunostaining of prostate cancer showing HPV positive 
(grade I) (x200)......................................... 134 
Figure 4-7: Immunostaining of prostate cancer showing HPV positive 
(grade II) (x200) ........................................ 134 
Figure 4-8: Immunostaining of prostate cancer showing HPV E6  positive 
(grade I) using HPV 16 and 18 anti E6 protein (abcam-C1P5) (x400) ... 136 
Figure 4-9: Immunostaining of prostate cancer showing P53 positive 
staining (x200) ......................................... 140 
Figure 4-10: Immunostaining of prostate cancer showing p16INK4a  positive 
staining (x400) ......................................... 143 
Figure 4-11: TUNEL in situ assay on prostate cancer sample showing the 
apoptotic cells as black small dots (x400) ...................... 147 
 
8 
 
 
 
 
LIST OF TABLES 
 
Table 1-1:  Definitions of clinical TNM ......................... 26 
Table 1-1 HPV type and associated lesions ...................... 30 
Table 1-2 HPVs proteins [96]. ............................... 33 
Table 2-1: Age distribution in the study and control population groups . 61 
Table 2-2: Prostate cancer staging in the three study subgroups ....... 62 
Table 2-3: The median of PSA value in the study and control ........ 63 
Table 2-4: The design of MY 09/11 and  GP5+/GP6+  primer sets, as well 
as SPF1/2 cocktail of six primers . ............................ 76 
Table 2-5: List of the primers used to study P53 codon 72 polymorphism.
 ..................................................... 89 
Table 3-1:  HPV positive results by conventional, nested, and multiplex 
PCRs. ............................................... 102 
Table 3-2: HPV types in HPV-DNA-positive prostatic carcinoma and 
benign prostatic hyperplasia samples ........................ 104 
Table 3-3: High-risk and low-risk HPV infection frequencies in the total 
prostatic carcinoma and benign prostatic hyperplasia samples. ...... 105 
Table 3-4: High-risk and low-risk HPV infection in the study and control 
sub-groups. ........................................... 106 
Table 3-5: The association between the HPV-positive cases and Gleason 
scoring. .............................................. 106 
Table 3-6: association between tumour stage and infection with high-risk 
HPV. ................................................ 107 
9 
 
 
 
Table 3-7: The mean of PSA value in HPV-negative, low-risk HPV, and 
high-risk HPV infections prostate cancer cases. ................. 108 
Table 3-8: The average high-risk HPV viral DNA concentration in the 
study and control groups. ................................. 110 
Table 3-9: The association between Gleason scoring and the high- risk 
HPV viral DNA concentration. ............................. 111 
Table 3-10: The association between TNM staging and the high-risk HPV 
viral DNA concentration. ................................. 112 
Table 3-11: Genotypes and frequencies of codon 72 p53 polymorphism 
variants in PCa and BPH cases. ........................... 113 
Table 3-12: Frequencies of codon 72 p53 polymorphism variants in high-
risk HPV-positive and HPV-negative prostate carcinomas ......... 114 
Table 4-1: Gleason scoring in the three cancer subgroups .......... 127 
Table 4-2: HPV status in the study and control groups by IHC using HPV 
antibody. ............................................. 131 
Table 4-3: Comparison between the negative results of IHC using HPV 
cocktail antibody and the multiplex PCR positive results using SPF1/2 
primer set. ............................................ 132 
Table 4-4: IHC grading of the positive HPV samples in the total study and 
control groups. ........................................ 133 
Table 4-5: E6 protein status in the total study and control group. ..... 136 
Table 4-6: E6 protein status in the study group using IHC. ......... 137 
Table 4-7: The association between the high-risk E6-positive cases and 
Gleason scoring ........................................ 138 
Table 4-8: association between tumour stage and infection with high-risk 
HPV. ................................................ 138 
10 
 
 
 
Table 4-9: P53 protein status in the study and control groups ....... 140 
Table 4-10: The association between p53 status and HPV status in the total 
PCa study group. ....................................... 141 
Table 4-11: The association between P53 and high-risk E6 protein in the 
study group using IHC. .................................. 142 
Table 4-12: p16INK4a transcription factor status in the study and control 
groups. .............................................. 143 
Table 4-13: Association between the p16INK4a and the HPV infections status 
in the study group. ...................................... 144 
Table 4-14: Association between the p16INK4a and the HPV infections 
status in the control group. ................................ 145 
Table 4-15: Association between TUNEL in situ assay score and high-risk 
E6 protein of the HPVs in the PCa study group. ................. 146 
 
  
11 
 
 
 
 
ABBREVIATIONS  
Adenovirus Ad
Bovine papillomavirus BPV
Bovine papillomaviruses BPVs
Conserved region 1 CR1
Conserved region 2 CR2
Cottontail rabbit papillomaviruses CRPVs
Cyclin-dependent kinase inhibitors CKIs
Deoxyribonucleic acid DNA
Digital rectal examination DRE
Epidermal growth factor EGF
Focal adhesion kinase FAK
Haematoxylin and Eosin H&E
Heat-induced epitope retrieval HIER
Histone deacetylases HDACs
Human papilloma viruses HPVs
Long control region LCR
Non-coding region NCR
Nuclear export sequence NES
12 
 
 
 
 
 
 
  
Open reading frames ORFs
Phosphate-buffered saline PBS
Platelet-derived growth factor PDGF
Polymerase Chain Reaction PCR
Promyelocytic oncogenic domains PODs
Promyelocytic oncogenic domains PODs
Prostate-specific antigen PSA
Retinoblastoma tumour suppressor protein pRb
Room temperature RT
Transitional cell carcinoma TCC
Trans-rectal Ultrasound TRUS
Transurethral resection of prostate TURP
Ultraviolet UV
United Arab Emirates UAE
Upstream regulatory region URR
Virus-like particles VLP
13 
 
 
 
DECLARATION 
 
I declare that this thesis has been composed and written entirely by myself, 
and the work contained herein to have been principally conducted by 
myself. 
 
 
 
 
Mous’ab Azzawi 
 
  
14 
 
 
 
ACKNOWLEDGEMENTS 
I would like to express my sincere gratitude to my director of studies Dr 
Mahmoud Naase for giving me the opportunity to work on this project 
under his great supervision. His encouragement and support were pivotal 
to completing this project. 
Special thanks for my supervisor Prof Stephen Dilworth for his guidance 
during the stage of the write up of this thesis.  
I would also like to thank Prof Ray Iles for his guidance and brilliant ideas 
regarding the research material. 
 
I am indebted to Dr Huw Jones for his kindness, support, and advice at 
several stages of my research, including his invaluable advice on the 
statistical analysis and writing up my thesis. 
 
Deep thanks to Dr Lucy Ghali for her indispensable help and guidance in 
the histology laboratory, without which, I would not have been able to 
accomplish this task. 
 
Finally, I cannot forget to thank Dr Beata Karoli for all of her generous 
help and advice during all my work in the molecular laboratory.  
 
 
 
 
 
 
 
  
15 
 
 
 
ABSTRACT 
Human papillomavirus (HPV) infections are associated with benign and 
malignant lesions of the female and male anogenital tract. In the current 
study, we aimed to investigate the role of high-risk HPVs infection in the 
pathogenesis of prostate cancer  among nations or ethnic groups, in 
addition to testing the role of homozygosity of arginine form at codon 72 
of the p53 gene among prostate cancer patients whose prostate tissues 
were infected with high-risk HPVs.  
 
Formalin-fixed paraffin-embedded tissue samples of 123 primary prostate 
adenocarcinoma cases and 267 control tissues of benign prostatic 
hyperplasia were used in the study.  Genomic DNA was purified and 
amplified through MY09/MY11 degenerate primers, GP5+/GP6+ 
consensus primers, SPF1/2 cocktail of six primers using conventional, 
multiplex and nested PCR techniques, and subsequently subjected to viral 
load quantification, genotyping, testing of polymorphism of codon 72 of 
the p53 gene and apoptosis index assessment by in situ assay. Also, the 
status of the  p53 tumour suppressor gene, p16INK4a transcription factor as 
well as the E6 protein of the high risk HPVs have been tested by 
immunohistochemistry in both the study and control groups.  
 
High-risk HPVs were detected in 30 of 123 (24.3%) PCa and 16 of 267 
(5.9%) BPH samples with positive HPV-DNA. The detection rate of the 
high-risk HPV infections was 4%, 44% and 29% among the ethnic 
subgroups from the Middle Eastern, Caucasian, and Afro-Caribbean of the 
PCa patients. There was no association between the existence of high-risk 
HPV infections and their viral load in PCa patients and the tumour 
staging, grading, PSA level and patient survival rate in those patients. 
Likewise, there was no significant difference in the frequency of p53 Arg 
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homozygosity between the high-risk HPV-positive and the HPV-negative 
PCa samples. Moreover, it has been found that the existence of the high-
risk HPV E6 protein within the PCa samples was independent of the 
status of the p53 gene, p16INK4a transcription factor, and the apoptosis 
index in these samples.  
 
Our data showed that HPV infections do exist in PCa and BPH samples 
with different prevalence within ethnic groups with the least occurrence in 
the Middle Eastern patients. However, the infections with high-risk HPVs 
are not associated with the prostate cancer grade, stage, patient’s PSA 
level, and survival rate. Therefore, our data do not support the role of 
HPV infection in the pathogenesis of prostate carcinoma.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Prostate cancer epidemiology 
Prostate cancer accounts for around 13% of male deaths from cancer in the 
UK and it is considered the second most common cause of cancer deaths 
in men after lung cancer and the first most common cancer in non-
smoking men. There are around 26,400 new cases per year and 
approximately 9,600 deaths per year in the United Kingdom [1].  
 
Survival from prostate cancer has greatly improved since the 1970s, and 
rates now stand at 84%, 60%, and 28% at one, five and ten years 
respectively.  One reason for the improved survival could be attributed to 
the huge increase in the number of patients presenting with early stage 
over the past 10 years, due to the implementation of prostate-specific 
antigen (PSA) testing as a core approach for urinary tract symptoms 
assessment in elderly men by the general practitioners. The reason may be 
attributed to the wide adoption of the regular digital rectal examination 
(DRE) of the prostate by almost all the family doctors in the United 
Kingdom for all adult men over 45 years old when the patients present 
themselves with signs and/or symptoms of a prostatic pathology [2]. 
 
The highest prostate cancer incidence rates are in the developed world and 
the lowest rates are in Africa and Asia [3]. There are no sufficient data about 
the prostate cancer epidemiology and mortality from the Middle East and 
Afro-Caribbean countries [4]. The extremely high rate in the USA (125 per 
100,000), more than twice the reported rate in the UK (52 per 100,000), is 
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likely to be due to the particularly high rates of PSA testing in the USA or 
can be attributed to other environmental and social factors [5]. Figure 1-1 
shows the incidence and mortality rates in a number of countries in the 
world during the year 2002 [3, 6, 7]. 
 
Figure 1-1: Age standardised (world) incidence and mortality rates of prostate cancer in selected 
countries during the year 2002.  
 
1.2. Prostate cancer risk factors 
There are several risk factors correlated with the development of 
prostate cancer, with different levels of involvement in the 
complexity of the prostate cancer pathogenesis.  
Age is one of the most important factors in developing prostate cancer. 
The disease is very rare below the age of 40 years, but becomes 
increasingly common with increasing age [8]. However, most prostate 
cancers do not achieve clinically recognizable and aggressive states and 
that is why many cases of prostate cancer are only diagnosed during post-
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mortem examination. However, increasing age is associated with a higher 
risk of high-grade prostate cancer in men of different ethnic origins [9].  
 
The incidence of prostate cancer is 10 times higher in the western world 
than Asian countries [10]. This might be explained by genetic factors [11]. 
However, the incidence of prostate cancer also tends to increase in Asian 
immigrants to western countries, mainly after one generation. This may 
suggest the involvement of environmental factors as well [12].  
 
Balck skinned men from African balck origin have the highest incidence 
and mortality from prostate cancer in the world. In the UK, the incidence 
of prostate cancer is approximately triple in men of African origin than in 
white men, and lowest in Asian and Middle Eastern men, suggesting a 
strong ethnic influence [13]. Even after adjusting for stage at diagnosis, 
black men have higher mortality rates than white men. Multiple reasons 
have been postulated to explain these findings including access to care, 
attitudes about care, socio-economic and education differences [14, 15], 
differences in type and aggressiveness of treatment, dietary, and genetic 
differences [11]. While each reason may contribute to the higher incidence 
or higher mortality, likely combination of reasons will best explain all the 
findings. Also, with recent advances in the understanding of genetic 
variations in the human genome, in general, and in the genes involved in 
pathways relevant to prostate cancer biology, in particular; a number of 
genes with alleles which differ in frequency between black and white men 
have been proposed as a genetic cause or contributor to the increased 
prostate cancer risk in black men [13].  
 
It has been shown that the prevalence of prostate carcinoma in the UAE, 
like other Arabian Gulf and Asian countries, is very low compared to 
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Western countries despite the high intake of calories and consumption of 
animal fat, which are considered as contributing factors to the increased 
risk of development of prostate cancer [16, 17]. However, interaction of 
genetic and environmental factors believed to be involved in the complex 
aetiology of prostate cancer in those countries and elsewhere await further 
investigations [18-20]. 
 
It has been reported that there is a strong association between early onset 
of prostate cancer and the positive family history of the disease [21]. This 
is mainly governed by the number of relatives with prostate cancer and 
their age at diagnosis. Dominant pattern of inheritance with high 
penetrance is responsible for 5% to 10% of all prostate cancer cases, and as 
much as 30% to 40% of early onset disease [22]. 
 
Inflammation is frequently present in prostate biopsies, radical 
prostatectomy specimens and tissue resected for treatment of benign 
prostatic hyperplasia. Also, inflammatory infiltrates are often found in 
and around foci of atrophy that are characterized by an increased 
proliferative index. These foci, called proliferative inflammatory atrophy, 
may be precursors of early prostate cancer or may indicate an intra-
prostatic environment favourable to cancer development. Epidemiological 
studies have indirectly examined the role of chronic inflammation in 
prostate carcinogenesis through studies of pro-inflammatory and anti-
inflammatory factors. When taken together studies of sexually transmitted 
infections, clinical prostatitis, and genetic and circulating markers of 
inflammation and response to infection hint at a link between chronic 
intra-prostatic inflammation and prostate cancer[23]. However, there has 
been an increasing evidence of the association of chronic inflammation of 
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the prostate in the form a chronic prostatitis, which can be septic or 
aseptic, with the development of prostate cancer [24].  
 
Being a hormone dependant cancer, one of the postulated theories about 
the pathogenesis of prostate cancer was based on the elevated androgen 
level in Afro-Caribbean men [25-27]. While reports of racial differences in 
gonadal steroid hormone levels in middle-aged men have produced 
conflicting results, there is evidence that high sex hormone-binding 
globulin (SHBG) and androstenedione levels are more common among 
young adult African American men than white men [28]. Furthermore, it 
has been approved that the concentrations of androstenedione, testosterone, 
and progesterone were notably higher in African-American compared with 
Caucasian or Hispanic women [29]. The  latter data are consistent with 
hypotheses that in-utero hormonal exposures may explain some of the 
ethnic group differences in cancer risk [30]. Moreover, it has been shown 
that the androgen levels in the Arab population are significantly lower than 
the levels in the Caucasian population [31].  
 
1.3. Prostate pathology  
The prostate is pathologically subdivided into 3 anatomical regions, with 
histologic compositions reflective of their respective functions. The 
anterior prostate makes up approximately 20% of the volume of the 
prostate and is composed of nonglandular fibromuscular stroma. The 
peripheral portion of the gland (commonly referred to as the peripheral 
zone) is comprised primarily of acinar tissue and forms the posterior and 
lateral surfaces of the prostate. In a normal prostate, the peripheral zone 
represents approximately 70% of the total glandular volume[32]. The vast 
majority of prostate carcinomas arise in the peripheral zone. The central 
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gland makes up the remainder of the prostate. The transitional zone is the 
periurethral tissue located in the central. The transitional zone 
hypertrophies with age and results in BPH [33](Figure 1-2 and Figure 1-
3)[34].  
 
  
 
Figure 1-2: Prostate cross section (coronal): (1) transitional zone, (2) central zone, (3) peripheral 
zone, (4) ejaculatory ducts, (5) verumontanum, and (6) vas deferens.   
 
 
  
Figure 1-3.: Prostate cross section (sagittal): (1) transitional zone, (2) central zone, (3) peripheral 
zone, (4) ejaculatory ducts, (5) urethra, and (6) seminal vesicles.  
 
 
Benign prostatic hyperplasia (BPH) is defined by proliferation of smooth 
muscle and epithelial cells in the transitional zone of the prostate, causing 
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gland enlargement and often resulting in lower urinary tract symptoms 
(LUTS). In men over 60 years of age, 50% have been diagnosed with BPH, 
and 75% of men over the age of 70 have 1 or more symptom attributable to 
BPH. By 85 years of age, 90% of men have symptoms of BPH [35]. BPH 
manifests clinically as LUTS, which include increased frequency of 
urination, nocturia, urgency, hesitancy, and weak urine stream. These 
symptoms are caused by disturbances in normal urine retention or 
voiding, which may be due to structural distortion and functional 
abnormality of the bladder neck, prostate, distal sphincter, or urethra. 
BPH alone is rarely a life-threatening condition but can significantly 
reduce the quality of life. The effect on quality of life is highly variable, 
and objective measures do not correlate well with the severity of 
symptoms [35, 36]. 
 
 
The most common primary prostatic malignancy is adenocarcinoma of the 
ductal or acinar epithelium [37]. The basal layer is normally absent and 
therefore there is infiltration into the prostatic stroma[38]. 
Macroscopically, the gland tends to be hard and white, though a soft 
mucin-producing variance exists. Less commonly, the transitional cell 
carcinoma (TCC) might primarily present in the prostatic urethra, or the 
prostate may be invaded by a primary TCC of the bladder [39]. 
Rhabdomyosarcoma of the prostate is rare but may be seen in childhood. 
Secondary deposits (metastases) from other sites are also rare [40]. 
 
About 75% of adenocarcinomas occur in the peripheral zone of the 
prostate and most (85%) are multifocal. 20% appear to arise from the 
transition zones and 5% from the embryologically distinct central zone [40, 
41].  
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The tumour spreads locally through the poorly formed prostatic capsule 
into surrounding tissue, at which time it is termed as ‘locally advanced’. 
Hence, the disease may involve the urethral sphincter, corpora of the 
penis, seminal vesicles, and trigone of the bladder including the distal 
ureters. Local spread is often along the course of autonomic nerves in the 
form of perineural invasion [42]. The most frequent sites of metastasis are 
lymph nodes and bone, although lung, liver, testis, and brain are not 
uncommon. Bone metastases are characteristically sclerotic, rarely lytic. 
The axial skeleton, which comprises the spine and pelvis, are most 
commonly affected, followed by the proximal long bones, ribs, clavicles, 
and the skull [40]. 
 
The Gleason grading system of prostatic carcinoma is the quintessential 
prognostic factor in predicting findings in radical prostatectomy, 
biochemical failure, local recurrences, lymph node or distant metastasis in 
patients receiving no treatment, radiation therapy, radical prostatectomy 
and other therapies, including cryotherapy and high intensity focal 
ultrasound therapy. Clinicians use various tools to predict outcomes, 
including the pathological stage or prognosis following radical 
prostatectomy or radiotherapy. All of these tools incorporate the Gleason 
score [43]. 
 
Donald F. Gleason in 1966 created a unique grading system for PCa based 
solely on the architectural pattern of the tumour, using a five-point scale, 
where patterns 1–3 represent tumours which most closely resemble 
normal prostatic glands and patterns 4 and 5 tumours show increasingly 
abnormal glandular architecture (Figure 1-4). An innovative aspect of this 
system, based on a study of 270 patients from the Minneapolis Veterans 
Administration Hospital, was that, rather than assigning the worst grade 
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as the grade of the carcinoma, the grade was defined as the sum of the two 
most common patterns and reported as the “Gleason score”[44]. 
 
 
Figure 1-4: Gleason scoring grades . 
(1) Gelason grade1: Very well differentiated, small, closely-packed, uniform, glands in 
essentially circumscribed masses, (2) Gleason grade 2: Similar (to pattern 1) but with 
moderate variation in size and shape of glands and more atypia in the individual cells; 
cribriform pattern may be present, still essentially circumscribed, but more loosely 
arranged, (3) Gleason grade 3 : Similar to pattern 2 but marked irregularity in size and 
shape of glands, with tiny glands or individual cells invading stroma away from 
circumscribed masses, or solid cords and masses with easily identifiable glandular 
differentiation within most of them. (4) Gleason grade 4: Large clear cells growing in a 
diffuse pattern resembling hypernephroma; may show gland formation, (5) Gealson 
grade 5: Very poorly differentiated tumours; usually solid masses or diffuse growth with 
little or no differentiation into glands. 
 
 
Staging involves determination of the anatomic extent or spread of a 
disease at the time of diagnosis based on clinical and pathologic criteria. 
Cancer’s stage is based on the primary tumour’s size and location and 
whether the tumour has spread to other areas of the body. The objective of 
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staging is to group malignancies with similar prognosis and therapeutical 
approach, to be able to compare clinicopathologic data from different 
institutions to perform clinical trials or studies on homogeneous patient 
populations. The TNM staging is the most widely used system for PCa 
staging and assesses the extent of primary tumour (T stage), the absence or 
presence of regional lymph node involvement (N stage), and the absence 
or presence of distant metastases (M stage) [45] (Table 1-1) [46].  
 
Table 1-1:  Definitions of clinical TNM  
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour neither palpable nor visible by 
imaging 
T1a Tumour incidental histologic finding in ≤5% of tissue resected 
T1b Tumour incidental histologic finding in >5% of tissue resected 
T1c Tumor identified by needle biopsy (e.g. because of elevated PSA) 
T2 Tumor confined within prostate 
T2a Tumor involves one-half of one lobe or less 
T2b Tumor involves more than one-half of one lobe but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostate capsule 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal 
vesicles such as external sphincter, rectum, bladder, levator 
muscles, and/or pelvic wall 
Regional lymph nodes (N) 
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NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
 
The p53 tumor-suppressor gene is a transcription factor that regulates cell 
cycle progression, DNA repair, and apoptosis, thus serving as the 
checkpoint of cellular behaviour in response to DNA damage. The p53 
gene is the most commonly mutated or deleted gene in human cancer [47, 
48]. Although the reported frequency of p53 mutations in primary prostate 
cancer varies between 45% and 80%,most agree that p53 mutations are 
common in advanced prostate cancer[49, 50]. p53 protein expression in 
localized primary prostate carcinoma has been correlated with a higher 
Gleason grade and pathological stage. Alos, in advanced prostate cancer, 
ample evidence points to an increased incidence of p53 mutations as a late 
event that correlates with progression, recurrence, and overall poor 
prognosis[51-54]. 
 
Loss of chromosome 9p21 harbouring the p16INK4a tumour suppressor 
genes is frequently observed in human cancers. In prostate cancer, 9p21 
loss is relatively rare (7–20%) in localized disease, but occurs more 
frequently in locally advanced disease and metastasized disease, and 
predicts unfavourable prognosis [55-57].  
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The role of p16INK4a in prognosis prediction is different for patients treated 
with surgery when compared to irradiated patients. High levels of 
p16INK4a in prostatectomy specimens predicted more rapid treatment 
failure, whereas decreased expression of p16INK4a after radiotherapy 
predicted poor prognosis[58, 59]. The initial finding of p16INK4a 
overexpression being associated with poor prognosis after prostatectomy 
may be explained by the fact that increased p16INK4a expression is often 
tolerated by tumour cells carrying loss of other tumor suppressor genes 
such as Rb [60]. This seems likely, since p16 INK4a exerts a G1 block through 
inhibition of Rb and p16INK4a expression is induced upon DNA 
damage[61]. Low p16INK4a expression is often found in metastatic 
lesions[58, 60]. 
A normal functioning p16INK4a mediated inhibition of Rb is required for a 
proper response to cellular stress such as oxidative stress and DNA 
damage[62]. Under normal circumstances, these conditions would lead to 
the induction of p53 and p16INK4a, which would result in apoptosis or cell 
cycle arrest. Incorrect functioning of either of these axes may lead to the 
induction of cellular transformation and disruption of both pathways is 
required for cancer[63-67].  
1.4. Human papilloma viruses (HPVs) 
In 1933, Shope observed that the infection with the cottontail rabbit 
papillomavirus led to subsequent development of keratinous lesions, 
some of which progressed to invasive epithelial neoplasm’s [68]. This 
observation led to the discovery of the first deoxyribonucleic acid (DNA) 
virus that caused tumours in mammals [69]. Papillomaviruses are highly 
specific for their respective hosts and have been shown to infect epithelial 
mucosa or cutaneous  surfaces in almost all vertebrate species [70]. 
Infection results in primarily benign, self-limiting warts or epithelial 
tumours [71]. Extensive researches have linked some human 
29 
 
 
 
papillomavirus (HPVs) types to malignant and premalignant lesions of the 
uterine cervix, vulva, penis, conjunctiva, and upper aerodigestive tract 
[72-78]. HPV infections are associated with about 10% of the worldwide 
cancer burden, most of which are anogenital cancers, and HPV DNA is 
present in over 95% of cervical tumours worldwide [79-81]. 
 
HPVs belong to the Papovaviridae family, which includes the subfamilies 
papillomaviruses and polyomaviruses [82]. The family name of 
papovaviruses is a combination of papillomaviruses, polyomaviruses and 
vacuolating simian virus, the latter is an early name of SV40, a virus now 
included in the polyoma subfamily [71]. Papillomaviruses infect a broad 
spectrum of vertebrates, including humans [83]. They are highly species 
specific and do not infect over the species barrier [84]. Therefore, the 
different papillomaviruses are named after the species they infect, and 
they are numbered according to the order of their discovery [85]. The 
papillomaviruses that have been studied most extensively are cottontail 
rabbit papillomaviruses (CRPVs), bovine papillomaviruses (BPVs) from 
cattle, and human papillomaviruses (HPVs) [85-89]. So far, 85 different 
HPV genotypes have been fully characterized and approximately 30 
additional putative genotypes have been partially described [88]. Initially, 
the definition of an HPV type was based on viral DNA re-association 
according to the liquid hybridization technique [87]. Later, in the early 
1990’s a novel HPV type was defined according to differences detected in 
the nucleotide sequences of the E6, E7 and L1 open reading frames (ORFs) 
of the HPV genome [85]. Since 1995 a new HPV type was defined when a 
sequence difference exceeded 10% in the L1 ORF, upon comparison with 
that of an established genotypes [89].  
 
30 
 
 
 
HPVs have a strict tropism for epithelial cells and are often divided into 
two sub-groups depending on which epithelial surface they most 
commonly infect [90]. There are mucosal HPV types and cutaneous HPV 
types, of which selected examples are listed in Table 1-1 [87]. 
 
Table 1-1 HPV type and associated lesions 
Subgroup HPV infection type Preferentially found in 
  1   Plantar warts   Cutaneous  
2,4 Common warts Cutaneous  
5 Benign/ malignant verrucae lesions Cutaneous  
6,11 Condyloma, laryngeal papilloma Mucosal, low-risk 
7 “Butcher's warts", oral papilloma (HIV patient) Mucosal , cutaneous  
16 Anogenital cancer and precursors Mucosal, high-risk 
18 Anogenital cancer and precursors Mucosal, high-risk 
19-25 Epidermoid dysplasia verruciformis lesions Cutaneous  
30 Laryngeal carcinoma Mucosal 
31,33 Anogenital cancer and precursors Mucosal, intermediate-risk 
42,43,44 Anogenital benign lesions Mucosal, low-risk 
45.56 Anogenital cancer and precursors Mucosal, high-risk 
51-52, 58 Anogenital cancer and precursors Mucosal, intermediate-risk 
53-55 Anogenital benign lesions Mucosal 
70 Vulvar papilloma Mucosal 
72,73 Oral papilloma (HIV patient) Mucosal 
80 Normal skin Cutaneous  
 
HPVs can be divided into so called low-risk, intermediate risk and high-
risk HPV types, depending on if they are commonly isolated from benign 
or malignant cervical lesions [91]. HPV types that are found commonly in 
anogenital and other cancers are 16, 18, 31, 33, and 5 [87]. HPV types 39, 5, 
51, 52, 56, 57, 58, 59, and 61 may also be present less frequently in 
dysplastic and malignant pathologies of other anogenital sites [89]. HPV 
16 is the most commonly found in squamous cell cancers of the cervix, 
whereas HPV18 predominates in adenocarcinomas of the cervix [78, 91]. 
The molecular basis for the tissue specific distribution of these two high-
risk HPV types is still not clear [92]. The low-risk HPV types include 
HPV6, 11, 13, 32, 34, 40, 42, 44, 53, 54, 55, and 63, which are usually 
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associated with benign lesions such as cervical condylomas [89, 93, 94]. 
High-risk HPV types can induce increased chromosomal abnormalities 
and aneuploidy in the infected cell and encode oncoproteins (E6, E7) that 
interact specifically with the cellular proteins (p53, Rb) which are 
responsible for the control of cell growth and proliferation [95]. Because 
high- and low-risk HPV categorising primarily emerges from studies of 
cervical neoplasia, it is likely that additional HPV types, which are found 
less frequently in other malignant tissues, may also share some of the 
properties with the high-risk HPV types [96]. This is almost true with the 
anal cancers [97].  Sequence comparisons between high-risk and low-risk 
HPV types have consistently revealed a single amino acid sequence 
difference at residue 21, for example; Asp 21 in HPV16 E7 protein 
corresponds to a glycine residue in low-risk HPV6 E7 [98]. Consequently, 
given the level of intragenomic variability within an HPV type, single 
amino acid substitutions in low-risk HPV E7 proteins may promote 
features normally characteristic of high-risk HPV E7 oncoprotein [99].  
 
1.5. Viral particle and its genomic organisation 
HPVs are non-enveloped, small circular double-stranded DNA viruses 
with an icosahedrical capsid [100]. The capsid is made of 72 capsomers 
and it is approximately 55 nm in diameter [101]. 
 
The DNA of HPV is chromatin-like and covered by histones [86]. Virus 
particles contain a circular, double stranded, covalently closed DNA of 
about 8 kilo base pairs in length [101, 102] . The viral genome is organised 
into three general segments of unequal size (Figure 1-5) [89]. About 10% of 
the genome is contained within the long control region (LCR) and 
functions in the regulation of viral gene expression. The remainder of the 
genome is organized into early (E) or late (L) genes, encoded by 50% and 
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40% of the genome, respectively [103, 104]. All viral genes are encoded on 
one strand of DNA [105]. 
 
 
Figure 1-5: Genomic organisation of HPV 16 . 
 
1.6. Viral genes and proteins 
The genome is divided into three regions; the long control region (LCR) 
and the two open reading frames ORFs: the early (E) and the late (L) 
region [105]. The LCR is a non-coding region where the regulation of viral 
gene expression is controlled [95] . The early open reading frames (ORFs); 
(El, E2, E4, E5, E6 and E7) encodes for proteins involved in regulatory 
functions and  DNA replication [96], while the late ORFs (LI and L2) 
encodes for proteins that constitute the viral capsid [104] (Table 1-2). The 
early genes E3 and E8 are found in some papillomaviruses, but not in 
HPVs [106]. 
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Table 1-2 HPVs proteins [96]. 
 
Protein Size Interactions & functions Cellular location Expressed in 
Early (E) 
E1 68-85 kDa -DNA binding 
-ATPase and helicase activities 
-Initiation of viral replication 
Nucleus Basal and 
differentiating 
epithelial cells 
E2 43-48 kDa -DNA binding 
-Regulation of viral transcription and 
replication 
Nucleus Basal and 
differentiating 
epithelial cells 
E4 17-16 kDa -Interacts with keratin networks 
-Maturation and release of viral particles 
-Regulating gene expression, Gs arrest 
Cytoplasm Differentiating 
epithelial cells 
E5 44-91 aa -Interacts with EGF receptor Golgi apparatus, 
ER* and plasma 
membrane 
Differentiated 
epithelial cells 
E6 16-18 kDa -Interacts with E6-AP 
-Gene transcription 
-Prolonging of cellular lifespan 
-Up-regulation of telomerase activity 
Nuclear matrix Basal and 
differentiating 
epithelial cells 
E7 14-21kDa - Interacts with pRb proteins, cyclin A and E,
p21, p27and HDACs2 
- Induces cellular proliferation, 
- Immortalization and transformation 
Nucleus Basal and 
Differentiating 
epithelial cells 
Late (L)     
L1 55 kDa - Self-assembles into viral particles 
- Large capsid protein, 360 copies/viral particle 
Nucleus Terminally 
Differentiated 
epithelial cells 
L2 76-78kDa - Interacts with L1 and E2 
- Small capsid protein, 12 copies/viral particle 
Relocalizes L1 and E2 to PODs** 
Nucleus Terminally 
Differentiated 
epithelial cells 
 
*ER = endoplasmic reticulum, 2HDACs, histone deacetylases, ** = promyelocytic 
oncogenic domains (PODs). 
1.7. E1 protein of HPVs 
The El ORF is the largest and most highly conserved of all HPV ORFs 
and codes for a polycistronic RNA, which is translated into 68-85 kDa 
proteins [107]. The El protein is expressed at low levels in HPV positive 
cells and has site-specific DNA binding sequences that bind, weakly, to 
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the origin of replication and initiate DNA replication [86, 96]. DNA 
binding is stabilized by complex formation with the E2 protein [96] and 
once bound, El forms hexamers with high binding affinity for DNA 
[108]. Without El, there would be no viral DNA replication, since El is 
essential for its initiation [ 1 0 7 ] . A l s o ,  El is regulated through 
interactions with cyclin A and cyclin E by cyclin-dependent kinase-
mediated phosphorylation [107], resulting in inactivation of the El 
nuclear export sequence (NES), keeping El in the nucleus [109], where it 
can initiate viral DNA replication [102]. 
 
1.8. E2 Protein of HPVs 
The E2 ORF encodes for three proteins, which all act as transcription 
factors [86, 96]. These  proteins  have  a  DNA  binding  region  in  their  
C-terminal  and  regulate viral transcription and replication  by forming 
dimers at specific binding sites [100, 110]. The E2  proteins are essential 
for viral replication, since it directs El to its DNA binding sites and 
enhances the binding affinity of El to DNA [96, 107]. 
It has been suggested that El and E2 control the copy number of episomal 
HPV copies since the number of HPV copies increases when El or E2 
expression is increased [ 1 1 1 ] . The E2 ORF is frequently disrupted 
when the HPV genome is integrated. This leads to a more malignant 
phenotype as seen in cervical biopsies and cell lines derived from 
cervical cancer [112].  This phenomenon has been attributed to the loss 
of the E2 repression of the E6 and E7 transforming proteins [100, 113].  
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1.9.  E4 Protein of HPVs 
The E4 ORF is expressed in low amounts early in the life cycle of the 
virus, however, upon epithelial cell differentiation, the expression of 
E4 increases, and E4 is then the most highly expressed HPV protein 
[114]. The E4 ORF is translated from spliced transcripts together with 
the five first amino acids of El, resulting in an E1^E4 fusion protein, 
where the El sequence is used for initiation of translation [115]. E4 
proteins are exclusively found in the differentiating layer of the infected 
epithelium [86, 96] . High risk HPV E4 was suggested to be involved in 
facilitating release of viral particles [96], because E4 interacts with the 
keratin networks and causes their collapse. Furthermore, E4 may play a 
role in regulating gene expression, as it showed the ability to induce G2 
arrest in vitro in a variety of cell lines [96, 115]. 
 
1.10. E5 Protein of HPVs  
The E5 ORF encodes for a small highly hydrophobic membrane bound 
protein, which is lately expressed in the virus life cycle in differentiated 
epithelial cells [96, 116]. The E5 protein of high risk HPVs has weak 
transforming activities [96, 117], while the corresponding E5 protein in 
bovine papillomavirus (BPV) is the major transforming protein [118]. BPV 
E5 and HPV E5 do not share sequence homology and while BPV E5 acts 
through interactions with the platelet-derived growth factor (PDGF) 
receptor, the HPV E5 is proposed to interact with the epidermal growth 
factor (EGF) receptor [116, 118]. When HPV E5 is over expressed in the 
infected cells, it is generally accompanied by a considerable increased 
phosphorylation process of the EGF receptors [119]. 
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1.11. E6 protein of HPVs 
The HPV E6 protein is a r e l a t i v e l y  small polypeptides of 
approximately 150 amino acids and contain two zinc-finger motifs each 
of which consists of 2 CXXC sequences separated by 29 amino acids that 
each are related to the carboxyl terminal domain of E7 [120], whose 
integrity is essential for E6 function [121].  The E6 ORF e n codes for a 
basic protein,  w h i c h  has two zinc-binding motifs in the C- terminal 
[122]. The HPV E6 lacks any intrinsic enzymatic and specific DNA-
binding activities and functions by subverting host cellular protein 
complexes [123]. The E6 protein of high risk HPVs is classified as an 
oncoprotein and can transform human mammary cells [124, 125] and 
cooperate with E7 in transforming human cells [126]. E6 is expressed 
early after viral infection and facilitates viral production by inducing 
several cellular changes, and by prolonging of cellular lifespan through 
blocking of the cellular apoptosis pathway [96, 125]. HPV E6 interacts 
with a ubiquitin ligase and forms complexes with p53, which is then 
degraded through ubiquitin dependent mechanisms [127]. Moreover, E6 
can block translocation of p53 into the nucleus [128] and thereby 
inhibits the gene regulatory functions of p53 [128, 129]. The consequence 
of p53 degradation and blocking of p53 move into the nucleus is the  
disruption of p53 mediated cell cycle control, which means that the cell 
can continue to divide despite the DNA damage [96, 128]. 
 
The most studied biological activity of HPV16 E6 is the ability to associate 
with p53 and the ubiquitin ligase E6-AP, which leads to the ubiquitin-
mediated proteasomal degradation of the p53 tumour suppressor [130]. 
The p53 tumour suppressor senses cellular stress including aberrant S-
phase entry induced by expression of the HPV E7 oncoprotein. The 
activation of p53 results in transcriptional induction of abortive cellular 
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programmes such as G1 growth arrest and apoptosis, which have been 
collectively referred to as the trophic sentinel response [131]. Inactivation 
of p53 by the E6 protein presumably serves to abrogate this response, 
thereby allowing for persistent S-phase competence in differentiated cells 
[132]. HPV E6 expression also increases transcription of the catalytic 
subunit of telomerase, hTERT, which contributes to cellular 
immortalisation of primary human epithelial cell lines [133].  
 
High-risk HPV E6 proteins contain a short peptide sequence (S/T)-X-V-I-L 
at their carboxyl termini, which mediates association with cellular PDZ 
proteins [134]. The integrity of the PDZ binding sequence on E6 is 
important for the HPV viral life cycle , as well as the transforming 
activities of E6 [135].  Many PDZ proteins act as molecular scaffolds and 
regulate a number of important processes including cell polarity [136]. It is 
not clear whether high-risk HPV E6 proteins associate with one single 
PDZ protein or whether they can target multiple family members, since a 
number of different candidates have been reported [137]. Since PDZ 
protein and E6-AP binding on E6 are not mutually exclusive, E6-
associated PDZ proteins can be targeted for ubiquitination by E6-AP [138]. 
 
Many papillomaviruses E6 proteins associate with paxillin, and 
association with E6 leads to disruption of paxillin’s association with the 
focal adhesion proteins vinculin and focal adhesion kinase (FAK). This 
causes defects in the cellular actin cytoskeleton, as is typically observed in 
transformed cells [139].  
 
1.12. E7 Protein of HPVs 
The E7 ORF encodes for a 98 amino acid phosphoprotein that is actively 
transported to the nucleus, which has two zinc-binding motifs in the C-
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terminal half of the protein. These motifs are essential for proper 
protein folding and stability [100, 140]. The E7 protein has been detected 
in both the nucleus and the cytoplasm and shown to induce cellular 
proliferation, immortalization and transformation [111, 127, 141]. 
 
HPV16 E7 lacks any known intrinsic enzymatic activities and does not 
specifically associate with DNA sequences. Rather, it functions by 
associating with and functionally modifying host cellular regulatory 
protein complexes [142]. The high -risk HPV E7 can immortalize human 
cells, by interactions with factors involved in the control of the cell cycle 
[140, 143]. One of these interactions is with the proteins of the Rb 
family [113, 125] . Binding of E7 to pRb results in release of the E2F 
transcription factor,  which leads in turn  to the  activation of gene 
transcription factor p16INK4a  [114]. In addition, high risk HPV E7 
mediates degradation of pRb [144]. The Rb proteins play an essential 
role in cell cycle regulation promoting the transition from G1 into S-
phase. In normal cells, Rb is hypophosphorylated in early G1 and 
becomes increasingly phosphorylated towards S phase. In its 
hypophosphorylated form, Rb binds E2F transcription factors and 
actively represses transcription from promoters containing E2F sites [96]. 
By binding Rb in a hypophosphorylated state, E7 prevents it from 
binding to E2F and thereby promoting cell cycle progression [96, 145]. 
 
The ability of E7 to bind to pRb is shared between the high and low risk 
HPVs, although the interaction   between     high     risk     HPV     E7     
and     pRb     is     much     stronger [143] . Furthermore, E7 proteins also 
interact with the histone deacetylases (HDACs) which are normally 
recruited to the E2F inducible promoters by pRb and represses the E2F 
function [96, 125]. 
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Given its subcellular localization, HPV16 E7 has been shown to associate 
with nuclear as well as cytoplasmic cellular target proteins [142]. HPV16 
E7 shares sequence similarity to a small portion of conserved region 1 
(CR1), as well as the entire conserved region 2 (CR2) of the adenovirus 
(Ad) E1A oncoprotein [146]. The CR2 homology domain contains the pRB 
tumour suppressor core-binding site, LXCXE (L, leucine; C, lystein; E, 
glutamic acid; X, any amino acid residue), as well as a casein kinase II 
phosphorylation site [140]. The carboxyl terminus consists of two CXXG 
motifs separated by a 29 amino acid spacer region that forms a novel zinc 
binding structure [140]. Unlike Ad E1A and SV40, which target pRb 
through a stoichiometric mechanism, HPV16 E7 inactivates this tumour 
suppressor protein through ubiquitin-mediated proteasomal degradation, 
and sequences within the HPV16 E7 CR1 homology domain that do not 
contribute to pRb binding are necessary for this activity [134, 140, 147]. 
These HPV16 E7 sequences serve as a binding site for a cullin 2 containing 
ubiquitin ligase complex, which contribute to pRb degradation [146]. In 
addition, the CR1 homology domain also contains a binding site for the N-
end rule ubiquitin ligase p600 [148], which appears to play an important 
role in regulating aniokis, a form of apoptosis that is induced upon 
detachment of cells from a substratum [149]. The carboxyl terminus of 
HPV16 E7 contains additional sequences that are necessary for 
transformation [147]. While a large number of putative cellular targets, 
including histone-modifying enzymes that bind to carboxyl terminal 
sequences have been identified, it is not clear which of these interactions, 
if any, contribute to cellular transformation [150].  
 
HPV16 E7 has been shown also to associate with pyruvate kinase, and 
modulate the activity of alpha glycosidase and induce a metabolic switch 
from oxidative phosphorylation to glycosis [151]. In addition, HPV 16 E7 
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expression causes aberrant activation of the survival kinase AKT in 
differentiating keratinocytes, which has been linked to increased cell 
motility [152]. In addition, HPV16 E7 has been shown to cooperate with E6 
to induce expression of proteins that modules angiogenesis [147].  
 
1.13. L1 Protein of the HPVs 
The LI ORF is highly conserved between different HPV types [103, 104]. 
It e n codes for the major capsid protein, which is present in 360 copies 
per virion [96]. The LI protein self assembles into pentamers [153], 
which are the building blocks of the viral capsid and they can also 
self- assemble into virus-like particles (VLP) [102]. 
 
1.14. L2 Protein of the HPVs 
The L2 ORF encodes for the minor capsid protein,  which is present in 
around 12 copies per virion [154]. The L2 protein is highly 
phosphorylated and it is required for encapsidation of viral DNA into 
the capsid, and it   acts through relocalization of the LI protein to sub-
nuclear domains called promyelocytic oncogenic domains (PODs) [155]. 
In addition, the L2 protein also guides the E2 protein to the PODs and 
thus helps viral assembly and viral genome packaging [155]. Together 
L2 and LI proteins can self-assemble into VLPs [156]. 
1.15. Human papilloma viruses (HPVs) life cycle 
HPVs comprise a large and diverse group of viruses with over than 100 
subtype [85]. HPVs infect epithelial cells and all require terminal 
differentiation of the host infected cells to produce infectious virions [89]. 
For an active infection to occur, HPVs must gain access to the stem cells 
of basal layer of the epithelium through an abrasion or micro-wounds 
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[151]. For example, HPV types 1 and 2 need access to the stem cells 
of the cutaneousbasal epithelium, while types 6 and 16 should have 
access to the stem cells of the mucosal basal epithelium [89, 102, 157]. 
The virus then enters the host cell through i n  a mechanism that is not 
fully understood, but probably involves initial binding to heparin sulphate 
on the cell surface followed by receptor binding and viral uptake, although there 
is controversy regarding the identity of the virus receptor [102].  Following 
viral uncoating and transport to the nucleus, an initial surge of 
replication brings the viral genome to a copy number of between  50 to 
100 per cell as this copy number is type dependent [89, 151]. The viral 
genomes are maintained episomally at these low copy numbers in the 
nuclei of infected cells for a  long period, which may last for decades in 
the basal epithelium [151, 158]. During that period, the virus replicates in 
synchrony with the S-phase of the host cell [89, 90, 151]. 
However, the productive phase of the viral life cycle, which includes HPV 
genome amplification, production of capsid proteins, and packaging of 
newly synthesized genomes, occurs exclusively in the terminally 
differentiated cells where they can remain infectious over extended 
period [159].  
HPVs encode two proteins, E1 and E2, which directly contribute to the 
viral genome replication [160]. The E1 origin-binding protein is the only 
virally encoded enzyme and has intrinsic ATPase and helicase activities 
[108]. E1 forms a complex with the E2 protein, the major HPV-encoded 
transcriptional regulatory protein [161]. E2 binds with high affinity to 
specific DNA sequence AGCN6GGT in the viral regulatory region, 
whereas E1 binds to the AT-rich replication origin sequences with 
relatively low affinity [162]. The origin sequence is often flanked by E2 
binding sites resulting in high affinity binding of the E1/E2 complex to 
the origin of replication [163].  
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Viral gene expression is controlled by the long control region (LCR), 
which contains viral promoter and enhancer sequences and the origin 
of replication. The LCR is also commonly called the upstream regulatory 
region (URR) or the non-coding region (NCR) [86, 100]. The complex 
regulation of viral gene expression is controlled by both cellular and 
viral transcription factors [86, 100].  Examples of cellular transcription 
factors that bind to the LCR are NF-1, AP-1. Oct-1, TEF-1, TEF-2, SP-1 
and YY-1 [85, 86, 164]. Dysregulation of these transcription factors 
seems to be of importance for t h e  carcinogenesis process in HPV-
induced lesions [ 8 6 ] .  
 
The regulation of viral gene expression is a complex multifactorial 
process, which involves both viral and host factors [85]. In  the  basal  
cells  of  the  squamous  epithelium low  levels  of  early transcripts (E6, 
E7, E5, El and E2) are detected [107]. These transcripts are initiated at the 
early promoter, located upstream of the E6 ORF, in the LCR [165].  
 
With the exception of the E1/E2 origin-binding complex, HPVs do not 
encode enzymes that are necessary for viral genome replication and co-
opt the host DNA synthesis machinery [89]. It requires the cellular DNA 
machinery including DNA polymerase α/primase, DNA polymerase δ, 
replication protein A, PCNA and topoisomerases [109]. Because high-
copy number HPV genome replication and viral progeny synthesis is 
limited to terminally differentiated  cells, which are growth arrested and 
incompetent for DNA replication, a major challenge for the viral life cycle 
is to  re-establish and sustain a replication environment in these cells [90, 
96, 150]. To achieve that task, the HPV E7 protein acts to induce and 
maintain of S-shape competence in differentiating epithelial cells through 
a variety of mechanisms [150]. The most important of the latter is when 
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the HPV E7 proteins bind to the retinoblastoma tumour suppressor 
protein pRb and the related p107 and p130 pocket proteins [166]. These 
proteins have been involved in regulating the G1/S phase transition 
through the E2F transcription factors [167]. The G1 specific pRb/E2F 
complex is a transcriptional repressor that inhibits the S-phase entry[168]. 
In normal cells, pRb is phosphorylated by cycling/CDK complexes in late 
G1, the pRb/E2F complex dissociates, and DNA-bound E2Fs act as 
transcriptional activators [169]. The pRb/E2F re-forms when pRb is 
dephosphorylated at the end of mitosis [168]. This regulatory loop is 
subverted by HPV E7 proteins, which can associate with pRB and 
abrogates the inhibitory activity of pRb/E2F complexes [170]. E7 proteins 
encoded by the low-risk HPV associate with pRb in a lower affinity than 
high-risk HPV E7 proteins [171]. Additionally, high-risk HPV E7 proteins 
induce proteasome-mediated degradation of pRb [126]. Moreover, E7 
protein abrogate the action of Cyclin-dependent kinase inhibitors (CKIs) 
p21(Cip1) and p27(Kip1), which regulate cell cycle withdrawal during 
epithelial cell differentiation, thereby uncoupling epithelial cell 
differentiation  and cell cycle withdrawal [172]. This leads to the 
formation of hyperplastic lesions, warts and is necessary for the 
production of progeny virus [173].   
 
In addition, HPV E6 interacts with a ubiquitin ligase called E6-AP, which 
forms complexes with p53. This leads to rapid degradation of the p53 
protein. In these conditions p53 mediated cell cycle control is disturbed 
and the cell continues to divide in spite of DNA damage [174]. HPVE6 
also confers prolonged life span by up- regulation of the telomerase 
activity [175] (Figure 1-6) [111]. 
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Figure 1-6: HPV16 life cycle in cervical cancer.  
1.16. Viral Characteristics 
The HPV viruses are present in a latent form in proliferating cells, while 
the productive large-scale viral DNA replication, translation and the  
functional activities of the late proteins as well as the  viral assembly are 
restricted to the differentiating layers of skin and mucosa [86]. 
 
In mucosal HPV-associated tumours, high-risk viral DNA occurs in the 
tumour cell at a minimum of one viral copy per cell genome, is 
transcriptionally active, and is often, although not always, integrated 
[176]. However, in cervical cancers, a proportion of the cancers have only 
episomal HPV-DNA [177], and in skin cancer associated with 
epidermodysplasia verruciformis, the HPV genome remains episomal 
[178]. In very rare instances, such as squamous cell carcinomas in 
individuals with recurrent respiratory papillomatosis, low-risk HPV 
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types 6 and 11 may be found in tumours [176]. Thus, in cancers 
hypothesized to be associated with mucosal HPV, it might be expected 
that the genome of high-risk HPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
55, 56, 58, 59, 68, 73, 82, and 83) to be localized in tumour cell nuclei and 
to express viral oncogenes [88]. The presence of the viral genome in a 
variety of diseases, starting from premalignant lesions to carcinoma in 
situ, invasive disease, and metastatic cells, might hint to the importance 
of the virus in the initial promotion and maintenance of different 
malignant phenotypes [176]. 
 
The one-to-one tumour cell–virus relationship may not hold for all 
papillomavirus-associated tumours. For instance, in bovine alimentary 
tract cancers associated with bracken exposure and bovine 
papillomavirus type 4 (BPV-4) infections, the viral genome is lost from 
the tumour cells but is present in the benign papillomas from which they 
arise [176]. Although the hit-and-run role in genital HPV types in human 
tumours still controversial, it has been hypothesized for skin cancers [176, 
179]. Investigating this possible mechanism in humans would be difficult, 
since it would require an exhaustive search for the virus in premalignant 
lesions that are often subclinical [176, 179]. Such a hit-and-run role for the 
virus can  be suggestible when there is a strong association, after 
adjustment for possible confounding factors, between HPV L1 
seroreactivity and cancer risk in the absence of detectable HPV-DNA in 
tumours [176, 179]. There are as yet no consistent reports of such an 
association in the literature [180]. 
 
Detection of the genomic DNA by highly sensitive polymerase chain 
reaction (PCR) techniques alone is insufficient evidence for the presence 
of pathogenically significant virus [176]. However, a detailed study of a 
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single tumour can provide compelling preliminary evidence for the HPV 
aetiology of that tumour type such as testing the pathological effects of 
the virus on the apoptosis pathway in host genome [181].  
 
1.17. The role of HPV oncoprotiens in inducing genomic instability  
HPV- related cancers generally develop years or decades after the initial 
infection, and these tumours have suffered a multitude of genomic 
aberrations [182]. The acquisition of some of these genomic aberrations 
appears to define certain stages of disease progression [183]. The action of 
the high-risk HPV E6 and E7 oncoproteins on telomerase activity and the 
p53 and pRb tumour suppressors are sufficient to lead to extended 
uncontrolled proliferation and cellular immortalisation, but acquisition of 
additional host genome mutations is necessary for malignant progression 
[184]. A defining biological activity of high-risk HPV E6/E7 proteins is 
their ability to subvert genomic integrity [185]. Hence, high risk HPV 
E6/E7 oncoprotiens not only contribute to initiation but also play a key 
role in malignant progression [186].  
There are two principal mechanisms that lead to genomic instability; 
Subversion of cell cycle checkpoint mechanisms and DNA repair 
pathways can lead to perpetuation of mutations induced by 
environmental triggers such as UV irradiation or exposure to chemical 
compounds that cause DNA damage [187]. Alternatively, genomic 
instability can be triggered by active mechanisms that cause genomic 
destabilisation, which have been collectively referred to as mutator 
phenotype [188]. Expression of HPV E6/E7 oncoprotiens causes genomic 
instability by both of these mechanisms [134].  
 
HPV16 E7 has activities of mitotic mutator and its expression in primary 
human epithelial cells causes several types of mitotic abnormalities [189]. 
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These include induction of supernumerary centrosomes, lagging 
chromosomes, and anaphase bridges [189]. Of these, induction of 
supernumerary centrosomes has been studied in detail [190]. Centrosome-
associated multipolar mitosis is histopathological hallmark of high-risk 
HPV-associated cervical lesions. HPV16 E7 induces centrosome 
abnormalities through multiple, cooperating pathways. HPV16 E7 
expression causes aberrant activation of CDK2 through several 
mechanisms, including E2F- mediated transcriptional activation of 
expression of the CDK2 catalytic subunits cyclins E and A as a 
consequence of pR/p107/p130 degradation and inactivation of the CDK2 
inhibitors p21CIP1 and p27KIP1 [191]. Induction of supernumerary 
centrosomes by HPV16 E7 is strictly dependent on CDK2 activity [192]. In 
addition, HPV16 E7 associates with the centrosomal regulatory protein 
gamma-tubulin and inhibits its loading on centrosomes [192, 193]. 
Consequently, the process of centrosome duplication is uncoupled from 
the cell division cycle; result in the synthesis of multiple daughter 
centrioles from a single maternal centriole template [140]. Whereas 
expression of HPV16 in primary cells effectively induce centrosome 
overduplication, E6 co-expression is necessary for induction of multipolar 
mitoses [194].  
 
HPV16 E7 expression also causes a higher incidence of DNA double 
strand breaks, which can lead to breakage of fusion bridge cycles and 
chromosomal translocations [150, 194]. Specific recurrent chromosomal 
translocations are well documented drivers of haematological 
malignancies and, more recently, similar translocations have also been 
documented to contribute to the genesis of human solid tumours [195]. 
Chromosomal translocations are regularly detected in cervical cancer 
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specimens. The mechanistic basis of the formation of mitosis with lagging 
chromosomal material still awaits full investigation [196].  
 
The ability of the HPV16 E6 protein to contribute to genomic 
destabilisation is to large part based on its ability to inactivate the p53 
tumour suppressor. Therefore, the DNA damage-induced G1/S check-
point is non-functional, and HPV16 E6-expressing cells also exhibit mitotic 
checkpoints defects [150]. HPV16 E6-mediated p53 degradation also 
causes subversion of a post mitotic checkpoint that is specifically triggered 
in cells when they re-enter a G1-like state after a failed mitosis [197]. Such 
cells have a tetraploid rather than the normal diploid set of chromosomes 
and contain two centrosomes rather than one. Cells with p53 defects will 
disregard this checkpoint, re-enter S-phase, and may eventually undergo 
tetrapolar mitosis, which can lead to generation of aneuploidy progeny. 
Consistent with this model, HPV16 E6 expression cells show marked 
nuclear abnormalities [130, 150, 189].  
 
In addition to passive mechanisms of cell cycle checkpoint subversion, 
HPV16 E6 may also contribute to genomic destabilisation through active 
mutator mechanisms. HPV16 E6 has been shown to associate with single-
stand DNA break repair protein XRCC1 and induce degradation of O6-
methylguanine-DNA methyltransferase, which also involved in single-
stand DNA break repair [198]. It has also been reported that HPV16 E6 
expression decreases the fidelity of DNA end joining [199]. Moreover, 
while HPV16 E6 expression does not induce centrosome over-duplication, 
it greatly increases the incidence of multipolar mitoses in cells that contain 
supernumerary centrosome due to HPV16 E7 expression [186, 187].  
 
49 
 
 
 
1.18. Molecular mechanisms of high-risk HPV-mediated cellular 
transformation in cervical cancer 
The transforming activities of high-risk HPVS reflect the necessity of the 
virus to establish and maintain a replication- competent cellular milieu in 
terminally differentiated cells [200]. Three high-risk HPV proteins E5, E6, 
and E7- have been shown to exhibit transforming activities in cellular and 
animal systems [150, 200]. However, only E6 and E7 are regularly 
expressed in cervical carcinoma where the HPV genome is frequently 
integrated into a host chromosome [134]. The integration event is relatively 
nonspecific with the host chromosome [143]. Integration frequently 
involves common fragile sites [201], and in some cases, HPVs integrate in 
the vicinity of cellular proto-oncogenes like c-myc [202]. However, 
integration of high-risk HPV genomes often causes disruption and 
sometimes deletion of the E2 ORF, which encodes a transcriptional 
repressor of E6/E7 expression [203]. Moreover, HPV16 E6/E7 mRNAs are 
more stable when expressed from integrated copies as compared to 
episomal HPV16 genomes. Thus, E6, E7 oncoprotein expression is 
deregulated in cervical carcinomas [123]. Ectopic expression of HPV E6 and 
E7 in primary human epithelial cells facilities immortalisation, and when 
high-risk E6/E7 expressing cells are grown under conditions where they 
can form multi-layered, skin-like structures, they can exhibit cellular 
abnormalities that are reminiscent of high-grade premalignant cervical 
lesions [204]. Nonetheless, low-passage high-risk HPV immortalised cells 
are non-tumourigenic in immune-deficient mice but can undergo full 
transformation upon prolonged passaging [205], or when additional 
oncogenes such as ras or fos are expressed [150]. As such, this mimics the 
situation in vivo, where high-risk HPV-associated cervical lesions progress 
to cervical cancer after long-term persistent infection [123, 150]. Cervical 
cancers show hallmarks of chromosomal instability and are generally 
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aneuploidy [182]. Cervical cancers that arise upon expression of HPV16 
E6/E7 in basal epithelia from keratin K14 promoter in transgenic animals 
require chronic treatment with low doses of oestrogen, further supporting 
the notion that additional genomic aberration are necessary for cancer 
development [206]. Nonetheless, high-risk HPV E6/E7 oncoprotein directly 
contribute to malignant progression through induction of genomic 
instability [185]. Moreover, persistent HPV E6/E7 expression is necessary 
for maintenance of the transformed phenotype of HPV positive cervical 
cancer lines [186].    
 
The polymorphism at codon 72, which encodes for arginine or proline, of 
the p53 tumour-suppressor gene, in cervical cancer cases has been 
discussed as a possible determinant for cervical cancer risk [207]. Also, it 
has been suggested that the arginine form at codon 72 of p53 was  more 
susceptible to E6-mediated degradation than the proline form in actively 
infected cells with high risk HPVs [208]. Furthermore, it has been found 
that cervical cancer patients who are homozygous for the arginine form at 
codon 72 were approximately sevenfold more susceptible to HPV-
associated tumourigenesis than heterozygotes [209].  
 
It has been found that the apoptosis index using in situ apoptosis TUNEL 
assay was low in normal epithelium of cervical cancer cases but increases 
with the grade of the tumour [210]. This contradicts completely with the 
results reported from the morphological criteria of apoptosis with H& E 
staining using light microscopy [211]. Therefore, it has been concluded 
that the in situ apoptosis TUNEL assay indices might be useful marker to 
follow up the development of cervical cancer cases [211].   
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1.19. HPVs infections and prostate cancer  
Almost 29 papers between 1990 until March 2010 have studied HPVs in 
prostate tissues using mainly southern blotting and/or PCR using six 
primers at most [212]. In nine papers HPVs have not been found either in 
BPH or PCa cases, whereas in the other 20 papers the detection rate 
ranged from 2% to 63% [212]. Most of the researches, which did not find 
HPVs infections in PCa and BPH cases, were conducted in Western 
Europe [212].  
 The hypothesis of HPVs infection involvement in prostate cancer 
development was controversial over many years when different 
researchers came up with different conclusions. For example;  Leiros GJ et 
al. (2005) could establish the presence of HPV infection in 41.5% cases of 
prostate cancer cases in 41 studied cases by using PCR technology [213]. 
However, May M et al. (2008) could not establish any correlation between 
the HPV infection and the biopsies from prostate cancer patients using 
PCR in 213 cases [214]. These differences may be attributed to the 
variations in the level of infections with HPVs among nations, in addition 
to the incompatibility the different sensitivities of the rigorous laboratory 
tests used by the researchers [212]. 
 
Transmission of anogenital HPV16 infections have been consistently 
associated with sexual contact and the prevalence of cervical HPV 
infections increases between the ages of 15 and 40 years especially among 
women with multiple sexual partners [86, 103, 215]. Modes of 
transmission of HPV infection to the prostate have not been fully 
understood. However, the direct physical continuity between the prostate 
and the urethra, as the latter is being known as a reservoir for infection by 
HPV, may possibly explain why HPV DNA has been reported in prostatic 
tissues. According to this HPV-infected cells shed from the urethra into 
52 
 
 
 
seminal fluid likely explain why HPV-DNA has been detected in normal 
prostatic tissues, benign prostatic hyperplasia, and prostate cancer in 
some studies [216, 217].  
 
Several small HPV studies of heterosexual partners have been 
published[218]. In a study comparing HPV status in the cervix and semen 
of heterosexual partners, Kyo et al. demonstrated that 75% of women 
whose male partners were HPV positive had HPV DNA in their cervix, 
while only 39% of the men whose partners were HPV positive carried 
HPV DNA in their semen[219]. Campion et al. examined HPV disease in 
women whose sexual partners had penile condyloma, and found that 76% 
of the women had genital HPV infections, including 36% with abnormal 
cervical cytology and 27.7% with cervical HPV DNA detected by 
hybridization [220]. 
Although few studies define correlates of genital HPV infections in men, 
consistently positive associations between HPV detection and measures of 
sexual history, including lifetime and recent number of sexual partners 
and sexual frequency, have been observed [221]. Conversely, circumcision 
has been consistently associated with reduced detection of HPV infection 
in men. In an international study, HPV prevalence was significantly lower 
among circumcised men [222]. Less consistently, condom use has been 
associated with reduced risk of HPV detection in men [221]. Most studies 
found no association between age and genital HPV prevalence in men 
[218]. 
1.20. Host response towards HPV infection 
There is no viremic phase in the pathogenesis of HPV infection in 
humans, so the infection is not widely disseminated in the body [176]. 
Therefore, HPV-associated malignancies would occur at anatomic sites of 
exposure by direct contact with the virus [223]. In other words, HPV-
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caused primary tumours would occur only at sites where the virus can 
enter the body such as the genital tract, skin, and aerodigestive tract. 
Tumours of the solid internal organs, such as the brain, the kidney, and 
the liver, are unlikely to be HPV related [85]. 
 
Papillomavirus infection does not usually provoke a prominent immune 
response. However, HPV infections are in most cases cleared after 18 to 
24 months of the exposure [224]. The underlying process of virus 
clearance is not fully understood yet, but the host immune system in 
general and the cytotoxic response namely is proposed to be involved 
[225]. The serum antibodies in humans against HPV are type specific and 
their levels remain stable over time, after few weeks of infection. 
Nonetheless, not all the HPV infection individuals will show 
seroconversion subsequently [226].  
 
Individuals who have been exposed to HPV with or without an 
associated cancer may have serum antibodies to the viral capsid proteins. 
These anticapsid antibodies can be detected in many normal individuals 
because HPV infections are so common [227]. However, serum antibodies 
to the viral E6 and E7 proteins are strongly associated with invasive 
cancer and are rarely can be detected in patients without cancer. High 
levels of E6 and E7 serum antibodies have a greater than 95%–99% 
specificity and about a 50% sensitivity in invasive cervical cancer cancers 
[85, 150, 228, 229].  
 
Antibodies to E6 and E7 are not biomarkers for cervical cancer risk and 
do not play a role in the pathogenesis of disease, but rather they provide 
specific immunologic evidence for transcription of the viral genome in 
patients [229]. The specificity of these antibodies to individuals with 
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invasive cancer is possibly due to presentation of the oncoproteins to the 
immune system during or after the process of microinvasion [225]. 
Because of the modest sensitivity of E6 and E7 antibodies, seroreactivity 
may have limited benefit as a diagnostic method for an individual case 
[230].  
 
1.21. HPV Infections risk factors  
Sexual behaviours associated with increased risk of developing cervical 
cancer are, in large part, surrogate routes for HPV exposure [231]. It is 
likely that the transmission of viral infection to non-genital sites occurs in 
the context of some sexual behaviours, such as oral–genital contact, or by 
autoinoculation from a genital infection [232]. Sexual behaviours known 
to be associated with HPV exposure include a high number of lifetime 
sexual partners, young age at first intercourse, and a history of sexually 
transmitted disease [233]. Although other mechanisms such as 
intrapartum transmission as well as transmission through nonsexual or 
noncoital sexual contact are possible, they are unlikely to be common 
mechanisms [234]. Interactions between sexual behaviours and other 
known risk factors for cancers at a particular site must be considered. For 
example, in the case of head and neck cancers, alcohol consumption and 
smoking use may confound analysis of sexual behaviour [235, 236]. 
 
Malignancies that are causally associated with viral infections would be 
increased in individuals with immunosuppression [237]. This increase is 
presumably due to antigen-specific restricted responsiveness in patients 
with disorders of cell-mediated immunity [238]. All of the tumours with 
established associations with HPV are known to occur at greater than 
expected rates in individuals who are immunosuppressed because of HIV 
or immunosuppression treatment [239, 240].  
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1.22. Latency of HPV infections 
It is estimated that HPV may be harboured in a latent phase for 20 years 
or longer, before manifesting as a precancerous lesion of the cervix. The 
latency period between persistent HPV infection and low-grade cervical 
dysplasia is 5 years on average, and between low-grade lesions and the 
development of invasive cancer is about 15 years [241]. This relatively 
long time to progression is partly responsible for the successful reduction 
in the incidence and mortality statistics for cervical cancers in 
industrialized nations depending on the  cervical smear testing as well as 
the HPV vaccination for young female adults [242]. 
Once infected with an oncogenic HPV type, patients with persistent HPV 
may remain at least intermittently capable of transmitting the disease to 
sexual partners throughout their lifetime [243].  
 
1.23. Prevention from HPV infections 
It has been widely accepted that using condoms can reduce, but do not 
negate, the risk of infections with HPVs [244]. Moreover, preclinical studies 
in mouse model suggest that the polysaccharide carrageenan greatly inhibit 
HPV transmission, whereas the spermicidal compound nonoxynol-9 
appears to increase HPV transmission [245].  
The first generation prophylactic HPV vaccines consist of recombinant 
HPV L1 proteins that self-assemble into virus-like particles [246]. Gardasil 
vaccine has been approved by FDA  to vaccinate girls and young women 
between9 to 26 years. It is a quadrivalent formulation of the most prevalent 
low-risk (HPV6 and HPV11) and high-risk HPVs (HPV16 and HPV 18) and 
it promises to be properly efficient in providing type-specific protection 
from new infections with these HPV types [247]. Since these prophylactic 
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vaccines lead to the development of humoral immune response, they are 
not predicted to affect potential HPV infections at the time of vaccination 
[246]. It is not clear yet whether other no-vaccine high-risk HPV types will 
become more prevalent as HPV 16 and HPV18 are to be eradicated from 
the biological pool [248].  
 
1.24. Hypothesis  
It may be hypothesized that infections with high-risk HPVs play a role in 
the prostate cancer pathogenesis, which might be analogous to that of the 
cervical cancer, with different incidence among nations or ethnic groups. 
In addition, the patients who are homozygous for the arginine form at 
codon 72 of the p53 gene are more common among prostate cancer 
patients whose prostate tissues are infected with high-risk HPVs. We 
attempt to test this hypothesis using a variety of morphologic, molecular, 
quantitative, and qualitative techniques. 
 
1.25. Aims of the research 
The main aim of this research is to examine if infections with HPVs are 
involved in prostate cancer pathogenesis. In addition, this study aims to 
find out the genotypes and viral load of any detected HPV infections 
within the prostate cancer and control groups from different ethnic 
backgrounds.  
 
Furthermore, this study aims to look for any link between the patients’ 
medical background (PSA tumour marker titration, age), tumour grading, 
and tumour staging with HPVs infections in the prostate cancer and 
control groups.  
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Moreover, this research aims to assess the status of Rb and P53 tumour 
suppressor genes along with the apoptosis index to evaluate the activity of 
the high-risk HPVs infections in the study and control groups. 
 
Finally, this research aims to investigate any association between Codon 
72 polymorphism of the p53 gene and high-risk HPV infections in prostate 
cancer cases.  
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CHAPTER 2:  MATERIALS AND METHODS 
 
2.1. STUDY AND CONTROL SAMPLES  
 
2.1.1. Introduction 
In this study, patients with various stages of prostate cancer were selected. 
These patients were compared with age-matched patients diagnosed with 
benign prostate hyperplasia conditions.  
2.1.2. Case selection 
Specimens from the Middle East population (Group I) were obtained from 
Sheikh Khalifa Medical City and Tawam Hospitals in the United Arab 
Emirates (UAE). These were histology specimens obtained by TURP, and 
trans-rectal ultrasound (TRUS) biopsy. Both hospitals treat UAE nationals 
only. Ethical approvals from the local research ethics committees at both 
hospitals were obtained formally. Prostate cancer archival tissues were 
sent to the tissue bank at Middlesex University in London. The other two 
groups of Caucasians (Group II) and Afro-Caribbean men (Group III) from 
the East London Region were selected from the prostate cancer database, 
which were available at the tissue bank at Middlesex University in 
London. Only those cases with sufficient relevant clinical information 
were included in the study. Ethical approval was obtained from the 
natural sciences ethics sub-committee at Middlesex University.   
The archival tissues from the three groups were then anonymised to avoid 
any bias during the research course.   
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2.1.3. The study (prostate cancer) population 
Prostate tissue samples from the UK population (n= 74 cases) were 
subdivided into Caucasians (Group II-PCa, n=43 cases) and Afro-Caribbean 
men (Group III-PCa, n=31 cases) along with the Middle East population 
(Group I-PCa, n=49 cases). The first two groups from the UK population 
were randomly selected from the prostate cancer database over a five-year 
period between 1997 and 2002. However, because of the low prevalence of 
prostate cancer in the UAE population, the period was expanded to ten 
years between 1990 and 2000. All the patients were selected using hospital 
records, and cancer registry data. Ethnicity of all the cases was determined 
from the clinical notes, death certificates and patient questionnaires and 
questionnaires to relatives of deceased patients. Standardized data were 
extracted from hospital records sent with the paraffin-embedded samples to 
the tissue bank at Middlesex University. These data covered the stage of the 
disease at presentation, investigations procedures, biochemical results, 
treatments, and follow up status of each individual case.  
 
2.1.4. Inclusion criteria in the study group  
Patients with prostate cancer from Caucasians, Afro-Caribbean men as well 
as from the Middle East region were included in the study, from whom 
archived tissues were available for research at the tissue bank at Middlesex 
University. 
 
2.1.5. Exclusion criteria from the study group 
Six cancer patients were excluded from the groups mentioned 
above due to lack of relevant clinical information. Finally, only 
the numbers mentioned above were included in the study.  
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2.1.6. The control population 
Similarly, prostate tissue samples from the three population groups were 
obtained from the same sources; Middle East (Group I-BPH, n=99 cases), 
Caucasian (Group II-BPH, n=77 cases) and Afro-Caribbean (Group III-
BPH n=91 cases). Cases were selected upon examining the histology 
specimens obtained by TURP.   
 
2.1.7. Inclusion criteria in the control group 
Patients with benign prostatic hyperplasia (BPH) proven by microscopic 
histopathological examination of  TURP specimens of Caucasians, Afro-
Caribbean and Middle Eastern patients were included in the study, from 
whom archived  tissues were available for research at the tissue bank at 
Middlesex University. 
 
2.1.8. Exclusion criteria  from the control group 
Patients from other ethnic groups and those with insufficient clinical 
information were excluded. 
 
2.1.9. Age of the patients at presentation  
The age distribution of patients ranged between 54 – 90 years (mean=71.5 
years) in Group I, between 48 – 88 years (mean=72.2 years) in Group II and 
between 54 – 90 years (mean=71.5 years) in Group III (Table 2-1).  
There was no significant difference between the three groups in terms of 
age at presentation (Middle East vs. Caucasians P = 0.3451, Middle East vs. 
Afro-Caribbean men P = 0.4765, Caucasians vs. Afro-Caribbean men P = 
0.9994). Therefore, the process of age normalisation of the study and control 
cases was not required in this study.   
61 
 
 
 
 
Table 2-1: Age distribution in the study and control population groups 
Age groups Group I 
PCa 
Group I 
BPH 
Group II 
PCa 
Group II 
BPH 
Group 
III 
PCa 
Group 
III 
BPH 
40-49 1 0 0 3  1 8 
50-59 3 11 0 8 14 23 
60-69 15 42 9 23 12 39 
70-79 16 26 25 30 3 13 
80-89 10 17 9 13 1 0 
90-99 4 3 0 0 0 8 
Group I = Middle East Population. 
Group II = Caucasians Population.  
Group III = Afro-Caribbean Population. 
 
2.1.10. Prostate cancer cases staging at presentation  
Prostate cancer staging have been extracted from the accompanying clinical 
information of each case in the study subgroup (Table 2-2).   
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Table 2-2: Prostate cancer staging in the three study subgroups 
Stage (TNM) 
No. of 
patients and 
Groups 
Organ-
confined 
disease 
T1-2N0M0 
Locally advanced 
disease 
T3-4N0/xM0 
Metastatic  
T2-4Nx/+M1 
 Group I 18 8 23 
 Group II 32 5 6 
 Group III 21 7 3 
Total 
number of 
cases  
71 20 32 
Group I = Middle East Population. 
Group II = Caucasians Population.  
Group III = Afro-Caribbean Population. 
 
2.1.11. Serum prostate specific antigen (PSA) values 
Serum PSA values were extracted from the clinical history of each 
individual patient in the study and control groups since presentation and 
towards the surgical procedure. The average of the PSA value between 
presentation and the surgical procedure has been taken as the PSA value 
for each case (Table 2-3). 
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Table 2-3: The median of PSA value in the study and control 
 
 
 
 
 
 
Group I = Middle East Population. 
Group II = Caucasians Population.  
Group III = Afro-Caribbean Population. 
 
There was a significant difference in the presenting PSA values in the 
control subgroups between the Caucasians and the Middle East 
population, being higher in the former (Middle East vs. Caucasians P = 
0.0116), while there was no significant difference between the other 
groups (Middle East vs. Afro-Caribbean men P =0.1446, Caucasians vs. 
Afro-Caribbean men P = 0.7849).  
 
On the other hand, there was a significant difference in the PSA values in 
the study subgroups between the Afro-Caribbean group, being highest 
(median: 12.7) and the Caucasians (median: 9.5) and then the Middle East 
population (median 6.3) (P = 0.0029 and P < 0.0001 respectively). While 
there was no significant difference between the latter two groups (II & III) 
(P = 0.8865).  
 
2.1.12. Specimen collection and storage 
The archived tissue samples in the form of paraffin blocks were 
obtained from the tissue bank at Middlesex University.   
 
Patients 
PSA 
(Median μg/L) 
 Group I Group II Group III 
PCa 6.6 9.5 8.7 
BPH 3.58 6.3 5.7 
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Samples were anonymised by allocating each sample with a randomly 
distributed research reference number (identifier). This particular 
number was then used for the relevant clinical data for each tissue. 
 
  
2.2. DNA EXTRACTION FROM PARAFFIN-EMBEDDED TISSUES 
 
2.2.1. Introduction  
Archival, formalin-fixed, paraffin-embedded tissue is an invaluable 
resource for molecular genetic studies. Extraction of nucleic acid from 
archival tissue allows retrospective analysis and correlation of clinical 
endpoints or histological appearance structures with molecular biological 
markers. 
Three steps are involved in the DNA extraction from paraffin-embedded 
tissues: deparaffinization this is achieved via dissolution of the wax in 
xylene and ethanol, digestion of the cellular proteins; this is performed by 
the use of certain proteinases, and purification of the produced genomic 
DNA [249, 250].  
 
2.2.2. Materials 
The following reagents have been used in all the DNA extractions 
experiments: 
 Chloroform 
 EDTA, 0.5 M 
 Ethanol, absolute 
 Isoamyl alcohol 
 Phenol 
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 Proteinase K 
 Sodium acetate, pH 5.2 
 TE Buffer (Tris-EDTA), pH 7.4 
 Xylene 
 
 
The following preparation formulas have been used to prepare the 
working solutions used in the DNA extraction experiments: 
 
A. Chloroform/Isoamyl alcohol 24:1  
 Chloroform 24 ml 
 Isoamyl alcohol 1 ml 
 
B. DNA extraction buffer 
 1.5 ml 5M NaCL 
 5.0 ml 0.5M EDTA 
 0.5 ml Tween 20 
 93 ml of sterile water 
 
C. Proteinase K (10 mg/ml) 
100 mg Proteinase K was dissolved in 10 ml TE for 30 min at room 
temperature (RT). The stock was divided in to aliquots and stored at –20°. 
 
2.2.3. Method 
In Day 1 on the DNA extraction experiments slices (20 µm) of formalin-
fixed and paraffin-embedded tumour samples are cut using microtome. 
Samples are then put in 2 ml Eppendorf collection tubes. Tissues were 
incubated in xylene at 45°C for 15 minutes allowing the wax to dissolve. 
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Samples were then centrifuged 10 min at 14,000 rpm. Resultant 
supernatant is pipetted off, leaving the wax in the bottom of the tube. The 
latter steps were repeated once more. Then 1 ml 100% ethanol added to 
tissue pellet, vortexed and then centrifuged for 10 min at 14,000 rpm, and 
supernatant pipetted off. 1 ml 90% ethanol added to tissue pellet, 
vortexed, centrifuged for 10 min at 14,000 rpm, and supernatant pipetted 
off. 
The same step was repeated, with 70% ethanol this time. The resultant 
pellet was then dried in speed vac. Pellet is resuspended in 400 µl of DNA 
extraction buffer. 40 µl of Proteinase K (10 mg/ml) was added, vortexed 
briefly, and incubated at 55°C overnight in order to get rid of the protein. 
In Day 2 of DNA extraction experiments 440 µl of phenol was added, and 
was shaken vigorously by hand for 5 min, and centrifuged for 5 min at 
8000 rpm. Supernatant pipetted into a new tube, a solution of 220µl phenol 
plus 220µl chloroform/isoamyl alcohol (24:1) was then added, and shaken 
vigorously by hand for 5 min, and centrifuged for 5 min at 8000 rpm. The 
aim was to get rid of the Phenol. Again, the supernatant was pipetted into 
a new tube, 440µl chloroform/isoamyl alcohol (24:1) was added, shaken 
vigorously by hand for 5 min, and centrifuged for 5 min at 8000 rpm, to 
get rid of chloroform/isoamyl alcohol. Then, the resultant supernatant 
pipetted into a new tube (2 ml Eppendorf tube), 1/10 volume of sodium 
acetate (pH 5.2) added. In addition, 3 volumes of ice-cold 100 % ethanol 
was added, and tube kept overnight at –20°C. 
By day 3 of the DNA extraction experiments the tubes were centrifuged 
for 30 min at 4°C and the supernatant was removed. The pellet was dried 
in speed vac. 20-50 µl sterile water was then added. Tubes were then 
shaken gently in thermo mixer at 37°C for 2 hours [249, 250]. 
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2.3. ISOLATION OF DNA FROM HeLa CULTURED CELL LINE 
 
2.3.1. Introduction 
A HeLa cell line (also Hela or hela cell line) is a cell type in an immortal 
cell line used in scientific research. It is one of the oldest and most 
commonly used human cell lines. The line was derived from cervical 
cancer cells taken on February 8, 1951 from Henrietta Lacks, a patient who 
eventually died of her cancer on October 4, 1951. The cell line was found 
to be positive for HPV18 [251]. 
 
2.3.2. Materials 
 HeLa  cell line sample in a culture flask. 
 Lyophilized QIAGEN protease (QIAGEN). 
 50 ml FlexiGene DNA Kit (QIAGEN). 
 Isopropanol (100%). 
 Water bath. 
 Centrifuge. 
 70% ethanol. 
 Sterile 0.5 ml Eppendorf tubes (Fisher). 
 
2.3.3. Method  
 
HeLa cells were grown in a monolayer and could be harvested by 
detaching the cells from the culture flask using a cell scraper. By using a 
cell scraper, the appropriate number of cells was transferred to a 1.5 ml 
microcentrifuge tube and centrifuged for 5 min at 300xg. The supernatant 
was removed completely with extra care not to disturb the pellet and 
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discard. 300μl buffer FG1 were added to the cell pellet and mixed by 
pipetting up and down until the cells were resuspended. 300μl Buffer 
FG2/QIAGEN Protease were added, and then the tube was closed and 
inverted few times. Afterwards, the tube was put in the water bath, and 
incubated at 65°C for 10 min. At this stage 600 μl isopropanol (100%) were 
added and mixed thoroughly by inversion until the DNA precipitate 
becomes visible as threads or a clump. Complete mixing with isopropanol 
is so vital to precipitate the DNA and must be checked by inspection. Then 
the tube was centrifuged for 3 min at 10,000xg, but if the resulting pellets 
were loose, centrifugation could be prolonged or a higher g-force could be 
used. 
The supernatant was discarded, and briefly, the tube was inverted onto a 
clean piece of absorbent paper, taking care that the pellet remains in the 
tube. Then 600μl 70% ethanol were added and vortexed for 5 seconds, 
followed by centrifuging for 3 min at 10,000 x g, but if the resulting pellet 
was loose, centrifugation could be prolonged or a higher g-force could be 
used. 
The supernatant was discarded and the tube was left inverted on a clean 
piece of absorbent paper for at least 5 min, with extra care that the pellet 
remained in the tube. In rare cases, the pellet may be loose, so pouring was 
done slowly and with extra care not to lose the pellet. Inverting the tube 
onto absorbent paper minimized backflow of ethanol from the rim and 
sides of the tube onto the pellet. 
The DNA pellet was air-dried until all the liquid was evaporated for at 
least 5 min but without over-drying the DNA pellet, since over-dried 
DNA is very difficult to dissolve. 200 μl buffer FG3 was added then to the 
tube, vortexed for 5 s at low speed. The DNA was dissolved by incubating 
for 30 min at 65° C in a water bath. Nevertheless, if the DNA was not 
completely dissolved, the incubation was prolonged until the DNA is 
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completely dissolved. With some cell samples, traces of the pellet that do 
not contain DNA may remain undissolved after 1 h incubation at 65°C. 
They could be removed by centrifuging for 1 min at 10,000xg, and 
transferring the supernatant into a fresh tube. If a reduced volume of 
Buffer FG3 was used, incubation time was to be prolonged. 
 
 
2.4. DNA QUANTIFICATION AND NORMALISATION 
 
2.4.1. Introduction 
The Spectrophotometer is a useful tool in the laboratory for determining 
the quality and quantity of the DNA samples. The sample can be analyzed 
by passing various sized ultraviolet (UV) wavelengths through it. DNA 
samples are commonly scanned at wavelengths of 260 nm, 280 nm, 320 
nm, and 234 nm. DNA absorbs UV light at a maximum of 260 nm and a 
minimum of 234 nm. Absorbance at 320 nm may indicate a dirty cuvette 
or particulates in the sample [252].  
 
2.4.2. Materials 
 UV-3600 UV-Vis-NIR Spectrophotometer (Shimadzu). 
 DNA samples. 
 Microcentrifuge tubes.  
 Sterile water. 
 TE buffer. 
 Quartz Cuvette for UV-3600 UV-Vis-NIR Spectrophotometer 
(Shimadzu). 
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 Kimberly Clarke wipes. 
 
2.4.3. Method 
The quartz cuvette of spectrophotometer required at least 100 µl of liquid to 
cover the windows. Smooth sides of the cuvette were not touched at all 
times as any smudges on the windows could result in distorted readings. 
The cuvette was handled on the frosted sides only. To clean the quartz 
cuvette 100 µl of distilled water were added to the cuvette, and then the 
cuvette was emptied into a liquid waste beaker and carefully shaken to 
empty all water droplets from it, and then dried from the outside and the 
smooth sides with a Kimberly Clarke wipe. 
The first step to set up the Shimadzu of the spectrophotometer  software to 
read and record wavelengths was clicking on the Shimadzu icon on the 
computer screen connected to the spectrophotometer, then the system was 
zeroed preparedby clicking on the “Zero” button on the left side of the 
screen with the sample compartment empty and the door closed. Then 
“Setup” was clicked on the left side of the screen, then “Read at 
Wavelength” was chosen, and from the active drop menu, the desired 
wavelength was selected. Finally, Ok was clicked when the set up was 
completed.  
In a properly sized tube (i.e. microcentrifuge tube or 1.5 ml tube), the desired 
amount of the sample to be analysed was added. The desired dilution was 
obtained by adding the needed amount of TE buffer. With the cap of the 
tube on, the content was mix with a vortex for up to 1 minute. The 
spectrophotometer was zeroed then by pressing the “Zero” button to the left 
of the screen while the sample compartment is empty and the door is 
closed. After that 200 µl of the prepared sample were added to a quartz 
cuvette. 
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 Then, the quartz cuvette was placed in the square, black sample 
compartment in a way that the frosted sides will be facing the front and 
back, and the small windows will be facing the left and right. The 
spectrophotometer door was closed then and the “Read” icon on the 
software was clicked to obtain the reading wavelength value for the 
parameters set up. The same reading wavelengths procedure for any 
remaining samples were repeated for all the samples to be tested, so each 
subsequent sample will be added to the current page, making a list of data 
on the software.  
The following calculation formulas have been used:  
 
Concentration Formulas  
 
 
Purity Formulas 
 
 
Since both DNA absorb UV light maximally at 260 nm, the A260 value 
generated from the simple reads report is used. When the concentration of 
DNA is 50µl/ml, the absorbance reading is 1.0. When the concentration of 
RNA or single-stranded DNA is 40µl/ml, the absorbance reading is 1.0. To 
determine the concentration of the sample the already mentioned formula 
was used. 
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Calculating ratios such as the A260:A280 ratio and the A234:A260 ratio can 
be used to determine the purity of a sample of DNA. The A260:A280 ratio 
of DNA indicates protein or RNA contamination. This value should be 
between 1.8 and 1.9. A high A260:A280 ratio may be caused by RNA 
contamination while a lower ratio can be caused by protein contamination.   
The A234:A260 ratio is used to determine the presence of protein or phenol 
contamination. A sample contaminated with protein or phenol has a ratio 
greater than 0.50. The absorbency values can be found on the Simple Reads 
Report generated from the above procedure. To determine the above ratios 
the already mentioned formula for calculating the purity was used.  
The A320 reading was used to determine the presence of particulates in the 
sample or a dirty cuvette. If either exists, the reading may be skewed. The 
A320 value should be less than 5% of the A260 value. The already 
mentioned purity calculation formula was used to ensure readings are 
accurate. The final genomic DNA concentration has been normalised in all 
the study and control samples to be 100 ng/25 µl final PCR reaction. This 
could be done by diluting the extracted DNA if the DNA concentration was 
found over 100  ng/µl. When the DNA concentration found to be less than 
100 ng/µl, the starting DNA normalisation could be applied by adding 
sufficient amount of DNA sample to the PCR reaction to maintain the 
required concentration of the starting DNA in the PCR reaction. In the latter 
cases, the amount of the PCR graded water have been corrected before 
being added  to the final PCR reaction in line with the additional amount of 
DNA samples added to the reaction.   
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2.5. POLYMERASE CHAN REACTION (PCR) 
 
2.5.1. Introduction 
PCR is a method for amplifying a DNA base sequence using a heat-stable 
polymerase and two specific primers, one complementary to the (+ve)-
strand at one end of the sequence to be amplified and the other 
complementary to the (-ve)-strand at the other end. Because the newly 
synthesized DNA strands can subsequently serve as additional templates 
for the same primer sequences, successive rounds of primer annealing, 
strand elongation and dissociation produce rapid and highly specific 
amplification of the desired sequence. 
PCR, as currently practiced, requires several basic components. These 
components are as follows; DNA template, which contains the region of 
the DNA fragment to be amplified, in addition to two primers, which 
determine the beginning and end of the region to be amplified. Also, Taq 
polymerase (or another durable polymerase), which is DNA polymerase is 
required. This polymerase copies the region to be amplified. Moreover, 
deoxynucleotides-triphosphate is needed, from which the DNA 
polymerase builds the new DNA. Finally, a buffer is required, which 
provides a suitable chemical environment for the DNA polymerase.  
The PCR process is carried out in a thermal cycler, which is a machine that 
heats and cools the reaction tubes within it to the precise temperature 
required for each step of the reaction. To prevent evaporation of the 
reaction mixture (typically volumes between 15-100µl per tube), a heated 
lid is placed on top of the reaction tubes or a layer of oil is put on the 
surface of the reaction mixture. 
The DNA fragment to be amplified is determined by selecting primers. 
Primers are short, artificial DNA strands — often not more than 50 and 
usually only 18 to 25 base pairs long — that are complementary to the 
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beginning or the end of the DNA fragment to be amplified. They anneal 
by adhering to the DNA template at these starting and ending points, 
where the DNA polymerase binds and begins the synthesis of the new 
DNA strand. 
The choice of the length of the primers and their melting temperature (Tm) 
depends on a number of considerations. The melting temperature of a 
primer - not to be confused with the melting temperature of the template 
DNA - is defined as the temperature at which half of the primer binding 
sites are occupied. Primers, which are too short, would anneal at several 
positions on a long DNA template. This would result in non-specific 
copies. On the other hand, the length of a primer is limited by the 
maximum temperature allowed to be applied in order to melt it, as 
melting temperature increases with the length of the primer. Melting 
temperatures that are too high, i.e., above 80°C, can cause problems since 
the DNA polymerase is less active at such temperatures. The optimum 
length of a primer is generally from 15 to 40 nucleotides with a melting 
temperature between 55°C and 65°C [253]. 
2.5.2. Materials  
 Techne 3 Prime Thermal Cycler (Techne). 
 Sterile PCR tubes (ABgene). 
The PCR mix has been prepared as follows: 
 2.0μl of DNA. 
 2.5μl of MgCl2 (25mM). 
 2.5μl of 10X buffer (75mM Tris-HCl pH 8.8, 20mM 
(NH4)2SO4). 
 0.3μl of dNTPs (300μM of each of the dNTPs: dATP, 
dGTP, dCTP, dTTP) (ABgene). 
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 2.0μl of primers (forward and reverse: 2.5 pmol each) 
 0.2μl of Taq polymerase 5 units/μl (ABgene) 
 15.5μl of H2O 
 
2.5.3. Method 
In this research three primer sets have been used to detect the HPV 
infections in the extracted genomic DNA (Table 2-4); GP5+/GP6+ 
consensus primers [254], and MY09/11 degenerate primers [255] , in 
addition to broad-spectrum multiplex PCR primer set SPF1/2 [256]. These 
three PCR assays were designed to amplify distinct highly conserved L1 
ORF regions of the HPV genome with different amplimer sizes (Figure 2-
1) [256].  
The samples were screened for the presence of HPV using the standard 
nested PCR approach, consisting of the MY09/11 degenerate primer set as 
outer primers and the GP5+/GP6+ consensus primer set as inner primers. 
This nested PCR method has been collectively called MY/GP [257]. 
 
 
The Degenerate primers may be used to amplify DNA in situations where 
only the protein sequence of a gene is known, or where the aim is to 
isolate similar genes from a variety of species. A six or seven residue 
peptide sequence should be selected, corresponding to an oligo of about 
20 nucleotides. If the oligo is designed to amplify several similar protein 
sequences, then the most conserved regions of the proteins need to be 
selected. If some of the residues are not completely conserved, then the 
oligo sequence will need to accommodate all possible codons of all amino 
acid residues at that site. The peptide sequence should avoid amino acids 
that have a lot of codons, such as leucine (L), arginine (R), and serine (S). 
Instead, aim for regions that are rich in amino acids that have only one or 
76 
 
 
 
two possible codons (i.e. M, W, C, D, E, F, H, K, N, Q, Y). Inosine residues 
can pair with any nucleotide, and so can be used at sites where there is 
complete degeneracy. This reduces the number of oligos that have to be 
synthesised [258, 259]. 
 
Table 2-4: The design of MY 09/11 and  GP5+/GP6+  primer sets, as well as 
SPF1/2 cocktail of six primers .  
*Degenerate primers MixBase codes definition  
R= A, G 
Y= C, T 
M= A, C 
W= A, T 
** bio= biotinylated  
Primer 
Designations  
Sequence 5' → 3' Amplimer 
Size 
MY09* 5'-CGTCCMARRGGAWACTGATC-3' 450 bp 
MY11* 5'-GCMCAGGGWCATAAYAATGG-3' 450 bp 
GP5+ 5'-TTTGTTACTGTGGTAGATACTAC-3' 150 bp 
GP6+ 5'-GAAAAATAAACTGTAAATCATATTC-3' 150 bp 
SPF1A 5'-GCiCAGGGiCACAATAATGG-3' 65 bp 
SPF1B 5'-GCiCAGGGiCATAACAATGG-3' 65 bp 
SPF1C 5'-GCiCAGGGiCATAATAATGG-3' 65 bp 
SPF1D 5'-GCiCAAGGiCATAATAATGG-3' 65 bp 
SPF2B-bio** 5'-GTiGTATCiACAACAGTAACAAA-3' 65 bp 
SPF2D-bio** 5'-GTiGTATCiACTACAGTAACAAA-3' 65 bp 
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Figure 2-1: Primer targets of the HPV primer sets and their amplimer size  .  
 
Housekeeping genes primers were selected to check the integrity of DNA 
as internal control. So to exclude false-negative results, the adequacy of 
each  DNA sample was confirmed before any PCR assay to detect HPV 
DNA in each case by β-globin (110 bp) PCR assay using PCO3 primer 5'-
ACACAACTGTGTTCACTAGC-3' and PCO4  primer 5'-
CAACTTCATCCACGTTCACC-3'.  
 
All DNA samples extracted from the paraffin embedded tissues of study 
and control groups have been tested by PCR with each of the three sets of 
primers, in addition to the nested PCR method, separately. 
Positive and negative controls have been included in all the experiments. 
Extracted genomic DNA preparations from HeLa cell lines (containing 
HPV18) were used as positive controls. PCR grade deionized purified 
water was used instead of the DNA template as a negative control in each 
experiment. The starting DNA concentrations have been normalised 
among to be  100ng/μl in all the samples before all the PCR assays using 
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standard spectrophotometry and dilution method with PCR grade 
deionized purified water.  
For a 25 μl PCR run the following amounts were used: 1 μl of 100ng/μl 
DNA in addition to 1ul of each primer at 3.2 pmole/μl concentration or 
1.25 μl of each primer at 100ng/μl concentration. Also, 2.5 μl 10x PCR 
buffer (1.5mM) plus 0.5 μl 25mM MgCl2, 0.5 μl dNTP and 0.125 μl of 5 
unit/μl Taq. Finally, 18.37μl sterile water to equal a 25μl run was added.  
All the reagents were kept on ice, and the Taq was added at last, and was 
kept in the freezer until it was needed during the course of the preparation 
of the PCR experiment. The content of the PCR test tube was vortexed 
briefly and quickly spinned before starting the PCR machine. 
The optimised PCR conditions using MY09/11 degenerate primer set were 
5 minutes at 94°C for initial denaturation, 40 cycles of denaturation at 94° 
C for 1 minute, annealing at 54° C for 1 minute, elongation at 72° C for 1 
minute, and a final elongation step at 72° C for 6 minutes. In addition,  
GP5+/GP6+ primer set optimised protocol was 40 cycles included a 1 
minute denaturation step at 94 °C, an annealing step to 40 °C for 2 minutes 
and a chain elongation step to 72 °C for 5 minutes. The first cycle was 
preceded by a 4 minutes denaturation at 94 °C and the last cycle was 
extended by a 4 minutes elongation at 72 °C. Finally, the optimised 
conditions for multiplex PCR using SPF1/2 cocktail of primers were 
preheating step for 3 minutes at 94°C, which was followed by 40 cycles of 
1 minute denaturation step at 94°C, 1 minute for the annealing step at 
45°C, and a chain elongation step for 1 minute at 72°C and a final 
extension of 5 minutes at 72°C.  
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2.6. AGAROSE GEL ELECTROPHORESIS  
 
2.6.1. Introduction 
Gel electrophoresis is a widely used technique for the analysis of nucleic 
acids and proteins. Most every molecular biology research laboratory 
routinely uses agarose gel electrophoresis for the preparation and analysis 
of DNA. Agarose gel electrophoresis was used in this research to 
determine the presence and size of PCR products. 
Electrophoresis is a method of separating substances based on the rate of 
movement while under the influence of an electric field. Agarose is a 
polysaccharide purified from seaweed. An agarose gel is created by 
suspending dry agarose in a buffer solution, boiling until the solution 
becomes clear, and then pouring it into a casting tray and allowing it to 
cool. The result is a flexible gelatin-like slab. During electrophoresis, the 
gel is submersed in a chamber containing a buffer solution and a positive 
and negative electrode. The DNA to be analyzed is forced through the 
pores of the gel by the electrical current. Under an electrical field, DNA 
will move to the positive electrode and away from the negative electrode 
because of the ntural negative charge of the genomic DNA. 
Several factors influence how fast the DNA moves, including; the strength 
of the electrical field, the concentration of agarose in the gel and most 
importantly, the size of the DNA molecules. Smaller DNA molecules 
move through the agarose faster than larger molecules. DNA itself is not 
visible within an agarose gel. The DNA will be visualized by the use of the 
loading dye that binds to DNA. 
The purpose of the gel electrophoresis experiment is to determine the 
presence or absence of PCR products and quantify the size of the DNA 
molecule in the PCR product. 
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TBE or Tris/Borate/EDTA, is a buffer solution containing a mixture of 
Tris base, boric acid and EDTA. In molecular biology, TBE buffer is often 
used in procedures involving nucleic acids including electrophoresis. Tris-
acid solutions are effective buffers for slightly basic conditions, which 
keep DNA deprotonated and soluble in water. EDTA is a chelator of 
divalent cations, particularly of magnesium (Mg2+). As these ions are 
necessary co-factors for many enzymes, including contaminant nucleases, 
the role of the EDTA is to protect the nucleic acids against enzymatic 
degradation. But since Mg2+ is also a co-factor for many useful DNA-
modifying enzymes such as restriction enzymes and DNA polymerases, 
its concentration in TBE  buffers is generally kept low (typically at around 
1 mM). 
 
2.6.2. Materials 
The following materials and reagents have been used in the gel 
electrophoresis experiments:  
 
 Agarose powder (Sigma) 
 10 X TBE buffer 
 Gel casting tray with combs (BioRed) 
 Gel electrophoresis chamber (BioRed) 
 Gel electrophoresis power supply (BioRed) 
 Water proof paper based tape 
 500 ml flask  
 Sterile water  
 850 watt domestic microwave  
 Ethidium bromide (Sigma) 
 6X sample loading dye (Promega) 
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 500bp DNA ladder (Promega) 
 Transilluminator ultraviolet light-box (Techne)  
 UV protective eyewear (Techne) 
2.6.3. Method 
The following formula has been used to prepare the TBE buffer:  
 
Component Amount 10X Stock 
Concentration 
Fina1X 
Concentration 
Tris Base 108 g 890 mM 89 mM 
Boric Acid 55 g            890 mM 89 mM 
EDTA (pH 8.0) 40 ml                   20 mM 2 mM 
               
 
Usually for convenience, a concentrated stock of TBE buffer (10X) is made 
ahead of time and diluted with distilled water to 1X concentration prior to 
use. 
 
For preparing the 1% agarose gel; 2 g agarose powder was measured and 
added to a 500 ml clean flask, and then 200 ml TBE buffer was added to 
the flask. The total gel volume well may vary depending on the size of the 
casting tray used at the day of experiment. The agarose powder was 
melted then in a microwave until the solution becomes clear by heating 
the solution for several short intervals to avoid boiling the solution for 
long periods as it may boil out then of the flask. After that, the solution 
was left to cool down to about 50-55°C, by swirling the flask occasionally 
to cool evenly. At this stage 10µl of Ethidium Bromide were added to the 
agarose solution. 
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The ends of the casting tray were sealed with two layers of special water 
proof paper based tape and the combs were put in the gel-casting tray, 
then the melted agarose solution was poured into the casting tray and left 
to cool until it is solid for about 30-35 minutes. 
At this stage, the combs were carefully pulled out and the sealing tapes 
were removed, and the gel moved to the electrophoresis chamber. 
Enough TBE Buffer was added so that there is about 2-3 mm of buffer over 
the gel. 
Gels could be made several days prior to use and sealed in plastic wrap 
(without combs). If the gel became excessively dry, we could allow it to 
rehydrate in the buffer within the gel box for a few minutes prior to 
loading samples. 
6l of 6X sample loading dye were added to each of the 25 l PCR 
reaction. The order of each sample was loaded on the gel was recorded on 
the lab book, including the DNA template identifier number in addition to 
controls and ladder. At this stage, 20 l of each sample/sample loading 
dye mixture were pipetted carefully into separate wells in the gel. Also, 10 
l of the DNA ladder were pipetted into at least one well of each row on 
the gel, which is usually the first one on the left hand side.  
Once all the samples are loaded, the gel apparatus can be covered by its 
translucent lid. The leads of the gel apparatus can be connected then so 
that the red (positive) lead is at the end of the gel to which the DNA will 
migrate and the black (negative) lead is at the end of the gel containing the 
wells. At this stage, the power supply can be turned on to run the gel at a 
constant voltage of 200 volts. When the blue tracking dye (which runs in 
these gels along with a DNA fragment of about 65-450 bp) has migrated 
about 75% of the distance to the end of the gel (usually within 60-90 
minutes), the power supply can be turned off then and the power leads 
can be disconnected afterwards.  
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Then the DNA samples can be visualized with UV light-box on the Lumi-
Imager software. The gel should be disposed after the experiment in the 
clinical waste bin.  
In this research, the PCR products were electrophoresed in 1.5%, 2%, 2%, 
and 4% agarose gels and stained with ethidium bromide for the PCR 
products of MY09/11, GP5+/GP6+, MY/GP and SPF1/2 PCR assays 
respectively. The agarose gel concentrations had been optimised using 
positive control samples with each PCR assay product separately. 
 
 
2.7. HPV DNA QUANTIFICATION 
  
2.7.1. Introduction 
The MultiNA microchip electrophoresis system quickly and easily 
performs DNA and RNA nucleic acid size confirmation and 
quantification. This system uses microchip technology to conduct fully 
automated high-speed electrophoresis separation, and fluorescence 
detection to perform high-sensitivity analysis.  
 
2.7.2. Materials 
The following materials and reagents have been used for the DNA 
quantification of the multiplex PCR product using SPF1/2 primer sets:   
 MCE-202 MultiNA device with DNA-500 on-chip mixing mode 
(Shimadzu). 
 DNA-500 Reagent Kit for MultiNA (Shimadzu) Cat No: P/N 
292-27910-91. 
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 SYBR®Gold nucleic acid gel florescent dye manufactured by 
Invitrogen Cat No : S-11494 
 25 bp DNA ladder (20ng/µL) manufactured by Invitrogen Cat 
No: 10597-011. 
 
2.7.3. Method 
The first step for quantifying the HPV DNA concentration in multiplex 
PCR product using SPF1/2 primer sets was to return MultiNA proprietary 
reagents (separation buffer, markers) and fluorescent dye reagent to room 
temperature. Then the analysis schedule was created by starting the PC-
based MultiNA instrument control software. A new analysis schedule was 
registered on the MultiNA instrument control software according to the 
number of tested samples.  
The MultiNA reagents were prepared at this stage; firstly the separation 
buffer were prepared  by diluting the fluorescent dye and stirring it for 2 
minutes, and also the specified quantity of marker were prepared 
according to the mixture mode, and finally the required quantity of ladder 
for generating the size calibration curve were prepared.  
The instrument was loaded before the analysis is being conducted for the 
first time, and the microchip(s) were set in the instrument. The ladder was 
set then, sample, separation buffer, and marker at the position registered 
in the analysis schedule. The wash water was replenished and the waste 
liquid bottle was emptied. 
The samples analysis started after closing the top cover, and pressing the 
start button displayed in the MultiNA instrument control software. To 
interpret the results the view data file button was pressed in the MultiNA 
instrument control software. The viewer opened then to allow viewing of 
the results for samples already analysed, and give quantification of the 
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DNA concentration in the sample when each sample analysis page was 
opened. 
 
2.8. HPV GENOTYPING  
 
2.8.1. Introduction 
The reverse hybridization line probe assay technology is based on the 
reverse hybridization principle, in which part of the L1 region of the HPVs 
genome is amplified and denatured biotinylated amplicons are hybridised 
with specific oligonucleotide probe immobilised on a test strip. After 
hybridisation and stringent washing, streptavidin-conjugated alkaline 
phosphatase should be added to bind to any biotinylated hybrid 
previously formed. Thereafter, incubation with BCIP/NBT chromogen 
would give a purple/brown precipitate. The results can be interpreted 
then visually by looking for certain colour band according to the subtype 
of the HPV infection involved in the sample [260]. This technology is able 
to differentiate between high risk, low risk, and mixed HPV infections 
found in the samples and controls which showed positivity for HPV DNA 
using PCR.  
 
2.8.2. Materials 
 INNO-LiPA HPV Genotyping Extra Kit (Innogenetics). 
 Distilled or deionized water. 
 Disposable gloves. 
 Disposable DNA/Dnase-free pipette tips (aerosol resistant). 
 Forceps for strip handling. 
 Graduated cylinders (10, 25, 50, and 100 ml). 
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 Adjustable pipettes to deliver 1 - 20 μl, 20 - 200 μl, and 200 - 1000 μl. 
 Vortex mixer or equivalent. 
 Microcentrifuge. 
 Water bath (temperature adjustable to 49°C ± 0.5°C). 
 Aspiration apparatus. 
 Calibrated thermometer. 
2.8.3. Method 
In this research, 10 μl of multiplex PCR product amplified, containing 
biotin moieties at the 5′ ends of the SPF1/2 primers were denatured by 
adding 10 μl of NaOH solution. After 10 min, an INNO-LiPA strip was 
put into the tray. Two millilitres of prewarmed (37°C) hybridization buffer 
3× SSC (45 mM Na-Citrate and 450 mM NaCl, 0.3% Sodium Dodecyl 
Sulfate) was added and incubated at 50 ± 0.5°C for 1 h. The strips were 
washed twice for 30 s and once for 30 min at 50°C with 2 ml of 
hybridization solution. Following this stringent wash, the strips were 
incubated with 2 ml of alkaline phosphatase-streptavidin conjugate for 30 
minutes at room temperature. Strips were washed twice with 2 ml of rinse 
solution and once with 2 ml of substrate buffer. Two millilitres of 
substrate (5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium) was added and incubated for 30 min at room temperature. 
The reaction was stopped by aspiration of the substrate solution and 
addition of 2 ml of distilled water. After drying, the strip results were 
interpreted by eye by comparing the hybridization pattern to standard 
type-specific templates.  
The HPV type was determined by eye according to the following criteria. 
In most cases, the probe name is directly linked to the HPV type (e.g., a 
purple colour on probe line 16 indicates the presence of HPV-16). Probes 
c31, c56, and c68 are secondary probes, which were of interest only when 
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there is a positive hybridization with the probe line just above (31/40/58, 
56/74, or 68/45). These c probes were developed in order to discriminate 
between infections with single HPV genotypes and mixed infections. A 
true infection with HPV-31 yields positive hybridization with probe line 
31/40/58 as well as c31. The c probes c31, c56, and c68 will also react with 
other HPV types, which have completely matching sequences. Probe c31 
also reacts with amplimers from types 33 and 54.  
Since the INNO-LiPA does not contain a separate probe for HPV-54, a 
sample containing type 54 will react exclusively with probe c31. Similarly, 
amplimers of type 58 will show reactivity with probes 30/40/58, c56, and 
58. Probe c68 is also reactive with amplimers from types 68 and 39. HPV-
74 is identified by the probes 56/74 and 74. In summary, HPV genotypes 
6, 11, 16, 18, 34, 35, 39, 42 to 44, 51 to 54, 59, 66, and 70 are recognized by 
hybridization to a single probe line, whereas HPV types 31, 33, 39, 40, 45, 
56, 58, 68, and 74 yield a specific hybridization pattern on the INNO-LiPA 
system.  
 
2.9. p53 GENE CODON 72 POLYMORPHISM  
 
2.9.1. Introduction 
Several naturally occurring polymorphisms are found within p53 and one 
at codon 72, a C-G transition, alters p53 3D structure. At codon 72, either 
CCC encodes proline (Pro) or CGC encodes arginine (Arg). It has been 
shown that the E6 proteins from high-risk HPVs are able to target p53 
protien when the p53 gene codon 72 is homozygous for Arg more 
efficiently than p53 Pro to induce  a ubiquitin-mediated degradation of the 
p53 protein [261]. Consistent with this observation, the majority of HPV-
associated tumors so far analyzed are homozygous for the p53 Arg allele, 
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whereas the majority of the comparable normal population are 
heterozygous [262].  
 
 
2.9.3. Materials 
 Techne 3 Prime Thermal Cycler (Techne). 
 Sterile PCR tubes (ABgene). 
The PCR mix has been prepared as follows: 
 2.0μl of DNA. 
 2.5μl of MgCl2 (25mM). 
 2.5μl of 10X buffer (75mM Tris-HCl pH 8.8, 20mM 
(NH4)2SO4). 
 0.3μl of dNTPs (300μM of each of the dNTPs: dATP, 
dGTP, dCTP, dTTP) (ABgene). 
 2.0μl of primers (forward and reverse: 2.5 pmol each) 
 0.2μl of Taq polymerase 5 units/μl (ABgene) 
 15.5μl of H2O 
 For the purpose of this experiment, four PCR primers have been 
designed and synthesised to determine whether p53 codon 72 
polymorphism plays a role in prostate cancer pathogenesis[263]. 
Primer pairs were used for the amplification. For the Arginine 
allele p53+/Arg- of PCR product of 141 bp; for the Proline allele 
pro+/P53- gives a 177 bp product (Table 2-5). 
  
89 
 
 
 
 
Table 2-5: List of the primers used to study P53 codon 72 polymorphism. 
 
 
 
 
 
 
 
2.9.3. Method 
The p53 gene codon 72 polymorphism detection technique is based on 
differences in fragment size for the two forms of the codon 72 of the p53 
gene, which are the p53-Pro allele that yields a 177-bp fragment by PCR 
assay as well as the p53-Arg allele, which yields a 141-bp fragment by 
allele-specific PCR [264]. 
 
There possible PCR assay outcomes were: 1) if a PCR product (141 bp) was 
obtained only with the arginine-specific primers, the patient was 
considered arginine homozygous, 2) if only a proline-specific primer 
product (177 bp) was obtained, the patient was considered proline 
homozygous, 3) if the sample showed amplification with both two primer 
sets, the patient was considered heterozygous (Arg/Pro) (Figure 2-2)[265]. 
  
  Primer               Sequence     Length 
    P53+   TCC CCC TTG CCG TCC CAA  
       141     Arg –   CTG CTG CAG GGG CCA CGC 
    Pro +   GCC AGA GGG TGC TCC CCC  
       177     P53 –   CGT GCA AGT CAC AGA CTT 
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Figure 2-2: The functional domains of the P53 gene, the location of the 
polymorphism at codon 72, and the position of the primers used for PCR 
(indicated by arrows). 
The PCR optimised conditions were as follows for the p53-Pro72 allele: 
denaturation at 94°C for 5 minutes, then 35 cycles with denaturation at 
94°C for 1 minute, annealing at 56°C for 1 minutes and elongation at 72°C 
for 1 minute. In the last cycle, the elongation step was extended to 10 
minutes. For the p53-Arg72 allele, the PCR conditions were identical with 
the exception that annealing was performed at 62°C for 1 minute. The PCR 
products were separated in 3 % agarose gels.  
 
2.10. HAEMATOXYLIN AND EOSIN (H&E) 
 
2.10.1. Introduction 
H&E is the primary conventional stain for every histological specimen 
study under light microscope. Haematoxylin is a basic histological stain 
that stains basophilic structures in the cell blue. The basophilic structures 
are usually those containing nucleic acid like; ribosomes, nucleus, and 
cytoplasmic regions full of RNA. 
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Eosin is alcohol based stain with acidic PH, which colours eosinophilic 
structures bright pink. The eosinophilic structures are generally composed 
of intra and extra cellular proteins. The Eosin is used for full cellular 
details enhancement. 
 
2.2.2. Materials 
The following materials were required for H&E staining: slides glass rack, 
staining jar, xylene, absolute alcohol, alcohol 90%, alcohol 70%, distilled 
water, Giles haematoxylin, acid alcohol, eosin Y solution,  1% acid alcohol 
solution , xylene based mounting medium, glass slides cover slips.   
 
2.10.3. Method 
5 µm sections were cut from the paraffin blocks using standard 
microtome, then the sections were put in a 400 C water bath and picked up 
using glass slides and left to dry overnight. 
The slides were deparaffinised in 2 changes of xylene for 5 minutes each, 
then re-hydrated in 2 changes of absolute alcohol for 3 minutes each. The 
re-hydration continued in 90% alcohol for 3 minutes and 70% alcohol for 
another 3 minutes. The slides were washed briefly in distilled water and 
stained in Haematoxylin solution for 6 minutes. Differentiation of the 
sections was carried out in 1% acid alcohol for 20 seconds, and then the 
slides left under running water for 5 minutes. The slides were then 
counterstained in eosin Y solution for 30 seconds to 1 minute. 
Thereafter, dehydration through 70% alcohol was completed for 1 minute, 
followed by 90% alcohol for 3 minutes and finally 2 changes of absolute 
alcohol for 3 minutes each. The slides were cleared in 2 changes of xylene 
for 5 minutes each. Afterwards the slides were mounted with xylene 
based mounting medium and allowed to dry overnight. On the following 
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working day, the slides were cleaned using surgical knife and xylene to 
take out any excess of mounting media and then examined under the light 
microscope.   
 
2.11. TUMOUR GRADING BY GLEASON SYSTEM 
 
2.11.1. Introduction 
Although numerous grading systems exist for the evaluation of prostatic 
adenocarcinoma, the Gleason grading system is the most widely accepted 
[266]. The Gleason system is based on the glandular pattern of the tumour 
as identified at relatively low magnification [267]. Cytological features play 
no role in the grade of the tumour [268]. Both the primary (predominant) 
and the secondary (second most prevalent) architectural patterns are 
identified and assigned a grade from 1 to 5, with 1 being the most 
differentiated and 5 being the least differentiated [269].  
 
2.11.2. Method 
In Gleason pattern 1 and pattern 2, the tumorous tissues are composed of 
relatively circumscribed nodules of uniform, single, separate, closely 
packed, medium-sized glands. While, in Gleason pattern 3 the malignant 
tissues  infiltrates the non-neoplastic prostatic tissue, and the glands have 
marked variation in size and shape, with smaller glands than seen in 
Gleason pattern 1 or 2. In Gleason pattern 4 the cancerous glands are no 
longer single and separate as seen in patterns 1 to 3 and large, irregular, 
cribriform glands can be seen in contrast with the smoothly circumscribed 
smaller nodules of cribriform Gleason pattern 3. Tumours with this pattern 
have a significantly worse prognosis than those with pure Gleason pattern 3 
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[270]. Gleason pattern 5 tumour shows no glandular differentiation and is 
composed of solid sheets, cords, single cells, or solid nests of tumour with 
central comedonecrosis [271]. 
 
2.12. IMMUNOHISTOCHEMISTRY  
 
2.12.1. Introduction 
Immunohistochemistry (IHC) is a method for demonstrating the 
presence and location of proteins in tissue sections. 
Immunohistochemical staining is accomplished with antibodies that 
recognize the target protein. Since antibodies are highly specific, the 
antibody will bind only to the protein of interest in the tissue section. 
The antibody-antigen interaction is then visualized using either 
chromogenic detection, in which an enzyme conjugated to the antibody 
cleaves a substrate to produce a coloured precipitate at the location of 
the protein. 
To achieve a stronger IHC signal avidin-biotin complex (ABC) can be 
used. This technique utilizes the high affinity of avidin, a protein 
found in chicken egg white, for biotin, an enzyme co-factor in 
carboxylation reactions. Avidin has four binding sites for biotin and 
binding is essentially irreversible. 
 
2.12.2. Materials 
The following general materials and reagents have been used in all the 
IHC experiments: standard microtome, xylene, absolute alcohol, alcohol 
90%, alcohol 70%, distilled water, Giles haematoxylin, 1% acid alcohol, 
0.3% H2O2 in methanol or water, Phosphate-buffered saline (PBS) buffer , 
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eosin Y solution, xylene based mounting medium, staining jar , slide rack,  
glass slides and cover slips.   
In addition, other special materials have been used for the IHC 
experiments: immunohistochemistry  staining chamber for incubating 
the section, normal horse serum, primary antibody which was unique 
for every experiment, advanced avidin/biotin secondary antibody 
(Universal VECTASTAIN Elite ABC Kit, VECTOR LABORATORIES, 
USA) and DAB detection kit (ImmPACT DAB Peroxidase Substrate, 
VECTOR LABORATORIES, USA).  
Moreover, the following materials and reagents have been used for the 
Heat-induced epitope retrieval (HIER) process: Domestic (850W) or 
scientific microwave, microwaveable vessel with slide rack to hold 
approximately 400-500 ml, and HIER buffer (10mM Sodium Citrate, 0.05% 
Tween 20, pH 6.0). The latter HIER buffer has been prepared as follows: 
2.94 g of Tri-sodium citrate dihydrate were mixed to be dissolved in 1000 
ml of distilled water; afterwards 0.5 ml was added of Tween 20 and mixed 
well. The pH was adjusted to 6.0 with 1N HCl.  
 
2.12.3. Method 
Firstly, the tissue block were cut by a slandered microtome to the 
desired thickness for IHC which is ideally 5 microns , and affixed onto 
the glass slide, then the sections were put in a 400C water bath and 
picked up using glass slides and left to dry overnight. 
Before proceeding with the staining protocol, the slides have been 
deparaffinized and rehydrated as incomplete removal of paraffin can 
cause poor staining of the section. To accomplish the step of 
deparaffinization the slides were placed in a rack, and the following 
washes performed with 2 washes in Xylene for 5 minutes each, and then 
2 washes in absolute ethanol for 5 minutes; 5 minutes in 95% ethanol; 
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and then 5 minutes 70% ethanol. Afterwards the slides were put in 
running cold tap water for 10 minutes. 
The slides were kept then in the tap water until ready to perform 
antigen retrieval. At no time from this point onwards the slides left to 
dry as drying out can induce non-specific antibody binding and 
therefore high background staining which will make the assessment of 
staining difficult or impossible sometimes. 
Unless a different antigen retrieval method is stated on the primary 
antibody datasheet, the optimal HIER method for each antigen has been 
optimised experimentally.  
At this stage, the antigen retrieval buffer was added to the microwaveable 
vessel in a volume of antigen retrieval solution sufficient to cover the 
slides by at least a few centimetres as we were using a non-sealed vessel to 
allow for evaporation during the boiling process. Then the slides were 
removed from the tap water and placed in the microwaveable vessel. The 
vessel was placed then inside the microwave. Because we were using a 
domestic microwave, full power had been used until the solution came to 
the boil. The solution was boiled for 20 minutes from this point.  
When 20 minutes has elapsed, the vessel was removed and the cold tap 
water has been run into it for 10 minutes. This allowed the slides to cool 
enough so they may be handled, and allowed the antigenic site to re-
form after being exposed to high temperature. Afterwards, quenching of 
endogenous peroxidase activity has been applied by incubating the 
sections for 30 minutes in 0.3% H2O2 in either methanol or water. Then 
the slides have been washed in PBS buffer for 5 minutes. To avoid non-
specific staining the sections have been incubated for 20 minutes with 
diluted normal blocking serum, which was prepared from the species in 
which the secondary antibody is made, which was 10% horse serum in 
all the experiments, which took place in this study. Then the excess of 
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normal diluted horse serum has been blotted. At this stage, the sections 
have been incubated for 30 minutes with primary antibody diluted in 
PBS buffer, before being washed in PBS buffer for 5 minutes. Thereafter, 
the slides have been incubated for 30 minutes with diluted biotinylated 
secondary antibody solution, and washed afterwards for 5 minutes in 
PBS buffer. Then sections have been incubated for 30 minutes with 
VECTASTAIN® ABC Reagent, and washed afterwards in PBS buffer for 
5 minutes. To achieve the desired stain intensity the sections can be 
incubated in peroxidase substrate solution using the DAB detection kit. 
As soon as the desired stain intensity is achieved while looking at the 
slides under the light microscope, the reaction should be stopped and 
the sections moved to jar where they can be rinsed very gently under tap 
water. Then the sections need to be counterstained in Giles haematoxylin 
for 5 minutes then rinsed under tap water for 5 minutes. Afterwards, the 
staining differentiation was achieved by immersing the sections in 1% 
acid alcohol 3 times. Then the sections can be moved at this stage for 
final dehydration step by immersing the slides in 70% alcohol for 3 
minutes, followed by 90% alcohol for 3 minutes and finally 2 changes of 
absolute alcohol for 3 minutes each. The slides were cleared in 2 changes 
of xylene for 5 minutes each. Afterwards the slides were mounted with 
xylene based mounting medium and allowed to dry overnight.  
 
 
2.13. COLORIMETRIC in situ APOPTOSIS ASSAY  
 
2.13.1. Introduction 
Apoptosis is characterized by specific morphological features, including 
membrane blebbing, nuclear and cytoplasmic shrinkage, and chromatin 
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condensation. Cells undergoing apoptosis fragment into membrane bound 
apoptotic bodies that are readily phagocytosed and digested by 
macrophages or neighbouring cells without generating an inflammatory 
response. This is in contrast to the type of cell death known as necrosis, 
which is characterized by cell swelling, chromatin flocculation, loss of 
membrane integrity, cell lysis and generation of a local inflammatory 
reaction. 
The in situ apoptosis Terminal deoxynucleotidyl transferase dUTP Nick 
End Labelling (TUNEL) system end-labels the fragmented DNA of 
apoptotic cells. Biotinylated nucleotide is incorporated at the 3´-OH DNA 
ends using the Terminal Deoxynucleotidyl Transferase, Recombinant, 
(rTdT) enzyme. Horseradish peroxidase-labeled streptavidin (Streptavidin 
HRP) is then bound to these biotinylated nucleotides, which are detected 
using the peroxidase substrate, hydrogen peroxide, and the stable 
chromogen, diaminobenzidine (DAB). Using in situ apoptosis TUNEL 
system, apoptotic nuclei are stained dark brown. 
 
2.13.2. Materials  
DeadEnd™ Colorimetric TUNEL System (Promega Cat.# G7130) has been 
used for apoptosis detection in addition to the following materials and 
reagents: phosphate buffered saline (PBS), 0.3% hydrogen peroxide for 
blocking endogenous peroxidases, 4% paraformaldehyde, and mounting 
medium.  
We also used some additional materials for processing the paraffin 
embedded sections during the TUNEL experiments: xylene, ethanol 
(100%, 95%, 85%, 70% and 50%) diluted in deionized water, 0.85% NaCl 
solution, proteinase K buffer, DNase I (RQ1 RNase-Free DNase, Promega 
Cat.# M6101), and DNase buffer.  
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2.13.3. Method  
The paraffin-embedded sections have been deparaffinized by immersing 
the slides in fresh xylene in a Coplin jar for 5 minutes at room 
temperature. The latter step has been repeated for 5 minutes again. The 
slides have been washed by immersing the slides in 100% ethanol for 5 
minutes at room temperature in a Coplin jar. The latter step has been 
repeated for 3 minutes. Then, the samples have been rehydrated by 
sequentially immersing the slides through graded ethanol washes (95%, 
85%, 70% and 50%) for 3 minutes each at room temperature. Then the 
slides have been washed by immersing the slides in 0.85% NaCl for 5 
minutes at room temperature. Afterwards the slides have been immersed   
in PBS for 5 minutes at room temperature. To fix the tissue sections they 
have been immersed in 4% paraformaldehyde solution or 10% buffered 
formalin in PBS for 15 minutes at room temperature. The slides have been 
washed twice in in PBS for 5 minutes at room temperature. At this stage, a 
20 µg/ml Proteinase K solution has been prepared from the 10 mg/ml 
Proteinase K stock solution  by diluting 1:500 in PBS. 100 µl of the 20 
µg/ml Proteinase K solution have been added to each slide to cover the 
tissue section. The slides have been incubated at this stage for 10–30 
minutes at room temperature. After the incubation time is complete, the 
slides have been washed by immersing them in in PBS for 5 minutes at 
room temperature in a Coplin jar. The tissues have been refixed at this 
stage by immersing the slides in 4% paraformaldehyde solution for 5 
minutes at room temperature. 
The slides have been washed at this stage twice by immersing the slides in 
PBS for 5 minutes at room temperature. The excess of liquid have been 
removed by tapping the slides. Then the tissues have been covered with 
100 µl of Equilibration Buffer for 5–10 minutes. While the sections are 
equilibrating, thaw the Biotinylated Nucleotide was thawed and mixed on 
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ice to prepare sufficient rTdT reaction mix for all experimental and control 
reactions. One hundred microliters of reaction mix per slide were 
adequately able to cover the section. Then tissue papers were used to blot 
around the equilibrated areas then 100 µl of rTdT reaction mix were added 
to the sections on a slide. The sections were coved then with coverslips to 
ensure even distribution of the reagent. Then the slides were incubated at 
37°C for 60 minutes inside a humidified chamber to allow the end-labeling 
reaction to occur. 
At this stage the 20X SSC was diluted to 1:10 with deionized water. 
Remove the Plastic coverslips have been removed afterwards and the 
reactions were terminated by immersing the slides in 2X SSC in a Coplin 
jar for 15 minutes at room temperature. At this stage, the slides were 
washed by immersing the slides twice in fresh PBS for 5 minutes at room 
temperature to remove unincorporated biotinylated nucleotides. The 
endogenous peroxidases have been blocked at this stage by immersing the 
slides in 0.3% hydrogen peroxide in PBS for 3–5 minutes at room 
temperature. The slides have been washed twice afterwards in PBS for 5 
minutes at room temperature. The Streptavidin HRP solution has been 
diluted 1:500 in PBS, and 100 µl of which have been added to each slide 
and incubate for 30 minutes at room temperature. Then the slides have 
been washed twice by immersing the slides in PBS for 5 minutes at room 
temperature. The DAB solution components have been combined just 
prior to use. For the latter step, 50 µl of the DAB Substrate 20X Buffer have 
been added to 950 µl of deionized water. Then both have been add 50 µl of 
the DAB 20X Chromogen and 50 µl of Hydrogen Peroxide 20X then the 
DAB solution was ready. At this stage, 100 µl of DAB solution have been 
added to each slide and left to develop until there is a light brown 
background. The slides have been rinsed then several times in deionized 
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water. The slides were then ready for mounting in permanent mounting 
medium.  
To prepare negative controls a control incubation buffer was 
preparedwithout rTdT Enzyme by combining 98 µl of Equilibration 
Buffer, 1 µl of Biotinylated Nucleotide Mix and 1 µl of autoclaved, 
deionized water. On the other hand, to prepare positive controls we 
prepare a positive control slide by treating a sample with DNase I to cause 
DNA fragmentation. DNase I treatment of the fixed cells results in 
fragmentation of the chromosomal DNA and exposure of multiple 3´-OH 
DNA ends at which Biotinylated Nucleotides can be incorporated. This 
generally results in the majority of the treated cells demonstrating 
peroxidase labeling. 
 
2.14. STATISTICAL ANALYSIS  
 
Data was collected in a Microsoft Excel file. Statistical analysis 
was performed using SPSSTM computer software (IBM Inc.). Non-
parametric tests such as Mann–Whitney U and Kruskal Wallis 
tests were the main tests used for general comparison of data. 
Simple linear regression and Chi2 test as well as fisher exact test 
were also used where necessary. Survival/outcome was analysed 
using Kaplan Meier plots and estimates of survival curves were 
compared with Mantel-Cox test. 
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CHAPTER 3: MOLECULAR STUDIES RESULTS 
 
3.1. TESTING THE STUDY AND CONTROL GROUPS BY PCR 
The experiments on the total PCa and BPH populations using the 
MY09/11 degenerate primers have revealed that 43 cases were positive 
out of 123 cases in the PCa study group, while 25 cases out of 267 BPH 
control cases were positive. Also, the experiments on the total PCa and 
BPH populations using the GP5+/GP6+ consensus primers resulted in 
identical results to the results of MY09/11 degenerate primers. The 
experiments using nested MY/GP nested PCR method did not show any 
different results from the MY09/11 (Figure 3-1) or GP5+/GP6+ (Figure 3-
2) PCR assays. On the other hand, all the positive cases in the PCa and 
BPH groups came up positive with the SPF1/2 multiplex PCR assay 
(Figure 3-3), in addition to 6 PCa and 3 BPH cases from the ones which 
came up negative with the GP5+/GP6+ and MY09/11 primer sets as well 
as the MY/GP nested PCR (Table 3-1). The statistical analysis of the results 
of each set of primers by non-parametric test for independent samples 
using Mann-Whitney U test for two independent groups showed that the 
results are statically significant with the p-value = 0.0011 for each of  the 
MY09/11, GP5+/GP6+, MY/GP results on one hand and the SPF1/2 
results on the other hand. 
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Table 3-1:  HPV positive results by conventional, nested, and multiplex 
PCRs.  
Primers Group I-
PCa 
I-
BPH 
II-
PCa 
II-
BPH 
III- 
PCa 
III-
BPH 
Total  PCa Total BPH 
GP5+/GP6+ 
(conventional PCR) 
4 5 21 8 12 9 37(30%) 22 (8.2%) 
MY09/11 
(conventional PCR) 
4 5 21 8 12 9 37 (30%) 22 (8.2%) 
SPF1/2  
(multiplex PCR ) 
4 6 24 8 15 11 43(34.9%) 25 (9.3%) 
MY/GP  
(nested PCR) 
4 5 21 8 12 9 37 (30%) 22 (8.2%) 
Total Number of 
Cases  
49 99 43 77 31 91 123 267 
I = Middle Eastern population. 
II = Caucasians population.  
III = Afro-Caribbean population. 
 
 
Figure 3-1: MY09/11 PCR assay (450bp). M = DNA molecular weight marker. Sample of 
positive PCR- reactions are seen in specimens 3 and 6. + = positive control, - = negative control. 
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Figure 3-2: GP5+/GP6+ PCR assay (150bp). M = DNA molecular weight marker. Sample of 
positive PCR- reactions are seen in specimens 2 and 3. 1 = positive control, - = negative control. 
 
 
Figure 3-3: SPF1/2 PCR assay (65bp). M = DNA molecular weight marker. Sample of positive 
PCR- reactions are seen in specimens 1, 3, 4, 8 and 9. 1 = positive control, - = negative control 
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3.2. HPV GENOTYPING BY REVERSE HYBRIDISATION LINE 
PROBE ASSAY 
 
We used the reverse hybridization line probe assay method to genotype 
the HPV- positive samples. In this technology part of the L1 region of the 
HPVs genome is amplified using biotinylated SPF1/2 primer set in a 
multiplex PCR method, then the denatured biotinylated amplicons are 
hybridised with specific oligonucleotide probe immobilised on a test strip 
[272]. High-risk HPVs were detected in 30 of 43 (69.9%) of the total PCa 
cases, which came up positive by the SPF1/2 multiplex PCR assay for 
HPV DNA. Also, 16 of 25 (64%) BPH samples, which were positive for 
HPV-DNA, showed high-risk HPV infection. Low-risk HPVs were 
detected in 13 of 43 (30.2%) of the PCa cases, and 9 of 25 (36%) of the BPH 
specimens which were positive for HPV-DNA. It was notable that HPV-18 
was the predominant HPV type in PCa cases while HPV 16 was 
predominant in BPH samples (Table 3-2). These different frequencies of 
the high-risk and low-risk HPV infection within the total study and 
control groups are of statistical significance (Fischer's exact test with 
Woolf's approximation, p= 0.0013). 
Table 3-2: HPV types in HPV-DNA-positive prostatic carcinoma and 
benign prostatic hyperplasia samples. 
HPV Types 
 Low Risk HPVs High Risk HPVs Total HPV 
positive   HPV-6 HPV-11 HPV-16 HPV-18 
PCa 5 8 12 18 43 
BPH 4 5 9 7 25 
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Furthermore, high-risk HPVs were detected in 30 of 123 (24.3%) of PCa 
cases in the total study group and 16 of 267 (5.9%) of BPH samples in the 
total control group. On the other hand, low-risk HPVs were detected in 13 
of 123 (10.5%) and 9 of 267 (3.3%) of the total PCa and BPH samples 
respectively (Table 3-3). These results are statistically significant (chi-
squared test, p= 0.011). 
Table 3-3: High-risk and low-risk HPV infection frequencies in the total 
prostatic carcinoma and benign prostatic hyperplasia samples. 
Group  Low-risk HPV High-risk HPV Total cases  
PCa 13 (10.5%) 30 (24.3%) 123 
BPH 9 (3.3%) 16 (5.9%) 267 
 
Moreover, high-risk HPVs were found in 4%, 44% and 29% in the PCa 
subgroups of the Middle Eastern, Caucasian and Afro-Caribbean patients 
respectively. On the other hand, high-risk HPVs were found in 2%, 9% 
and 7.6% in the BPH subgroups of the Middle Eastern, Caucasian and 
Afro-Caribbean patients respectively (Table 3-4). The analysis of these 
results by chi-squared test showed that they are statistically significant 
(p=0.0018). 
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Table 3-4: High-risk and low-risk HPV infection in the study and control 
sub-groups. 
Group I-PCa I-BPH II-PCa II-BPH III- PCa III-BPH 
High Risk HPVs  2 (4%)  2 (2%) 19 (44%) 7 (9%) 9 (29%) 7 (7.6%) 
Low Risk HPVs  2 (4%) 4 (4%) 5 (11.6%) 1 (1.2%) 6 (19.3%) 4 (4.3%) 
Total number of 
cases  
49 99 43 77 31 91 
I = Middle Eastern population. 
II = Caucasians population.  
III = Afro-Caribbean population. 
 
The frequencies of high-risk HPV within the PCa study sub-groups were 
30%, 46.6% and 23.4% for Gleason 6, Gleason 7 and Gleason 8-10 
respectively. (Table 3-5).These results indicate that there is no association 
between Gleason scoring and HPV infection within the study group 
samples; (Fischer's exact test with Woolf's approximation, p= 0.09).  
 
Table 3-5: The association between the HPV-positive cases and Gleason 
scoring. 
Group *I PCa  **II PCa  ***III PCa  Total PCa 
Gleason 6 1 5 3 9 (30%) 
Gleason 7 2 7 5 14 (46.6%) 
Gleason 8-10   0 4 3 7 (23.4%) 
*I-PCa= Prostate cancer subgroup of the Middle Eastern population. 
**II-PCa= Prostate cancer subgroup of the Caucasian population. 
***III-PCa= Prostate cancer subgroup of the Afro- Caribbean population. 
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We found that the frequencies of high-risk HPVs were 16.9%, 45%, 28.1% 
in the T1-2N0M0, T3-4N0/xM0 and T2-4Nx/+M1 stages in the total study 
group respectively (Table 3-6). The statistical analysis of these results by 
Fischer's exact test with Woolf's approximation indicates that there is no 
association between the high risk HPV DNA existence and the staging of 
the prostate cancer in the total study group (p= 0.8). 
 
Table 3-6: association between tumour stage and infection with high-risk 
HPV. 
TNM Staging  Number of high- risk 
HPV infection cases  
Total number of 
cases  
Organ-confined disease 
T1-2N0M0  
12 (16.9%) 71 
Locally advanced disease 
T3-4N0/xM0  
9 (45%) 20 
Metastatic  
T2-4Nx/+M1  
9 (28.1%) 32 
 
Furthermore, it has been found, using chi-square test that there was no 
statistically significant difference (p=0.064) in the PSA level among the 
groups of PCa which are HPV-negative and the ones which are positive 
for low-risk or high-risk HPV infections (Table 3-7).  
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Table 3-7: The mean of PSA value in HPV-negative, low-risk HPV, and 
high-risk HPV infections prostate cancer cases.  
Groups  PSA(μg/L)  mean in 
HPV-negative PCa 
PSA(μg/L) mean in 
low-risk HPV cases 
PSA(μg/L) mean in 
high-risk HPV cases 
Group 1  6.1 5.9 5.4 
Group 2 8.9 7.8 7.6 
Group 3 8.2 8.8 7.9 
Group I = Middle Eastern population. 
Group II = Caucasians population.  
Group III = Afro-Caribbean population. 
 
Likewise, Using Kaplan-Meier survival estimates, there was no 
significant difference in survival between the PC subgroups, 
which were negative for HPV infection, the group, which was 
positive for low-risk HPV infections, and finally the group, which 
was positive for the high-risk HPV infections. The survival 
estimates have been summarized in a Kaplan-Meier survival plot 
(Figure 3-1). 
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Figure 3-4: Kaplan-Meier survival plot for the three PCa subgroups: a) negative for HPV DNA; 
b) positive for low-risk HPV DNA; d) positive for high-risk HPV DNA.   
 
3.3. QUANTITATIVE STUDIES RESULTS  
 
High-risk HPV viral DNA load was measured in each SPF1/2 multiplex 
PCR assay product, which showed positivity for high-risk HPV DNA. 
Each sample was tested anonymously using the technology of the 
Microchip Electrophoresis System for DNA/RNA Analysis (MCE®-202 
MultiNA).The results have shown that the average high-risk viral DNA 
concentration in the PCa samples was 1.40 ng/µl, while the average high-
risk viral DNA concentration was 0.97 ng/µl in the BPH samples (Table 3-
8; Figure 3-5).  
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Table 3-8: The average high-risk HPV viral DNA concentration in the 
study and control groups.  
Group Total PCa Total BPH  
Number of high-risk HPV-positive cases 
 
30 16  
High-risk HPV DNA  ng/µl (average) 1.40 0.97 
I = Middle Eastern population. 
II = Caucasians population.  
III = Afro-Caribbean population. 
 
 
Figure 3-5: Print Screen from Microchip Electrophoresis System for DNA/RNA Analysis 
(MCE®-202 MultiNA) interface showing the DNA concentration in sample no. 12 as 133.97 
ng/µl.  
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Furthermore, it has been shown that the average viral DNA concentration 
in the high-risk HPV positive cases was 1.54 ng/µl, 1.27 ng/µl and 1.41 
ng/µl in Gleason 6, Gleason 7 and Gleason 8-10 prostate cancer cancers 
respectively. These results are not statistically significant using Fischer's 
exact test with Woolf's approximation (p=0.89), which indicates that there 
is no association between the HPV DNA concentration and extent of the 
prostate cancer grade in the total study group (Table 3-9). 
 
Table 3-9: The association between Gleason scoring and the high- risk 
HPV viral DNA concentration.  
Gleason Scoring  HPV DNA 
ng/µl (Average) 
Total Number of 
cases  
Gleason 6 1.54 9  
Gleason 7 1.27 14  
Gleason 8-10   1.41 7  
 
 
Additionally, it has been found that the average viral DNA concentration 
in cases which showed positivity for the high- risk HPVs was 2.21 ng/µl, 
1.89 ng/µl and 2.18 ng/µl in T1-2N0M0, T3-4N0/xM0 and T2-4Nx/+M1 
prostate cancer cases respectively. These results are not statistically 
significant using Fischer's exact test with Woolf's approximation (p=0.79), 
which shows that there is no association between the HPV DNA 
concentration and the extent of prostate cancer metastasis in the total 
study group (Table 3-10). 
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Table 3-10: The association between TNM staging and the high-risk HPV 
viral DNA concentration.  
TNM Staging  HPV DNA 
ng/µl (average) 
Organ-confined disease 
T1-2N0M0  
2.02 
Locally advanced disease 
T3-4N0/xM0  
0.97 
Metastatic  
T2-4Nx/+M1  
1.21 
 
 
3.4. GENETIC POLYMORPHISM STUDIES 
  
The p53 gene codon 72 polymorphism detection technique was based on 
differences in fragment size for the two forms of the codon 72 of the p53 
gene, which are: the p53-Pro allele that yields a 177-bp fragment as well as 
the p53-Arg allele which yields a 141-bp fragment by allele-specific PCR 
[264]. 
The Arg/Arg genotype of the p53 codon 72 polymorphism was found in 
62 (50.4%) of the total 123 PCa cases, while the the Arg/Pro genotype was 
found in 57 (46.4%) and the Pro/Pro genotype was found in 4 (3.2%). On 
the other hand, out of the total 267 BPH cases 126 (47.1%) were Arg 
homozygous, 12 (4.4%) Pro homozygotes, and 129 (48.5%) remaining cases 
were heterozygous (Table 3-11; Figure 3-6). 
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Table 3-11: Genotypes and frequencies of codon 72 p53 polymorphism 
variants in PCa and BPH cases. 
 
 
 
Figure 3-6: p53 gene codon 72 polymorphism PCR assay. p53-Pro allele yields a 177-bp fragment 
which can be seen in samples 3 and 4. p53-Arg allele yields a 141-bp fragment which can be seen 
in samples 1 and 2. M = DNA molecular weight marker. 5 = negative control. 
 
Furthermore, the p53 codon 72 allelic frequencies amongst patients with 
HPV-positive and HPV-negative carcinomas were compared in order to 
evaluate whether an association between p53 Arg homozygosity and high-
risk HPV-positivity might exist. Out of 30 patients with high-risk HPV-
positive carcinomas, 14 were Arg homozygotes, 3 were Pro homozygotes 
and 13 were Arg/Pro heterozygotes. On the other hand from the 80 
patients with HPV-negative carcinomas, 44 were Arg homozygous, 4 were 
Pro homozygotes and 32 were heterozygotes (Table 3-12). 
  
p53 codon 72 allele     PCa 
 
BPH 
 
 
Arg/Arg 62 (50.4%) 126 (47.1%) 
Pro/Pro 4 (3.2%) 12 (4.4%) 
Pro/Arg 57 (46.4%) 129 (48.5%) 
Total 123 267 
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The statistical analysis using Fischer's exact test with Woolf's 
approximation test the samples showed that there was no significant 
difference (p=1.00) in the frequency of p53 Arg homozygosity between 
HPV-positive and HPV-negative prostate carcinomas. 
 
Table 3-12: Frequencies of codon 72 p53 polymorphism variants in high-
risk HPV-positive and HPV-negative prostate carcinomas 
 
p53 codon 72 allele     Prostate Carcinomas 
high-risk HPV (+)  HPV (-) 
 
Arg/Arg 14 (46.6%) 44 (55%) 
Pro/Pro 3 (10%) 4 (5%) 
Pro/Arg 13 (43.4%) 32 (40%) 
Total 30 80 
 
 
3.5. DISCUSSION 
 
Numerous broad-spectrum PCR primer sets have been designed for 
detection of multiple HPV types by a single PCR assay [273]. However, 
none of the currently available universal primer sets is able sufficiently to 
detect all HPV genotypes, as recent studies have shown that the overall 
prevalence of HPV can be underestimated considerably if only a single 
PCR assay is used [274]. 
To overcome the problem of underestimating the prevalence of HPV  
infection in this research three primer sets have been used to detect the 
HPV infections in the extracted genomic DNA (Table); GP5+/GP6+ 
consensus primers [254], and MY09/11 degenerate primers [255] , in 
addition to broad-spectrum multiplex PCR primer set SPF1/2 [256]. These 
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three PCR assays were designed to amplify distinct highly conserved L1 
ORF regions of the HPV genome with different amplimer sizes (Figure). 
More than one primer set had been used because it has been reported that 
using a single primer set led to underestimating the prevalence of HPV 
infection in many studies, and simultaneous use of more than one primer 
set is an important tool for the detection of HPV DNA [275]. Also, because 
it has been reported that the efficacy of each primers set for detection of 
human papillomavirus DNA by PCR in paraffin-embedded seemed to be 
inversely correlated to the size of the amplimer produced [273].  
 
Furthermore, to increase the sensitivity of HPV detection using the 
consensus and degenerate primers mentioned above, the samples were 
screened for the presence of HPV using the standard nested PCR 
approach, consisting of the MY09/11 degenerate primer set as outer 
primers and the GP5+/GP6+ consensus primer set as inner primers. This 
nested PCR method has been collectively called MY/GP [257]. 
 
The oncogenic role of HPV in cancers in several anatomical places, such as 
prostate, bladder, oesophagus, larynx and oral cavity, has been proposed, 
based on the detection of HPV-DNA in tissue samples taken from these 
cancers [85, 87, 212, 276], but these reports have been somewhat 
controversial so far [212, 276]. Since 1990, almost 32 publications have 
been conducted to detect HPV in PCa cases [212]. These studies have been 
carried out in different countries with different detection methodologies 
and have mostly been case – control studies [277-281]. Some studies have 
concluded that prostate carcinomas are related to HPV infection and have 
shown that the presence of HPV in PCa was varied between 2% to 80%. 
The most common types of HPV detected in PCa cases were HPV types 
16, 18, 33 and 31 [217, 277, 278, 282-285]. On the other hand, some 
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researchers have reported that HPV is equally prevalent in PCa and BPH 
and even in normal prostate tissue [283, 286, 287] and some studies have 
been unable to detect HPVs in normal and cancer prostate tissues [288, 
289]. 
 
 
In the current study, we detected that there is significant difference in 
HPV positivity between prostate carcinomas and hyperplasias in the 
analysed samples. The detected oncogenic types of HPV, in particular 
HPV types 16 and 18, are confirmed to be the major causative agent of 
both squamous and adenocarcinoma of the cervix [290-293], as well as 
intraepithelial neoplasia of the anogenital tract, which are precursor 
lesions of anogenital cancers [294-296].  
 
Our study showed that there was significant difference between PCa and 
BPH specimens regarding the presence of HPV-DNA. We found high-risk 
HPVs in 24.3% of PCa and 10.5% of BPH samples. Highly variable 
frequencies ranging between 2% and 53% have been reported for the 
detectability of high-risk HPVs in tissue obtained from BPH and prostate 
cancer specimens [297].  These differences could be attributed to different 
methodologies of tissue handling and the sensitivity of detection methods. 
Also, another possible explanation for the divergent frequencies of high-
risk HPV positivity in prostate cancer samples could be attributed to 
sociological, geographical, environmental, and genetic heterogeneities 
causes, which have not been researched yet. In addition, low educational 
level population revealed a higher prevalence of HPV infection in several 
studies, but this has not been investigated so far in the prostate cancer 
cases, which may deserves further multidisciplinary academic work in the 
future [298]. These divergent frequencies were noted in the current study 
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as high-risk HPV detection rate was 2%, 44%, and 29% of the PCa cases of 
the Middle Eastern, Caucasian, and Afro-Caribbean subgroups 
respectively. This might be because of the genetic makeup of the UAE 
nationals which comprise the cases in the Middle Eastern Group is mostly 
Asian with low penetration of prostate cancer genes, dietary intake devoid 
of saturated fats and consumption of a protective Mediterranean diet, in 
addition to the fact that all males in UAE are circumcised, usually in their 
early neonatal life. Furthermore, being raised in acovservative socail 
system that strictly prohibits extramarital sexual activities has led to low 
prevalence of STDs, and consequently low HPV infection rate. 
  
Moreover, our results are consistent with the data reported by Leiros et al., 
who found that 41.5% of the DNA extracted from paraffin embedded 41 
PCa cases were HPV-positive [213]. However, our results disagree with an 
independent study by Bergh et al., which was conducted in Sweden and 
did not find HPV sequences in any of the studied 352 prostate tissue 
samples [289]. 
 
Discrepancies could be also explained by technical differences in the 
sensitivity of the  tests used for detection the HPV DNA or can be 
attributed to the differences in sexual behaviour in the study populations, 
as HPV prevalences in healthy men demonstrate large variations 
worldwide, ranging between 4% and 64%[218].  
 
We found that the oncogenic high risk HPVs are predominantly type 16 
and 18, which may suggest that the HPV association with PCa cases is due 
to specific type of HPV, which is consistent with previous reports [299, 
300]. However, the presence of low-risk HPV 11 and HPV 6 DNAs in the 
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PCa samples indicates the possibility that HPV can infect the prostate, but 
these infections may also have no effect on the carcinogenic process. 
 
Most of the samples studied in this research were TURP specimens, which 
may be the underlying reason of a possible viral contamination of prostate 
tissue by HPV from neighbouring tissues – namely the urethra- during the 
sampling procedure. However, the significant differences in virus 
prevalence amongst the case and control groups minimize the 
contamination possibility. Based on this hypothesis it might be 
recommended that radical prostatectomy is the best tissue source for 
researching HPV prevalence in PCa cases, as well as careful 
microdissection of the neoplastic sample from the surrounding benign 
tissues. In this study radical prostatectomy samples could not be obtained. 
Also, microdissection was not possible because of limited tissues 
remaining in the paraffin blocks. Likewise, HPV contamination from the 
anal epithelium might be a common event during biopsy taking and 
sample manipulation because of the inevitable cotact with the anal 
epithelium during the process of taking the biopsy. This assumption can 
be supported in this study by the fact that that both carcinomas and 
hyperplasias showed some degree of HPV detection for both high-risk and 
low-risk HPVs.  
 
Moreover, small latent carcinomas, which occur in 30–50% of all prostates 
[300], might remain undetected within single BPH specimens during 
routinely performed histopathological examination [301]. Therefore, the 
high HPV level that was observed in our BPH samples may result from 
unrecognized microscopic carcinoma.  
 
A number of studies have compared the ability of different primer sets to 
detect HPV DNA in clinical materials obtained from cervical and 
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anogenital cancers [273, 302-305]. From these studies a few basic rules can 
be established. (i) Each set of HPV-PCR primers needs to be evaluated in a 
wider clinical context using other histopathological and biochemical 
markers since theoretical predictions may not accurately reflect the clinical 
status of the virus in the tissue [275]. (ii) The overall prevalence of HPV 
DNA in any given collection of clinical materials is underestimated if only 
a single detection method is used [257, 274, 306]. (iii) For samples 
processed from tissues originally fixed in formaldehyde and embedded in 
paraffin, the smaller the PCR amplification product, the higher the rate of 
HPV DNA detection [273, 304]. 
 
In this study we have compared the two major primer sets used for PCR 
amplification of HPV DNA in a group of PCa and BPH samples obtained 
from men from three different ethnic groups. The MY09/MY11 primer set 
has been used predominantly in epidemiologic studies originating in 
North and South America and Asia, whereas the GP5+/GP6+ primer 
system has been used primarily in Europe [304]. Each PCR method 
showed a high level of reproducibility when compared to itself, as 
previously demonstrated with the MY09/MY11 assay in different 
laboratories [307, 308]. There was also good agreement in the detection of 
HPV DNA-positive and DNA-negative status between the latter two PCR 
methods [309]. In addition, it has been reported that each HPV primer set 
amplified some HPV types better than others, as the most marked 
differences were seen in the ability of MY09/MY11 degenerate primers to 
amplify HPV-35 and GP5+/GP6+ consensus primers to amplify HPV 
types 53 and 61 [304], but this has not been shown in our study as these 
subtypes have not been detected using either of the primers sets.   
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There were reports that women infected by HPV were detected more 
efficiently by MY09/11 than by GP5+/GP6+ according to the analytical 
sensitivity results calculated for each primer set, mainly in cases of 
multiple infections [304]. These finding were based on the fact that 
MY09/11 consisting of a system of degenerated primers thereby 
promoting the identification of multiple infections [310]. This hypothesis 
could not be tested in our study in PCa cases because we only established 
single infections subgroups with HPV subtypes, and subsequently 
showed identical concordance between the GP5+/GP6+ consensus 
primers and MY09/11 degenerate primers.  
 
Several authors have recommended the use of frozen tissue instead of 
FFPE samples [7]. Other authors have argued that FFPE samples are a 
reliable DNA source as long as PCR products that are generated are 
smaller than 150 bp because of fixative-induced cross-links [1]. 
Nonetheless, it has been reported that HPV detection using PCR depends 
on the primer set that is utilized and unsuccessful amplification results are 
due to DNA damage caused during the process of formalin fixation and 
paraffin embedding [311]. Moreover, PCR assays yielded different results 
when different annealing temperatures were used. The most commonly 
used primer, MY09/MY11, which amplifies a highly conserved region of 
the L1 open reading frame, produced a 450-bp product in all of the human 
DNA samples at 40°C; however, increasing the annealing temperature to 
55°C eliminated this effect [312]. To address the problem of annealing 
temperatures, we reviewed the studies that employed MY09/MY11 
primers for the annealing temperature values. A vast majority of the 
studies used appropriate annealing temperature of 55°C except for one 
study that used 45°C [299]. Among the four studies that produced 
significant results, two used the MY09/MY11 primer. One of these studies 
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amplified the 450-bp fragment at 55°C [213], whereas the other study did 
not report the temperature that was used [313]. In the current research 
54°C has been used as annealing temperature when MY09/MY11 have 
been used.  
 
In this study we have combined GP5 +/GP6+ consensus primers and 
MY09/MY11 degenerate primers in a two-step amplification nested PCR 
to analyse further those cases that proved negative with either GP5 
+/GP6+ or MY09 /MY11. We found that the MY/GP Nested PCR 
experiments gave identical results to GP5+/GP6+ consensus primers and 
MY09/11 degenerate primers systems. This result agrees with few 
previous reports which followed the same methodology of MY/GP 
Nested PCR for detecting HPV infections in cervical cancer specimens 
[314]. However, our results contradict with another report, which found 
that the use of the MY/GP nested PCR increased significantly the 
positivity rate of HPV DNA detection [257]. This divergence in the latter 
report might be due to improper optimisation of one of the two primers 
sets, which will result in higher sensitivity with the nested PCR in 
comparison with each individual primer due to the compensating 
annealing process with the other primer set in the second round of the 
nested PCR.  
 
We found that the amplimer size of the SPF1/2 multiplex PCR system was 
only 65 bp, while the amplimer sizes of GP5 +/GP6+ and MY09/11 
systems were 150 and 450 bp, respectively. It has been reported that the 
sensitivity of DNA detection by PCR is inversely related to the size of the 
amplimer, as the kinetics of the PCR reaction favour smaller amplimers 
[315]. Furthermore, as the efficacy of PCR also depends on the quality of 
the DNA extracted from the clinical specimen, some researchers reported 
122 
 
 
 
that detection with small amplimers will be advantageous, especially 
when using formalin-fixed, paraffin-embedded materials [273, 316]. Taken 
together, the small amplimer size may explain the high sensitivity of the 
SPF1/2 assay in our study. On the other hand, the SPF1/2 multiplex PCR 
system uses a mixture of defined primers for the SPF1 and SPF2 target 
regions. These regions are also used for GP5 +/GP6+ and MY09/11 
priming, respectively. Because of the heterogeneity of the primer target 
sites, the SPF1/2 mixture of primers may be more effective than GP5 
+/GP6+ and MY09/11 primers. Moreover, our results showed that the use 
of one consensus and degenerate HPV primer pair with paraffin-
embedded tissues would underestimates the presence of HPV DNA in the 
studied population.  
 
The prognostic significance of HPV DNA in genital neoplasms, in terms of 
tumour staging and grading as well as the patients survival rate, is 
controversial [317]. In a large series of cervical carcinoma, which 
comprised 291 cases, it was reported that HPV DNA status was not 
predictive of survival in the whole study population, although there was a 
significant association between HPV-18 and poor prognosis in early stage 
tumours [318]. However, another study found that patients with HPV-16 
positive cervical tumours had significantly higher rates of pelvic 
metastasis to lymph nodes than patients with HPV-16 negative tumours 
[319]. Other studies also have shown an association between the presence 
of high-risk types and poor clinical outcome [320]. On the contrary, some 
investigators reported that the absence of HPV in the cervical tumour 
confers a worse prognosis [321]. One of these researchers analysed 106 
patients with cervical carcinomas, and concluded that patients with no 
detectable HPV DNA sequences had a 2.6 times higher risk of overall 
recurrence and 4.5 times higher risk of distant metastases than did HPV 
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positive patients [322]. Another interesting report confirmed that HPV 
negative status and c-myc overexpression are two independent prognostic 
indicators related to the risk of distant metastases in cervical carcinoma 
[323]. In a trial to explain the latter reports it was suggest that in HPV 
negative tumours, p53 and pRb may be mutated or deleted to account for 
functional inactivation of these important cell cycle regulators [321].  
On the other hand, there were two reports addressed the relation between 
HPV and prognosis of penile carcinoma. Both reports compared the 
clinical outcomes of patients with HPV positive versus HPV negative 
tumours, and found that there is no difference in patient age, tumour 
staging, or the Kaplan–Meier estimates of survival [317, 324]. Those latter 
reports seem in line with the results we found in the current study which 
suggest that HPV status of the PCa primary tumour does not influence the 
tumour prognosis indicators. In sum, little is known regarding the 
mechanisms involved in the invasiveness and metastatic process of HPV 
positive carcinomas; and further studies are required to provide further 
insight into those mechanisms.  
 
Although the data about the natural history of HPV infections are limited, 
the viral load in cervical cancer is presumably low during the latency 
period and first phase of infection but may increase over time, in parallel 
with the development of cytological aberrations [85, 87, 150, 186].  Several 
authors have reported a positive association between the viral burden of 
high-risk HPV with the high-grade intraepithelial lesion [23,24]. But, by 
contrast with the case-control researches in the cervical cancer cases [325], 
which examined the role of viral load in cervical cancer grade as well as 
stage, this study concluded that HPV viral load measured in the high-risk 
HPV positive PCa cases was not associated with the grade or stage of the 
PCa cases. There are several possible explanations for the conflicting 
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findings. First, comparison of HPV viral load values between studies is 
difficult because data are not given in terms of an absolute measure of 
viral genomes. Second, our study looked at an additive measurement of 
viral load for type 18 and 16 carcinogenic HPV types, whereas the 
previous studies focused only on type 16. Third, our results might differ 
from those of other studies in cervical cancer because of differences in 
sample anatomic origin and collection method which was mostly TURP 
and trans-rectal biopsies in our study, while the in the cervical cancer 
cases spatulas were probably used to collect samples which might led to 
different level of representation of cells infected with HPV from the 
transformation zone in cervical cancer. 
 
Furthermore, It is well known that the first line of defence against the viral 
infection is the interferon response, as E6 HPV oncoproteins can inhibit 
the interferon pathway [326, 327], which can lead to more aggressive 
disease. However, the results from our research do not support this 
hypothesis as no association could be established between the grade of the 
tumour represented by Gleason scoring and the HPV status in the PCa 
samples.  
 
Transrectal ultrasound-guided prostate biopsy is one of the most 
important methods used as a first confirmatory test in prostate cancer 
[328]. The main indication for prostate biopsy is elevation of the serum 
PSA level, together with unfavourable digital rectal examination result. 
However, the PSA level is not only elevated in men with prostate cancer 
[329]. Other diseases, including benign prostatic hyperplasia and 
symptomatic chronic prostatitis, as well as prostate manipulations, can 
increase the serum PSA level [330]. On the other hand, the prostate 
volume is variable and could result in variations in the serum PSA level in 
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men without prostate cancer [331]. Considering the wide range of 
situations that can increase the serum PSA level, many patients undergo 
prostate biopsy because of an elevated PSA level, and an important 
percentage of them do not have prostate cancer [332]. Also, according to 
published reports, prostate biopsies may fail to detect cancer in up to 30% 
of patients [333]; thus, many urologists recommend repeat biopsies to 
their patients, sometimes with more specimens taken in an attempt to find 
a possible previously undetected area of cancer [334]. All of these factors 
can contribute to an increase in the PSA level, and make it harder to 
predict which factor is the direct causative agent fort the increase of the 
PSA level [335]. In addition, it has been reported that there was an 
association between prostate epithelium disruption and serum PSA 
increase [330] which might be, in theory, caused in the course of HPV 
infection within the prostatic tissues. But, also it has been concluded in the 
same study that the extension of the inflammatory infiltration incurred 
was not related to an increase in serum PSA [330]. However, in the current 
research there was no association between the PSA level and the status of 
HPV infections within the study group. That could be explained by the 
lengthy latency period of the HPV infections which does not induce any 
prominent disruption of prostatic epithelium, along with the fact that any 
real increase in the PSA level in an HPV-positive case might not be noticed 
in this research because of the other actions which may be taken during 
the course of assessing any prostatic pathology in the other cases which 
are HPV-negative. Therefore, the latter observation will make the 
statistical analysis difficult of the PSA levels as they cannot be analysed 
statistically for every individual case but rather they should be taken as a 
statistical value for a group of cases.   
 
We assessed the allelic frequencies of the p53 gene codon 72 
polymorphism (Arg, Pro or Arg/Pro) in the cases of the study and control 
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groups in order to evaluate the possibility of increased cancer 
susceptibility associated with the Arg/Arg genotype. However, no 
statistically significant differences amongst the Arg/Arg and Arg/Pro 
genotypes frequencies could be established, neither by comparing patients 
with PCa and BPH nor between high-risk HPV-positive and High-risk 
HPV-negative carcinomas.  
 
In cervical cancer, several studies of the p53 codon 72 polymorphism have 
been accomplished after the initial report which concluded a higher cancer 
risk associated with the Arg allele [264]. Some of these researches 
disagreed with the original report [265] whereas others support it [336, 
337]. In our assessment of the p53 polymorphism at codon 72, we could 
not find an indication that the Arg allele confers a higher risk for prostate 
cancer, including those tissues positive for high-risk HPV.  Moreover, it  
has been reported that the Pro/Pro genotype is associated with a reduced 
risk of developing prostate cancer [338]. However, in the current study we 
could not evaluate this hypothesis due to the low populational frequency 
of the rare Pro/Pro genotype in our study and control populations. 
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CHAPTER 4: MORPHOLOGICAL STUDIES RESULTS 
 
4.1. TUMOUR GRADING USING GLEASON SCORING SYSTEM  
All the study cancer subgroups have been examined to assess Gleason 
scoring in each case after being stained using H&E method and examined 
by light microscopy. Gleason scoring results are essential starting points to 
investigate any association between the grade of the prostate cancer cases 
and any of the other direct and indirect indicators of HPVs infections in 
the study and control groups.  
 
The results have shown that the tumour grade within the Middle Eastern 
population were 34.6%, 30.8% and 34.6% for Gleason 6 (Figure 4-1), 
Gleason 7 (Figure 4-2) and Gleason 8-10 (Figures 4-3; 4-4) respectively. 
While it was 34.8%, 48.8% and 16.4% for Gleason 6, Gleason 7 and Gleason 
8-10 respectively within the Caucasian population. As for the Afro-
Caribbean population, the distribution was 29%, 54.8% and 16.2% for 
Gleason 6, Gleason 7 and Gleason 8-10 respectively (Table 4-1). 
Table 4-1: Gleason scoring in the three cancer subgroups 
Group I-PCa* II-PCa** III-PCa*** Total Number 
of PCa Cases  
Gleason 6 17 (34.6%) 15 (34.8%) 9 (29%) 41 (33.3%) 
Gleason 7 15 (30.8 %) 21 (48.8%) 17(54.8%) 53 (43%)  
Gleason 8-10 17 (34.6%) 7 (16.4%) 5 (16.2%) 29 (23.7%) 
Total number 
of PCa cases  
49 43 31 123 
* I-PCa= Prostate cancer subgroup of the Middle Eastern population. 
** II-PCa= Prostate cancer subgroup of the Caucasian population. 
***III-PCa= Prostate cancer subgroup of the Afro-Caribbean population. 
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Figure 4-1: Sample of Gleason grade 3+3=6 (x400) 
 
 
Figure 4-2: Sample of Gleason grade 4+3=7(x200) 
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Figure 4-3: Sample of Gleason grade 4+4=8 (x400) 
 
 
 
Figure 4-4: Sample of Gleason grade 5+5=10 (x400) 
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4.2. HPV EXPRESSION IN THE TOTAL STUDY AND CONTROL 
GROUPS  
For the purpose of investigating the HPV presence within the study and 
control groups using IHC methodology we have used a monoclonal broad 
spectrum HPV cocktail antibody which reacts with a 56 kilodalton protein 
present in human HPV subtypes 1, 6, 11, 16, 18 and 31. This novel 
antibody was raised against the major capsid protein L1 of human 
papillomavirus types 1, 6, 11, 16, 18 and 31 using a recombinant vaccinia 
virus that expresses the L1 protein of HPV types 1, 6, 11, 16, 18 and 31 as a 
target for the immunohistochemical reaction.  
 
The immunohistochemical testing of the total PCa and BPH populations 
has been optimised firstly on cervical cancer tissue samples known for 
being positive for HPV infection, then performed on the study and control 
group samples using diluted 1:150 mouse monoclonal HPV cocktail 
antibody (ab2417, abcam, UK). Positive controls from cervical cancer 
samples have been included in all the experiments. The negative controls 
have been prepared by following the same IHC staining protocol but 
without the step of adding the primary antibody.  
 
The IHC experiments revealed that 25 cases were positive out of 123 cases 
in the PCa study group (Figure 4-5), while only 10 cases were positive out 
of 267 BPH control cases (Table 4-2). These results are statistically 
significant by applying  non-parametric test for independent samples 
using Mann-Whitney U test for two independent groups (p-value= 
0.0016). 
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Table 4-2: HPV status in the study and control groups by IHC using HPV 
antibody. 
*PCa= total prostate cancer population  
** BPH = total benign prostatic hyperplasia population. 
 
 
 
Figure 4-5: Immunostaining of prostate cancer showing HPV positive (x400) 
 
Moreover, the results have shown that all the positive samples for HPV 
infection by IHC from the PCa and BPH subgroups were also positive by 
multiplex PCR using SPF1/2 primer set. On the other hand, the results 
have shown that 18 samples of the 98 negative PCa samples by HPV 
Group   PCa* BPH**  
HPV positive by IHC 25 (20.3%) 10 (3.7%) 
HPV negative by IHC  98 (79.6%) 257 (96.2%) 
Total number of cases   123 267  
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cocktail antibody were positive for HPV viral DNA by multiplex PCR 
using SPF1/2 primers. Likewise, it is has been shown that 15 samples of 
the 247 negative BPH samples from the control groups which have been 
tested by the HPV cocktail antibody were positive by the same PCR 
method (Table 4-3). 
 
 
Table 4-3: Comparison between the negative results of IHC using HPV 
cocktail antibody and the multiplex PCR positive results using SPF1/2 
primer set. 
*PCa= total prostate cancer population. 
** BPH = total benign prostatic hyperplasia population. 
 
Given that the PCR test is more definitive in confirming the presence of 
the HPV viral genome in the tissue sample, it has been used as standard 
parameter to calculate the sensitivity and specificity of the HPV cocktail 
antibody IHC test in PCa cases by IHC, which came as 58.1% and 100%, 
respectively.  
 
In addition, the slides of each specimen in the study and control groups 
were examined by looking for cytoplasmic/membrane staining. The 
number of the positively stained cells in four medium power fields (x200)  
was counted and an average of the number of positive cells was made. 
The grade of the reaction was quantified using a visual analogue scale as 
Grade I where 1-10 stained cells per medium power field , Grade II where 
Group  PCa* BPH** 
HPV-negative by IHC 98  257  
HPV-positive by PCR 18 15 
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11-20 stained cells per medium power field are found,  and Grade III 
where 20< stained cells are found per medium power field.  
 
The study of IHC grading in the total PCa group using HPV cocktail 
antibody resulted in the frequency of 84%, 16% and 0% for IHC Grade 1 
(Figure 4-6), Grade 2 (Figure 4-7) and Grade 3 respectively, while the 
frequencies of the IHC grading in the total BPH group showed the 
frequency of 90%, 10% and 0% for IHC Grade 1, Grade 2 and Grade 3 
respectively (Table 4-4). These results are statistically significant using 
Mann-Whitney U test for two independent groups (p-value<0.0001).  
Moreover, the statistical analysis of the distribution of the IHC grading in 
the total PCa using non-parametric Chi-Square goodness-of-fit test 
resulted in rejection of the null hypothesis that the IHC grades in PCa 
group categories happen in equal probabilities (p< 0.001). In addition, it 
has been noted that most of the cases which are positive for HPV infection 
are at IHC grade 1.  
Table 4-4: IHC grading of the positive HPV samples in the total study and 
control groups. 
 
*PCa= total prostate cancer population. 
** BPH = total benign prostatic hyperplasia population. 
Group PCa* BPH** 
Grade 1 21 (84%) 9 (90%) 
Grade 2 4 (16%) 1 (10%) 
Grade 3 0 (0%)  0 (0%) 
Total number of cases  25 10 
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Figure 4-6: Immunostaining of prostate cancer showing HPV positive (grade I) (x200) 
 
 
 
Figure 4-7: Immunostaining of prostate cancer showing HPV positive (grade II) (x200) 
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4.3. DETECTION OF E6 PROTEIN OF THE HIGH-RISK HPVs  
In the current study, we have designed IHC experiment using anti E6 
protein primary antibody (abcam-C1P5), which can detect the high-risk 
HPV16-E6 as well as the HPV18-E6 proteins in the tissues of the study 
and control groups. The direct aim of this experiment was to detect if 
there is a deletion of the L1 ORF in any sample during the process of 
integration of the high-risk HPV DNA within the host genome. This 
process can happen as a part of the active phase of infection, which will 
result in loss of expression of the L1 capsid protein by the integrated HPV 
DNA but keep expressing the E6 protein if the virus is in active form. 
Moreover, due to the difference in the sensitivity threshold between PCR 
and IHC technologies, this experiment might be helpful in differentiating 
any latent infection by high-risk HPV, which is expressing E6 in several 
copies per cell but not in an enough number to be detected by IHC, 
though it would be positive by PCR methods.  
 
Firstly, the immunohistochemical protocol has been optimised firstly on 
cervical cancer samples known for being positive for HPV-18 infection, 
before it was performed on the study and control group samples. In this 
IHC experiment we have used diluted 1:50 mouse monoclonal anti E6 
protein (abcam-C1P5). Positive controls from cervical cancer tissues have 
been included in all the experiments. The negative controls have been 
prepared by omitting the step of adding the primary antibody.  
 
We found that 8 cases showed positivity for E6 protein by IHC out of 123 
PCa cases in the study group. On the other hand, there was no BPH case 
showing positivity for E6 protein by IHC in the total control group (Table 
4-5). It was noted that only few cells were stained positively for E6 
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protein in all the cases, which showed positivity for E6 protein, which put 
them all at Grade 1 of IHC staining (Figure 4-8).  
 
Table 4-5: E6 protein status in the total study and control group.  
*PCa= total prostate cancer population. 
** BPH = total benign prostatic hyperplasia population. 
*** E6 = E6 protein of the high-risk HPVs type 16 and 18. 
 
 
Figure 4-8: Immunostaining of prostate cancer showing HPV E6  positive (grade I) using HPV 16 
and 18 anti E6 protein (abcam-C1P5) (x400) 
 
Group PCa BPH 
E6***-positive  
 
8 (6.5%) 0 (0%) 
E6***-negative 
 
115 (93.5%) 267 (100%) 
Total Number of Cases   123 267 
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Moreover, it has been found that out of the 8 cases which showed positive 
IHC stating for high-risk E6 protein, 3 cases were infected by type 16 of 
the HPVs, and the rest were infected with type 18 (Table 4-6). In other 
words, we did not find any case positive for E6 protein but negative for 
the high-risk HPV infections.   
 
Table 4-6: E6 protein status in the study group using IHC.  
HPV Types 
 HPV 
Negative 
Low Risk HPVs High Risk HPVs Total 
number 
of cases  
HPV-6 HPV-11 HPV-16 HPV-18 
PCa* 80 5 8 12 18 123 
E6**-positive  0 0 0 3 5 8 
*PCa= total prostate cancer population. 
** E6 = E6 protein of the high-risk HPVs type 16 and 18. 
 
Additionally, we found that the frequencies of HPV high-risk E6 protein 
within the PCa study sub-groups were 37.5%, 50% and 12.5% for Gleason 
6, Gleason 7 and Gleason 8-10 respectively (Table 4-7). The statistical 
assessment of these results by Chi-Square goodness-of-fit test indicates 
that there is no association between the high-risk HPV-E6 existence and 
the grading of the prostate cancer in the total study group (p= 0.417). 
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Table 4-7: The association between the high-risk E6-positive cases and 
Gleason scoring. 
Group E6*-positive  
Gleason 6 3 (37.5%) 
Gleason 7 4 (50%) 
Gleason 8-10   1 (12.5%) 
Total number of cases  8 
* E6 = E6 protein of the high-risk HPVs type 16 and 18. 
 
Likewise, we found that the frequencies of high-risk HPV were 62.5%%, 
25%, 12.5%% in the T1-2N0M0, T3-4N0/xM0 and T2-4Nx/+M1 stages in 
the total study group respectively. The statistical analysis of these results 
by Chi-Square goodness-of-fit test indicated that there is no association 
between the high-risk HPV-E6 existence and the staging of the prostate 
cancer in the total study group (p= 0.197). 
 
Table 4-8: association between tumour stage and infection with high-risk 
HPV. 
TNM Staging  E6*-positive  
Organ-confined disease 
T1-2N0M0  
5 (62.5%) 
Locally advanced disease 
T3-4N0/xM0  
2 (25%) 
Metastatic  
T2-4Nx/+M1  
1 (12.5%) 
Total number of cases  8 
* E6 = E6 protein of the high-risk HPVs type 16 and 18. 
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4.4. THE STATUS OF THE P53 PROTEIN IN THE TOTAL AND 
STUDY GROUPS  
 
To evaluate the involvement of p53 inactivation in the development of 
prostate cancer, we have investigated the status of the p53 gene in the total 
study and control groups by IHC method. The immunohistochemical 
protocol optimisation procedure on breast cancer samples, which are 
known to be positive for p53 mutant protein, has been followed, before it 
was performed on the study and control group samples, and resulted in 
an optimal dilution of 1:50 for the anti-p53 primary mouse monoclonal 
antibody (PAb 240, abcam, UK) which recognizes mutant p53 proteins but 
not wild type p53 protein in its native form [339]. Positive controls from 
breast cancer cases have been included in all the experiments on the study 
and control groups. The negative controls were prepared by following all 
the steps stated in the IHC protocol apart from the step of adding the 
primary antibody.  
 
The IHC experiments have revealed that 29 cases were positive out of 123 
cases in the PCa study group (Figure 4-9). Nevertheless, interestingly, 
there was no case showing positive signal for the p53 protein out of 267 
BPH control (Table 4-9). These results are statistically significant by Mann-
Whitney U test for two independent groups (p-value<0.001). 
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Table 4-9: P53 protein status in the study and control groups 
 
*PCa= total prostate cancer population. 
**BPH= total benign prostatic hyperplasia population 
 
 
Figure 4-9: Immunostaining of prostate cancer showing P53 positive staining (x200) 
 
Moreover, it has been shown that only 2 cases out of 30 PCa cases (6.6%), 
which showed positivity to high-risk HPV DNA test by reverse 
hybridization line probe assay method, were positive for P53 by IHC 
staining. In addition,   3 cases of the 13 cases (23%) which showed low-risk 
HPV infections were P53 positive. On the other hand, testing the status of 
Group   PCa* BPH** 
Anti-P53 
positive results 
29 (23.5%) 0 (0%) 
Anti-P53 
negative results 
94 (76.5%) 267 (100%) 
Total number of cases   123 267 
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the P53 gene in the PCa cases, which showed negativity for the high-risk 
HPV DNA test by the same methods, showed that it was positive in 24 out 
of 80 cases (30%) in this subgroup. (Table 4-10).  
Table 4-10: The association between p53 status and HPV status in the 
total PCa study group.  
HPV Types 
 HPV 
Negative  
Low Risk HPVs High Risk HPVs Total 
number 
of cases  
HPV-6 HPV-11 HPV-16 HPV-18 
P53 
Positive  
24 1 2 0 2 29 
PCa* 80 5 8 12 18 123 
*PCa= total prostate cancer population. 
Furthermore, testing the association between high-risk E6 proteins and the 
p53 status within the PCa study group using IHC revealed that when the 
IHC signal for E6 was positive, there were 12.5% of the cases showing p53 
positive signal and 87.5% negative for p53. On the other hand, when there 
was no IHC signal for E6 protein, there were 24.3% of the cases showing 
positive signal for the p53 while the remainder 75.7% were negative for 
p53 (Table 4-11). These results are not statistically significant using fisher 
exact test (p=0.679).  
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Table 4-11: The association between P53 and high-risk E6 protein in the 
study group using IHC. 
P53 status High-risk HPV E6 status in PCa* cases 
E6** positive E6** negative 
P53 positive 1 (12.5%) 28 (24.3%) 
P53 negative 7 (87.5%) 87 (75.7%) 
Total number of cases  8 115 
*PCa= total prostate cancer population. 
** E6 = E6 protein of the high-risk HPVs type 16 and 18. 
 
4.5. THE STATUS OF THE p16INK4a IN THE TOTAL STUDY AND 
CONTROL GROUPS 
 
To investigate the status of the p16INK4a transcription factor in the study 
and control groups, we examined all the samples in the study and control 
groups anonymously by IHC using diluted 1:200 anti- p16INK4a primary 
antibody (2D9A12, abcam, UK). The dilution and the other IHC protocol 
steps have been optimised on cervical cancer sections before starting the 
actual experiments on the study and control groups. Also, positive and 
negative controls from cervical cancer cases have been included in all the 
IHC experiments. The negative controls have been prepared by following 
all the IHC protocol steps apart from the step of adding the primary 
antibody.  
 
The IHC experiments showed that 24 cases were positive out of 123 cases 
in the PCa study group (Figure 4-10). Also, it was found that 2 cases out of 
267 BPH control cases were positive for the p16INK4a (Table 4-11). These 
results are statistically significant by non-parametric test for independent 
samples Mann-Whitney U test for two independent groups (p-
value=0.014). 
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Table 4-12: p16INK4a transcription factor status in the study and control 
groups. 
*PCa= total prostate cancer population. 
** BPH = total benign prostatic hyperplasia population. 
 
 
Figure 4-10: Immunostaining of prostate cancer showing p16INK4a  positive staining (x400) 
 
Furthermore, it has been found that p16INK4a positive signal could be 
detected in different frequencies within the HPV positive as well as the 
HPV negative subgroups in the PCa cases (Table 4-13). Also, it was 
Group   PCa*  BPH** 
Anti- p16INK4a 
positive results 
24 (19.5%) 2 (0.74%) 
Anti- the p16INK4a 
negative results 
99 (80.5%) 265 (99.26%) 
Total number of cases   123 267 
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notable that the statistical analysis of those results using Chi-Square 
goodness-of-fit test for one categorical variable showed that there is no 
association between HPV status and the p16INK4a transcription factor 
(p=0.688). 
 
Table 4-13: Association between the p16INK4a and the HPV infections 
status in the study group.   
HPV Types 
 HPV 
Negative  
Low Risk HPVs High Risk HPVs Total 
number of 
cases  
HPV-6 HPV-11 HPV-16 HPV-18 
p16INK4a 
Positive  
13(16.2%) 1(20%) 2(25%) 3(25%) 5(27.7%) 24(19.5%) 
PCa* 80 5 8 12 18 123 
*PCa= prostate cancer population. 
 
Moreover, it has been found that 1 of the 2 BPH cases, which showed 
positivity for p16INK4a transcription factor by IHC, was positive for high-
risk HPV DNA. However, the other BPH case was negative for high-risk 
HPV DNA (Table 4-14).    
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Table 4-14: Association between the p16INK4a and the HPV infections 
status in the control group.   
HPV Types 
 HPV 
Negative  
Low Risk HPVs High Risk HPVs Total 
number of 
cases  
HPV-6 HPV-11 HPV-16 HPV-18 
p16INK4a 
Positive  
1(0.4%) 0 0 1(11%) 0 2 (0.7%) 
BPH* 242 4 5 9 7 267 
*BPH = total benign prostatic hyperplasia population. 
 
 
4.6. in situ TUNEL APOPTOSIS ASSAY  
 
TUNEL in situ assay experiments were carried out according to the 
manufacturer instructions (Promega DeadEnd apoptosis detection 
system), using 5µg/ml proteinase k incubation for 5 minutes. A positive 
control slide was included in each run according to the protocol, and a 
negative control slide without adding TUNEL reaction mixture was 
included. 
 
For TUNEL scoring, the average number of positive nuclei was calculated 
in 10 high-power microscopic fields (×400) selected from a central region 
of the tumour areas avoiding areas containing necrosis. TUNEL technique 
is based on the specific binding of TdT to 3'-OH of DNA fragments in 
apoptotic nuclei, permitting the in situ visualisation of apoptotic cells 
(Figure 4-11). However, a very careful approach has been flowed when 
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evaluating the morphologic results as necrotic cells and some 
inflammatory cells, including neutrophils and lymphocytes, are stained 
sometimes.  
 
Due to the small amount of tissues remained in the paraffin blocks we 
were only able to do the TUNEL in situ assay on 42 samples of the total 
study groups of 123 PCa cases. The TUNEL in situ assay score results 
obtained from this PCa study group along with the E6 status were 
summarised in (Table 4-15).  
 
Statistical analysis using Chai-Square goodness-of-fit test showed that 
these results are not statistically significant (p=1). Thus, these results 
showed that there is no direct association between the presence of E6 of 
the high-risk HPV infections and the extent of apoptosis in the PCa total 
study group.   
 
Table 4-15: Association between TUNEL in situ assay score and high-risk 
E6 protein of the HPVs in the PCa study group.  
High-risk E6 protein    Number of samples  TUNEL in situ assay score median 
(interquartile rang) 
E6-positive 5 5(2-10) 
E6-negative  37 5(2-11) 
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Figure 4-11: TUNEL in situ assay on prostate cancer sample showing the apoptotic cells as black 
small dots (x400) 
 
4.7. DISCUSSION  
 
When Gleason compared his grading system with survival rates, it was 
noted that in tumours with two distinct tumour patterns, the observed 
number of deaths generally fell between the numbers expected based on 
the primary pattern and that based on the secondary pattern [267]. 
Because both the primary and the secondary patterns were influential in 
predicting prognosis, there resulted a Gleason sum obtained by the 
addition of the primary and secondary grades. If a tumour had only one 
histological pattern, then for uniformity the primary and secondary 
patterns were given the same grade. Gleason sums range from 2 (1 + 1=2), 
which represents tumours uniformly composed of Gleason pattern 1 
tumour, to 10 (5 + 5=10), which represents totally undifferentiated 
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tumours [44]. Synonyms for Gleason sum are combined Gleason grade 
and Gleason score [44]. Pathologists may assign only a Gleason pattern 
rather than a Gleason sum in cases with limited adenocarcinoma of the 
prostate on needle biopsy [340]. However, it should be made perfectly 
clear by the pathologist that she or he is assigning only a pattern and not a 
sum. Cases in which the pathologist signs out a case as Gleason grade 4 
(i.e., Gleason pattern 4) may be misconstrued as Gleason sum 4. 
Consequently, for the purpose of the current research it has been agreed to 
assign both a primary and a secondary pattern even when presented with 
limited cancer so as to not give rise to any confusion. The Gleason system 
does not account for the existence of a tertiary (third most prevalent) 
pattern [341]. In radical prostatectomy specimens, it has been 
demonstrated that tertiary high-grade components adversely affect 
biologic behaviour [342]. It is proposed that the Gleason system for radical 
prostatectomy specimens be modified, either by recording the Gleason 
grade as a combination of the most common pattern along with the 
highest grade pattern or by giving the routine Gleason grade (primary and 
secondary patterns) with a note stating that there is a tertiary high-grade 
pattern [343]. 
 
One of the aims of this research was to test the reliability of a monoclonal 
broad spectrum HPV antibody, which was raised against the major capsid 
protein L1 of human papillomavirus types 1, 6, 11, 16, 18 and 31. There is a 
big debate about the usefulness, sensitivity and specificity of different IHC 
antibodies as a detecting tool for the HPV infections. This debate is even 
more pronounced when paraffin-embedded tissues are used. In the 
present study, the results obtained were compared with the results of the 
multiplex PCR using SPF1/2 primer set to determine reliability of this 
antibody in detecting HPV L1 protein in paraffin-embedded malignant 
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and benign prostate samples in terms of the sensitivity, specificity of this 
IHC test.  
 
The modest sensitivity of this HPV cocktail antibody test, which was 
58.1%, tells how likely this test it to be positive in samples which are 
confirmed to have HPV viral DNA by multiplex PCR. This means that this 
test would not be suitable candidate for being a screening test, which can 
precede the other conventional molecular tests, which rely on detecting 
the viral DNA like PCR and hybrid capture II. On the other hand, the 
specificity of this test, which came as 100%, tells how likely the test is to 
come back negative in a sample which is known to be negative for HPV 
viral DNA by multiplex PCR. This means that IHC test would be a very 
suitable candidate as complementary test after the initial confirmation has 
been made by another method. The latter conclusion seems to put the 
HPV IHC test in the middle between the Pap test which usually shows 
variable (poor to moderate) sensitivities (30 to 87%) [344], when equivocal 
cases need to be repeated to improve diagnostics, and the other 
chromatographic hybridisation technologies like hybrid capture II, which 
has higher sensitivities up to 85% [345, 346].  
 
However, the proportion of both HPV-positive in malignant and benign 
specimens, as would be detected by a purely qualitative assay like IHC or 
PCR, strongly depends on the sensitivity of the respective assay. 
Decreasing the limit of detection would increase the number of positive 
samples detected and vice versa. Therefore, our data offer direct 
experimental evidence of the notion that different assay sensitivities of the 
various molecular tests are one reason for the contradictory results 
reported thus far. 
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The E6 protein of high- risk HPVs is classified as an oncoprotein and 
can transform human mammary cells and cooperate with E7 in 
transforming human epithelial cells [106]. E6 is expressed early after 
viral infection and facilitates viral production by conferring several 
cellular changes and by prolonging cellular lifespan by disrupting the 
p53 role as tumour suppressor gene [150]. To achieve the latter effect high-
risk HPV E6 interacts with a ubiquitin ligase, called the E6 associated 
protein (E6-AP), and forms complexes with p53 protein, which is then 
degraded through ubiquitin dependent mechanisms [187, 208]. 
Moreover, E6 can block translocation of p53 into the nucleus and 
thereby inhibit the gene regulatory functions of p53 [347].  
 
Only a few systematic studies exist on the expression of E6 protein of the 
oncogenic HPV types in prostate tissues. But, there are few 
epidemiological data, in addition to cell culture experiments, indicate a 
possible role of HPVs for the pathogenesis of prostate tumours [300, 348]. 
However, this subject remains controversial, in large part due to 
contradictory results regarding the detection of the viral nucleic acids 
within prostate cancer [300].  
 
In our study (E6) has been found in 6.5% of the total PCa study group. 
This result supports conclusions drawn from earlier investigations on the 
presence of HPV16 and HPV18 DNA in prostate specimens [278, 349]. 
In principal, the low numbers of E6 oncoprotiens detected by IHC in a 
subset of prostate tissue specimens have been reflected in the fact that all 
the E6-positive samples were at IHC Grade 1. Therefore, it can be 
proposed that the cells bearing the virus are either present within the 
sample in a very low frequency, or that only a fraction of the cells is 
carrying the viral DNA. 
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In addition, it has been reported that the deletion of L1 ORF of the high-
risk HPVs might be a common phenomenon during the active integration 
phase of HPV infections in cervical cancer which might be up to 41% [274]. 
In these circumstances it is very common to have negative amplification 
signal by testing these cases by PCR method using primers targeting the 
L1 ORF, alongside a parallel positive signal for the E6 protein in a 
considerable proportion of the samples which do have integrated DNA 
but deleted L1 ORF region. However, in our study we did not find any 
results as such, which may indicate L1 deletion is not common in high-risk 
HPV infections in prostate cancer cases and high-risk HPV viral DNA 
integration prevalence might not be so frequent .  
 
Similarly, it has been reported that because L1 capsid protein is also the 
major target of cellular immune response and its loss at early stages of the 
transformation process may lead to ineffective stimulation of immune 
responses. Therefore, lack of L1 capsid protein may occur to reduce the 
cellular immune responses, thereby promoting further transformation of 
immature epithelial cells. However, we did not find an evidence, which is 
in line with this hypothesis in our study group as all the cases which 
showed E6 positive signal by IHC actually did have positive amplification 
signal for the L1 region of the high-risk viruses by multiplex PCR.  
Furthermore, it is well known that DNA tests, such as PCR cannot 
differentiate among latent, subclinical, and clinically relevant infections. 
Also, it has been suggested that the normal immune system suppresses 
latent and clinical HPV cervical infections and that the efficiency of 
suppression may be HPV type-specific [350]. According to the latter 
context of HPV latency, there would be low copy numbers of the virus 
which are enough for the maintenance of the viral life including the capsid 
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proteins which are encoded by the L1 ORF, but not in an enough copy 
number to get the E6 protein detectable by IHC method.  This hypothesis 
is concordant with our observation, and might explain why only 26.6% of 
the total number of PCa cases, which had high-risk HPV infections, 
expressed E6 protein.  
 
Infections with HPVs can lead to inactivation of the p53 tumour 
suppressor gene product by binding to the HPV encoded E6 protein, 
which leads to a rapid degradation of p53 through the ubiquitin pathway. 
The latter event has been considered as an important pathway for 
malignant progress in HPV-infected cells [351]. In contrast, mutations of 
the p53 gene have been found in HPV-negative cervical carcinoma cells 
[187].  Also, the current dogma in cancer biology is that p53 alterations to 
be found in every tumour type, and mostly result from point mutations. 
However, p53 gene mutations are not limited to a late event in prostate 
cancer progression. They can occur early in cancer development and it is 
now generally accepted that mutations of p53 occur infrequently in early 
invasive carcinomas [352]. However, the limitation of current sampling 
techniques and technology prohibits an accurate determination of the p53 
status in early stage disease [353]. In addition, p53 is commonly mutated 
in advanced stages of prostate cancer, as well as in recurrent and 
metastatic disease, as inferred by immunocytochemical demonstration of 
accumulated protein or by direct mutational analysis [354]. It is also 
known that p53 mutations are associated with increased micro-vessels 
density, androgen-independence, and metastasis in PCa, raising the 
possibility that tumourigenesis and acquisition of metastatic ability occur 
simultaneously, and not sequentially, in PCa cases [355, 356].  
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The results of our study revealed that p53 expression is also not related to 
an HPV infection. In fact, there were HPV-negative cases in our study 
with p53 expression. Also, based on the cervical carcinoma model in which 
mutations in p53 are very rare and high-risk HPV infections are very 
frequent in primary tumours in over 90% of the cervical cancer cases, 
which strengthens the view that p53 inactivation by high-risk HPVs 
proteins plays a major role in the pathogenesis of cervical cancer, we 
looked for any association between the high-risk HPV infections and the 
P53 status.  We found that P53 mutant protein was detectable with and 
without concurrent high-risk HPV, and interestingly no mutant p53 
protein was detected in the BPH cases. Moreover, our results showed that 
p53 protein expression happens less frequently when the E6 oncoprotein 
of the high-risk type 16 and 18 HPVs are detectable in the same PCa 
samples, which may suggest that the p53 gene mutation or the presence of 
the high-risk HPVs oncogenic protein E6 could be involved in the 
development of prostate cancer, also, high-risk HPVs could participate in 
P53 inactivation by E6 in prostate cancer cases. Nonetheless, such a 
causative relationship need more work to confirm as other causes might 
be responsible for the low incidence of P53 mutation in the samples other 
than the effects of being infected with high-risk HPVs. One of these causes 
is the loss of chromosome 17p, which occur in advanced stages of prostate 
cancer and metastatic disease [357], deleting a region that includes the p53 
locus [358]. In addition, it is well known that the frequency of p53 
mutations seems generally to be lower in prostate cancer than in other 
cancers [359]. A relatively minor role for p53 in prostate carcinogenesis is 
consistent with the observation that Li-Fraumeni patients carrying 
germline p53 mutations have a low incidence of prostate cancer [360].  
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The E7 protein of the high-risk HPVs binds and phosphorylates the 
tumour suppressor pRb and inhibits its binding to E2F. Released E2F 
transcriptional factor stimulates p16INK4a transcription, leading to 
p16INK4a overexpression, which is also caused by the loss of the negative 
feedback from free pRb, disrupted by HPV E7 [361]. Moreover, over-
expression of p16INK4a is known to be observed in cancers of the uterine 
cervix [362], and is associated in the majority of the cases in this group of 
cancers with HPV infections [363]. 
 
A comprehensive review of the literature reveals that to the best of our 
knowledge there are no studies, which have simultaneously analysed 
HPV status and p16INK4a in PCa or BPH cases. Nevertheless, only a few 
studies have analysed the correlation between the p16INK4a expression 
and HPV infections in the female genital tract [364].  
 
In the current investigation, which is the first to evaluate simultaneously 
HPV status and p16INK4a immunoreactivity in these prostatic 
pathologies, we observed that 22 of 30 the high-risk positive prostatic 
neoplasms failed to show the type of diffuse strong p16INK4a staining 
that one would expect to see in HPV-positive tumours based on the 
observation of HPV-positive cervical neoplasms [365]. Moreover, we 
found p16INK4a immunoreactivity in 13 cases of the of the total 80 HPV-
negative cases of PCa cases. We also detected few cases where p16INK4a 
was strongly expressed and no HPV was detected. One explanation for 
our observations could be because the levels of HPV were too low for 
detection by IHC method or the HPV types may be present but are not 
amplified by the SPF1/2 system.  In addition, this study is consistent with 
the hypothesis that p16INK4a overexpression in the female genital tract 
and cervical cancer namely might not be related to HPV carcinogenesis 
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effect [366]. The latter conclusion contradicts with another report, which 
found that p16INK4a overexpression is a very useful surrogate biomarker 
to detect high-risk HPV infections in cervical cancer cases [363]. 
Nevertheless, the results of our study revealed that p16INK4a 
overexpression is also not related to an HPV infection. In fact, many cases 
in our study with p16INK4a overexpression were HPV-negative. 
Therefore, it can be concluded that in the absence of HPV infection, 
mutations in the Rb gene or E2F transcription factor gene appear to be 
playing a role in prostate cancer tumourigenesis, and p16INK4a is not a 
suitable candidate to act as high-risk HPV surrogate marker in prostate 
pathologies.  
On the other hand, few reports argued that hit and run oncogenesis might 
be involved in prostate cancer and other cancers [180] which may explain, 
if true, why p16INK4a overexpression could be found in high-risk 
negative samples. According to this hypothesis the oncogenic virus may 
infect its target tissue, trigger a misdirected immune response, mutagenic 
activity, or a permanent chromatin reorganization, which in turn activates 
oncogenes or silences tumour suppressor and DNA repair genes. 
Thereafter, cells may become malignant and remain so, even if virus-
triggered recombinogenic activities lead to the secondary loss of the virus 
[180]. For hit and run-mechanisms one would consider a transient, but 
regular presence of viral genomes or parts thereof at an early stage of the 
respective tumour [367].  Also, to conclusively prove hit and run-
oncogenesis, a complete chain of evidence from epidemiology, histology, 
serology and molecular biology is required [179]. However, the results 
from our current retrospective case-control study cannot at its own affirm 
or reject the hit and run hypothesis concerning HPV infections. So, it 
might be proposed that a comprehensive prospective cohort study might 
be essential to assess if the high-risk HPV hit and run oncogenesis is 
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actually involved in prostate neoplasia, which mainly should rely on the 
novel high throughput sequencing methods that allow the identification of 
viral genomes or parts thereof in pre-dysplastic tissue and in early stages 
of neoplastic development [180]. 
 
Repair of damaged DNA is the only natural way to ensure survival in 
unicellular organisms. Repair, growth arrest, and apoptosis at present can 
be considered a response to DNA damage in human tissues, although 
their fate in many cases depends on cell type, location, environment, and 
extent of damage [368]. Therefore, alterations either in the machinery that 
senses DNA damage or in the mechanisms that implement a response to 
DNA damage are considered important in predisposition to cancer [369, 
370]. There are two main checkpoints in the control of cell cycle 
progression: G1/S prior to the replication process of DNA, and G2/M 
preceding the process of mitosis [371]. The p53 gene is  activated as a 
response to DNA damage, followed by cell cycle arrest and activation of 
the apoptosis cascade [372]. Activation of p53 is carried out through a 
phosphorylation process that regulates its DNA-binding affinity [373]. 
One of the main observations about the interaction between the high-risk 
HPVs protein E6  and the functionality of the p53 gene in anogenital 
cancers [374] and skin cancers [375] indicate that the high-risk E6 protein 
interacts with a ubiquitin ligase, called the E6 associated protein (E6-AP), 
and forms complexes with p53 protein, which is then degraded through 
ubiquitin dependent mechanisms [89], in addition to blocking t h e  
translocation of p53 into the nucleus and thereby inhibit the gene 
regulatory functions of p53 [187]. If the latter effects of the high-risk HPV 
are substantial in prostate cancer they would result in lower levels of 
apoptosis index within the samples which are positive for the high-risk E6 
protein. However, in the current study, no apparent association could be 
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established between the presence of HPV-DNA or the high-risk E6 protein 
and apoptosis indices, suggesting that HPV itself is not directly involved 
in the apoptosis regulatory pathways in prostate cancer. Our results are in 
agreement with another report, which could not establish any correlation 
between the high-risk HPV presence and the apoptosis indices in paraffin 
embedded cervical cancer samples [376]. In contrast with the latter report, 
a recent study has confirmed that high-risk E6 protein are capable of 
arresting apoptosis in head and neck HPV-positive cancer cell lines [377]. 
In conclusion, there is a need for further studies on prostate cancer cell 
lines after being transfected with E6 DNA to confirm our finding in 
paraffin embedded samples.   
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 CHAPTER 5: GENERAL DISCUSSION  
 
Prostate cancer is one of the most common malignancies in the Western 
world. In 2008, the number of new cases in the 27 countries of the 
European Union was 338,730 (25% of all new cancers) and the number of 
deaths reached 70,820 (10% of deaths from cancer) [1].  
 
Small foci of PCa are harboured by the prostates in 80% of men over 80 
years old [378], and many of these patients die from other causes without 
knowing they suffer from PCa [379]. In fact, clinically significant PCa 
generally affects men in their sixties but is probably initiated years or 
decades earlier; therefore, it is difficult to establish the primary insult that 
triggers prostate carcinogenesis [380]. Causative factors have been found 
in other genitourinary malignancies, which can be targeted, like smoking 
in cases of bladder cancer [381] and the human papillomavirus in cases of 
cervical cancer [88]. However, the principal risk factors in PCa are not 
modifiable, which are mainly related to patients’ genetic makeup such as 
African-American origin or having a strong history PCa running in the 
family [382]. In addition, after the introduction of PSA screening in the 
early 1990s, PCa incidence has drastically increased along with a shift to 
earlier stages among newly diagnosed cases [382]. Even if PCa is 
successfully managed, which is the usual outcome in localised disease, 
treatment may be accompanied by functional consequences like; erectile 
dysfunction and incontinence [383]. These side effects impair deeply the 
patient's quality of life. In addition, there are limited therapeutic options 
available for advanced PCa, and metastatic disease remains incurable. 
Finally, the management of PCa within a large population of elderly men 
imposes an economic burden on health care systems, particularly in the 
gradually aging Western populations. Finding a potentially modifiable or 
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preventable risk factor in PCa, such as HPV infection of the genitourinary 
tract, would be of great medical importance. 
It has been suggested that PCa is associated with septic or aseptic chronic 
inflammation, the source of which may be prostatic infection and other 
mechanisms [384]. Also, it has been reported that patients with a history of 
prostatitis were more likely to develop PCa [385]. However, a large 
population-based case-control study did disagree with the latter 
conclusion [386].  
 
HPV has been the most extensively investigated pathogen in studies to 
determine an infectious cause of PCa cases because it has been established 
as the main etiologic factor in cervical carcinoma and several other 
anogenital malignancies. The first report of investigating of HPV viral 
DNA in prostate cancer tissues was in 1990 using PCR. However, this 
report failed to establish a significant difference between PCa patients and 
a group of BPH patients [277]. The promising yields of HPV detection and 
the indecisive conclusion of that study encouraged other researchers to 
conduct more research on the same subject.  
Twenty nine tissue-based studies from 1980 to December 2012 [212, 213, 
217, 278-280, 283, 284, 288, 289, 299, 300, 313, 349, 387-401] were identified 
for the purpose of this study, 22 of which are case-control studies, whereas 
the remaining 7 papers only analysed PCa samples. The current study was 
different from all the previous studies in assessing the effects of HPV 
infection on P53 and Rb genes as well the apoptosis rate within the 
samples without limiting the scope of the research to detect the viral DNA 
in the study and control groups. On the other hand, the current study is to 
the best of our knowledge, the only study that tested the hypothesis of 
HPV infection in three different ethnic groups at the same time and by the 
same methodologies.  
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Moreover, the earlier studies previously covered the same subject of the 
current research were not homogenous. The diversity of the respective 
study designs and  methods; the sample size which ranged from 17 
subjects to over 300 as in the current study; the varied definition of 
controls  as either BPH or healthy subjects; scope of HPV types detected  
which  were usually 16 and 18; detection methods which were  PCR in the 
majority of studies; primers used  which mostly targeted L1 or E6/E7 or 
other gene sequences; sample harvesting, which varied amongst open 
surgery, transurethral and transrectal approaches; and processing and 
storage conditions of the prostate tissues as formalin-fixed, paraffin-
embedded or  frozen samples.  
 
Statistically significant differences between PCa patients and a control 
group have been established in 4 publications out of the 29 studies earlier 
mentioned. In one of the early studies [388], HPV DNA of different HPV 
types was detected in the prostates of 28 out of 68 Japanese PCa patients, 
whereas all the BPH controls were HPV-free. In addition, the detection 
rate in this study was correlated with the disease stage and Gleason score, 
which contradicts with the results of our current study. Another group in 
Germany used competitive quantitative PCR to detect HPV 16/E6 DNA 
sequences. One to two copies of viral DNA were detected in most of the 
benign and malignant frozen samples that were obtained via radical 
retropubic prostatectomy. Thus, some degree of positivity was observed in 
most of the samples. With a cut-off value of 300 copies, 21% of the PCa 
samples were HPV 16 positive (P = 0.02) vs. 3% of the BPH controls [300]. 
Another group in Argentina detected different HPV types in 42% of PCa 
transrectal biopsy samples, whereas all the BPH specimens were negative 
(P < 0.0001) [213]. It is interesting to note that both studies employed 
surgical microdissection to maximize the number of tumour cells in the 
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sample. In contrast, several other trials yielded null results using the 
microdissection technique [217, 279, 299]. It was notable that PCa patients 
from Northwestern Mexico were 4 times more likely to harbour HPV 
DNA in their prostates than their BPH counterparts (P = 0.027) [313]. 
Nevertheless, none of the remaining 24 studies from other countries 
demonstrated any differences in the presence of HPV DNA between PCa 
patients and noncancerous controls. 
 
The following potential limitations of laboratory studies that are based on 
the direct detection of pathogens in prostatic tissue have been proposed: 
(1) they are restricted to hypotheses that involve persistent prostatic 
infections; therefore, if a pathogen interacts with the tissue using a hit-
and-run mechanism, it may not be detected at the time of analysis; (2) they 
are usually small in size; (3) they are prone to some selection bias; (4) they 
do not allow for the assessment of temporal relationships between 
infection and cancer; (5) the results vary depending on the specific genetic 
sequences being investigated; (6) the results may vary depending on the 
amount and location of the tissue sampled, including the possibility of 
missing a focal infection; and (7) specimens may be contaminated during 
collection and processing [402].  
 
One specific drawback of large epidemiologic studies of PCa is the 
definition of the control group. The latent existence of clinically 
unapparent lesions is an inherent characteristic of PCa. If controls are only 
defined as “cancer-free” or “PCa-free,” men with subclinical undiagnosed 
lesions may be included in the control group, which would shift the 
statistics towards the null [2].  
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After several years of HPV-DNA analysis in benign and malignant 
prostate samples, the causal involvement of HPV in prostate 
carcinogenesis is still a matter of controversial debate. However, the 
association of HPV with prostate cancer, if substantiated, would be 
unexpectedly good news for cancer prevention prospects. The discrepant 
results and methodological insufficiency of these analyses have already 
been discussed in by few researchers [212, 279, 281, 348, 403-407]. It has 
been speculated that, due to the detection of HPV-DNA in urethral [408] 
and anal [409] tissues, the discrepancies are probably as a result of HPV 
contamination from nearby tissues during the sampling procedure. Based 
on these data some authors have recommended radical prostatectomy as 
the tissue source, as well as an exhaustive microdissection of the 
neoplastic sample [279]. We propose microdissection of the neoplastic 
samples to exclude contaminating skin tissue and minimize stromal 
content from the samples. 
Another reason for the conflicting results might be in line with the 
researches, which reported that in cervical cancer there were cases of 
persistent infection without production of HPV viral particles, which is 
usually attributed to the viral genomes in the long-living basal epithelial 
cells, which do not express L1 Cpasid protein. Thus, loss of L1 Cpasid 
protein expression may be the case in two statuses of viral DNA; one is the 
integration of viral DNA into the host genome with the loss of the L1 
region and the other is latent infection with low or no synthesis of HPV 
oncoprotein and no HPV production. 
 
Some other recent studies [289, 392] have also observed no associations 
between prostate cancer and HPV. The proposed reason for these 
observations was mainly that prostate cancer does not meet some of the 
expected features of HPV-caused cancers, as prostate cancer is not 
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squamous cell in origin and does not occur at anatomic sites of exposure 
by direct contact [410].  
 
Our data give additional evidence to explain some of the previously 
reported contradictory findings regarding the prevalence of viral DNA in 
prostate cancer and BPH specimens. However, to further analyse the 
potential role of oncogenic HPVs in a subset of prostate cancers, additional 
quantitative investigations, aiming at the detection of viral DNA on the 
cellular level, will be necessary.  
 
In our view, these discrepancies, observed by different researchers, could 
be due to different methodologies used, different interpretation criteria, 
and possibly other technical aspects. 
 
In this study, we investigated the question of whether the presence of 
HPV DNA in the tumours samples, and staging of prostatic neoplasms 
could be considered as prognostic factors. Our investigation and analysis 
revealed that the survival of these tumours seems to be independent of 
HPV status. 
 
Moreover, compromised immunity during the course of prostate cancer 
development might be responsible for reactivation of a latent HPV 
infection due to the cancer cachexia and might not be responsible for 
causing prostate cancer.  
 
Further research in the field of PCa and infections may bring new insights 
into the matter, especially if modern laboratory techniques are used, as a 
definitive discovery of an infectious agent like the HPV that is directly 
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associated with PCa could have significant therapeutic implications for 
millions of patients in the UK and worldwide [378]. 
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APPENDICES  
APPENDIX 1:  Data extraction sheet  
Information to be extracted from patients’ notes 
 
PATIENT DETAILS: 
Patient code: 
DOB: 
Place of birth: 
Ethnic Origin (delete as appropriate):    White / African-Caribbean/ Middle 
Eastern  
  
CLINICAL HISTORY  
 
Previous prostate problems?  Yes/No  delete as appropriate 
 
If yes: 
 
Mode of presentation: 
 
1. GP referral 
2. Inpatient referral 
3. Emergency 
4. Incidental 
5. High PSA Level  
6.          Others (please specify): 
 
Clinical presentations: 
1. Lower urinary tract symptoms 
  
• Acute urinary retention 
• Nocturia 
166 
 
 
 
• Frequency 
• Dysuria 
• Hesitancy 
• Urgency 
• Poor stream 
• Haematuria 
• Other (please specify) 
 
2. Urinary tract infection 
3. Sexually transmitted diseases 
4. Weight loss 
5. None of the above 
 
Family history of prostatic cancer? 
Yes/No delete as appropriate 
 
 
Past medical history: 
 
1. Diabetes 
2. Hypertension 
3. Cardiac 
4. Others (please specify): 
 
Prostate cancer?    
Yes/No delete as appropriate 
 
If yes: 
 
Rectal examination findings: 
 
1. Normal prostate 
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2. Enlarged benign prostate 
3. Clinically suspicious prostate 
 
Clinical stage: 
Investigations (please circle appropriate response) 
1.  TRUS  YES  NO 
2.  CXR              YES  NO 
3.  PSA   YES  NO 
4.  BONE SCAN           YES  NO 
5.  CT SCAN  YES  NO 
6.  MRI  YES  NO 
7.  OTHERS (please specify): 
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APPENDIX 2: Table showing the tumour grading, staging, PSA and 
survival for each individual prostate cancer case which showed 
positivity for the high-risk HPV infections, along with the P53 codon 72 
polymorphism, viral load, P53, P16 and E6 protein statuses. 
 
 
Case Gleason 
Grading 
Staging PSA 
(μg/L) 
Survival  
(months) 
P53 codon 72 
polymorphism 
Viral 
Load 
ng/µl 
E6 P53 p16INK4a 
1 7 T1-2N0M0 5.2 36 Arg/Arg 1.21 Neg Neg Neg 
2 6 T3-4N0/xM0 7.1 49 Pro/Arg 1.37 Neg  Neg Pos 
3 7 T2-4Nx/+M1 7.8 34 Arg/Arg 0.98 Neg Neg Neg 
4 7 T1-2N0M0 6.9 60 Arg/Arg 1.59 Pos Neg Pos 
5 8-10 T1-2N0M0 7.9 - Pro/Arg 1.98 Neg Pos Neg 
6 6 T3-4N0/xM0 7.5 12 Pro/Arg 1.32 Pos Neg Neg 
7 7 T1-2N0M0 7.3 16 Arg/Arg 1.14 Neg Neg Neg 
8 6 T2-4Nx/+M1 5.8 43 Arg/Arg 1.23 Neg Neg Pos 
9 7 T3-4N0/xM0 8.2 18 Pro/Arg 1.36 Neg Neg Neg 
10 8-10 T3-4N0/xM0 7.8 22 Pro/Arg 1.41 Neg Neg Neg 
11 7 T1-2N0M0 7.7 37 Pro/Arg 1.19 Pos Neg Neg 
12 7 T2-4Nx/+M1 7.9 - Arg/Arg 0.99 Neg Neg Neg 
13 7 T3-4N0/xM0 6.9 - Arg/Arg 0.98 Pos Neg Neg 
14 6 T2-4Nx/+M1 6.1 18 Arg/Arg 1.47 Neg Neg Neg 
15 8-10 T1-2N0M0 8.3 46 Pro/Arg 1.18 Neg Neg Neg 
16 7 T3-4N0/xM0 5.2 49 Pro/Pro 1.21 Neg Neg Pos 
17 6 T1-2N0M0 5.7 20 Pro/Arg 1.23 Pos Neg Pos 
18 6 T3-4N0/xM0 6.1 38 Arg/Arg 1.32 Neg Pos Neg 
19 7 T1-2N0M0 5.1 14 Pro/Arg 1.45 Neg Neg Neg 
20 7 T1-2N0M0 7.4 52 Arg/Arg 1.58 Neg Neg Pos 
21 8-10 T2-4Nx/+M1 8.1 - Pro/Arg 0.89 Neg Neg Neg 
22 6 T3-4N0/xM0 5.8 60 Pro/Pro 1.26 Pos Neg Neg 
23 8-10 T2-4Nx/+M1 8.2 58 Pro/Arg 1.59 Neg Neg Neg 
24 7 T2-4Nx/+M1 7.3 43 Arg/Arg 1.25 Neg Neg Neg 
25 8-10 T1-2N0M0 6.9 19 Pro/Arg 1.41 Neg Neg Pos 
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26 7 T2-4Nx/+M1 6.2 22 Pro/Pro 1.32 Pos Neg Neg 
27 7 T1-2N0M0 5.2 28 Arg/Arg 1.15 Neg Neg Pos 
28 6 T2-4Nx/+M1 5.4 57 Arg/Arg 1.82 Pos Neg Neg 
29 6 T3-4N0/xM0 8.0 58 Arg/Arg 1.34 Neg Neg Neg 
30 8-10 T1-2N0M0 7.4 62 Pro/Arg 1.40 Neg Neg Neg 
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